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Paclitaxel, an antimitotic agent widely used for the treatment of solid tumors, has the 
neuropathy as its dose limiting toxicity. In the majority of the patients the neuropathy resolves 
after finishing the treatment; however, in severe cases the nerves can be irreversibly damaged 
affecting permanently patients’ quality of life. In addition, neuropathy-induced dose reductions 
and treatment suspensions are common and may lead to sub-optimal disease treatment and 
increased likelihood of relapse. The individual genetic background has been suggested to explain 
a substantial proportion of the inter-individual variability observed in paclitaxel toxicites. Thus, 
the main goal of this Thesis was to identify genetic markers associated with paclitaxel-induced 
peripheral neuropathy. First, we evaluated the role of previously proposed genetic markers. And 
second, we performed whole exome and targeted next generation sequencing to discover new 
genetic variants associated with the neuropathy.  
 
With regard to the previously proposed genetic variants, we confirmed the association of 
the common polymorphisms rs7349683 in EPHA5, rs301927 in EPHA6 and rs209709 in EPHA8 
with an increased risk of peripheral neuropathy. Concerning CYP2C8*3, we only found a 
tendency towards increased risk.  
 
Applying whole exome sequencing to patients with severe neuropathy, we identified 
CYP3A4 defective variants associated with increased risk of severe neuropathy and higher 
probability of treatment modifications due to this adverse effect. Furthermore, targeted 
sequencing of candidate genes led us to discover that low frequency coding variants in EPHA5, 
EPHA6 and EPHA8 contributed to the susceptibility to paclitaxel-induced neuropathy.  
 
To sum up, this Thesis supports a role for CYP3A4 and EPHAs genetic variants in 
paclitaxel-induced neuropathy development. It also recognizes the use of next generation 
sequencing techniques as novel approaches to detect low-frequency variants associated with drug 
adverse events. Moreover, the involvement of EphA receptors in neuronal repair function 
suggests they could also be risk markers for other neurotoxic drugs. The genetic markers 
identified in this Thesis may help to personalize paclitaxel treatment by identifying, beforehand, 
those patients with an increased neuropathy risk and that may benefit from alternative drugs and 
an extensive follow-up along the therapy. 
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El paclitaxel, un fármaco antimitótico ampliamente utilizado en el tratamiento de tumores 
sólidos, tiene la neuropatía periférica como su toxicidad limitante de dosis. En la mayoría de los 
pacientes, esta neuropatía desaparece al finalizar el tratamiento; sin embargo, hay casos en los 
que la neuropatía es tan severa que los nervios quedan irreversiblemente dañados y la calidad de 
vida del paciente resulta afectada de forma permanente. Además, habitualmente se tiene que 
reducir la dosis del paclitaxel o suspender el tratamiento debido a la neuropatía, lo que puede 
resultar en un tratamiento sub-óptimo de la enfermedad y en un incremento del riesgo de recaída. 
Se ha sugerido que la variación genética puede explicar una parte sustancial de la variabilidad 
inter-individual observada en la toxicidad del paclitaxel. Por ello, el objetivo principal de esta 
Tesis fue la identificación de marcadores genéticos asociados a neuropatía periférica producida 
por el paclitaxel. Primero evaluamos el papel de marcadores genéticos sugeridos previamente. En 
segundo lugar llevamos a cabo estudios de secuenciación de exoma completo y de secuenciación 
de genes candidatos para descubrir nuevas variantes genéticas asociadas a la neuropatía. 
 
Con respecto al primer punto, confirmamos la asociación de los polimorfismos rs7349683 
en EPHA5, rs301927 en EPHA6 y rs209709 en EPHA8 con un mayor riesgo de neuropatía 
periférica. En relación a la variante CYP2C8*3, solo detectamos una tendencia a mayor riesgo de 
neuropatía.  
 
Mediante la secuenciación de exomas completos identificamos variantes que producían 
la pérdida de función del CYP3A4 en pacientes con neuropatías severas. En concreto, encontramos 
que los portadores de estas variantes tenían mayor riesgo de sufrir neuropatía severa y mayor 
probabilidad de tener modificaciones de tratamiento debidas a este efecto adverso. Además, la 
secuenciación de genes candidatos nos permitió descubrir que variantes codificantes de baja 
frecuencia en EPHA5, EPHA6 y EPHA8 contribuían a la susceptibilidad de desarrollar neuropatía 
producida por paclitaxel. 
 
En resumen, esta Tesis respalda la implicación de variantes genéticas en CYP3A4 y en 
EPHAs en el desarrollo de la neuropatía inducida por el paclitaxel. Además, subraya la utilidad 
de las técnicas de secuenciación de nueva generación como estrategias idóneas para detectar 
variantes de baja frecuencia asociadas a efectos adversos producidos por fármacos. La función de 
los receptores de efrina tipo A en la reparación neuronal sugiere que éstos también podrían ser 
marcadores de riesgo para otros compuestos neurotóxicos. Los marcadores genéticos 
identificados en esta Tesis podrían ayudar a la personalización del tratamiento con paclitaxel, 
identificando de antemano, pacientes con alto riesgo de sufrir neuropatía y que podrían 
beneficiarse de fármacos alternativos y de un seguimiento más estrecho durante la terapia.  
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FDA: Food and Drug Administration 
FGD4: FGD1-related F-actin binding protein 
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NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events 
NGS: Next Generation Sequencing 
OATP1B1: Solute carrier Organic Anion Transporter family member 1B1  
OATP1B3: Solute carrier Organic Anion Transporter family member 1B3  
OR: Odds Ratio 
PCR: Polymerase Chain Reaction 
PIK3IP1: Phosphoinositide-3-Kinase Interacting Protein 1 
PRX: PeRiaXin 
QST: Quantitative Sensory Test 
RWDD3: RWD domain-containing protein 3 
SEPT9: SEPTin 9 
SGCG: Gamma-SarcoGlyCan 
SH3TC2: SH3 Domain and TetratriCopeptide repeat-containing protein 2 
SKAT: Sequence Kernel Association Test 
SLCO1B1: SoLute Carrier Organic anion transporter family member 1B1  
SLCO1B3: SoLute Carrier Organic anion transporter family member 1B3  
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1. Cancer pharmacogenetics 
Individuals exhibit a great heterogeneity in the way they respond to clinical drugs (Lin, 
2007, Evans et al., 2001). Standard drug therapy may result in life-threatening adverse drug 
reactions (ADR) in some patients, while others may lack the desired therapeutic effect. This 
variability represents a major challenge in the clinics. It has been estimated that the overall 
incidence of severe ADR in hospitalized patients is around 6%, making ADR between the fourth 
and sixth leading cause of death in developed countries (Lazarou et al., 1998, Pirmohamed and 
Park, 2001). This is of special relevance for drugs with narrow therapeutic indexes such as anti-
cancer agents in which the dose required to obtain a therapeutic effect is close to the one that 
produces toxicity, and where treatments are in general very toxic. Regarding drug response, the 
efficacy rates observed for many widely used therapeutic agents are low, ranging from 25% to 
80% (Spear et al., 2001).  
Many factors have been shown to contribute to the variability in drug responses: 1) 
environmental (e.g. concomitantly administered drugs, nutritional factors, alcohol consumption); 
2) pathological (e.g. concomitant diseases); 3) physiological (e.g. age, gender, body mass index); 
4) clinical (e.g. mis-dosing, medication errors) and 5) genetic factors (e.g. genetic variants in drug 
metabolizing enzymes critically altering drug pharmacokinetics) (Weinshilboum and Wang, 
2004).  
The recognition that a part of this variation is inherited initiated the field of 
pharmacogenetics fifty years ago (Meyer, 2004). Pharmacogenetics studies how genetics affects 
drug response. It has been described that any two humans differ only in 0.1% of their genome 
(Kruglyak and Nickerson, 2001) and this is mainly due to polymorphisms. A polymorphism is 
defined as a variant with a minor allele frequency >1%, when the frequency is <1%, the variant 
is classified as low frequency/ rare. Single nucleotide polymorphisms (SNP) are the most common 
genetic variation with more than 15 million SNPs distributed throughout the human genome. 
When located in a gene, they can change the encoded amino acids (non-synonymous variant) or 
can be silent (synonymous variant) or simply occur in noncoding regions. They may influence 
promoter activity, messenger RNA (mRNA) stability or splicing efficiency among others 
processes (Komar, 2009). There are other forms of genetic variation including small insertion and 
deletions (INDELs), short tandem repeats (STR) also known as microsatellites, variable number 
tandem repeats (VNTR), and variants spanning large segments of DNA (>1kb) known as copy 
number variations (CNVs) (Haraksingh and Snyder, 2013). Several international projects have 
been developed to compile genetic variation among different populations (e.g. HapMap, the 1000 
Genomes Project) and among different cancer types (e.g. The Cancer Genome Atlas, the 
International Cancer Genome Consortium) leading to the creation of multiple databases (e.g. 
dbSNP, Ensembl, UCSC browser, COSMIC, cBioPortal) (Apellaniz-Ruiz et al., 2016). 
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Regarding the oncology field, despite the significant advances made during the last 
decades, due to the aggressiveness of these treatments, anti-cancer drugs still cause a high number 
of ADRs. Some of these lead to treatment discontinuation while others can be fatal. In addition, 
therapy failure is still high. Indeed, cancer treatment is especially complex because a combination 
of inherited variations within the individual (germline) and acquired variations within the tumor 
(somatic) influence disease outcome and the response/ toxicity to the drug therapy (Paugh et al., 
2011, Filipski et al., 2014). Germline variation may alter drug pharmacokinetics and 
pharmacodynamics leading to toxicity and/or lack of efficacy. One example in pharmacokinetics 
is the use of genetic testing to identify patients with thiopurine-S-methyltransferase deficiency to 
avoid the development of fatal hematopoietic toxicity when treated with mercaptopurine (Evans 
and Johnson, 2001, Patel and Papachristos, 2015). On the other hand, somatic mutations can be 
relevant to predict tumor response (Paugh et al., 2011). This is the case of Vemurafenib, a 
selective B-Raf inhibitor that has shown extraordinarily results in metastatic melanoma patients 
with V600E mutation in BRAF (Hertz and McLeod, 2013).  
Therefore, if differences in drug outcomes are linked to genetic variants, it could be 
possible to perform a genetic test to select the best medication and dose for a patient and 
personalize cancer therapy (Paugh et al., 2011, Patel et al., 2014). Advances in cancer 
pharmacogenomics, in large part derived from the development and implementation of 
genotyping panels and next generation sequencing (NGS) technologies, are providing a more 
complete view of the human genome and improving cancer treatment (Gillis et al., 2014, 
McCarthy et al., 2013).  
 
2. Taxanes  
Microtubules, crucial components of the cytoskeleton, are highly dynamic polymers 
composed of α-tubulin and β-tubulin heterodimers. They play key roles in cell movement, 
intracellular transport and cell division, assuring the integrity of the segregated DNA. For decades 
they have been known as effective targets for cancer therapy (Desai and Mitchison, 1997) and 
nowadays different microtubule binding anti-cancer agents (e.g. taxanes, vinca alkaloids, 
epothilones) are used as chemotherapeutic drugs for the treatment of several solid and 
hematologic tumors (Jordan and Wilson, 2004, Perez, 2009, Pasquier and Kavallaris, 2008). 
Taxanes are among the most important additions to the chemotherapeutic arsenal in the 
late twentieth century. The most widely used taxanes are paclitaxel (Taxol®, Bristol-Meyers 
Squibb) and the semi-synthetic analog docetaxel (Taxotere®, Sanofi).  
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The need for new compounds with higher solubility and less toxicity have guided the 
development of new taxanes such as the already approved nanoparticle albumin–bound paclitaxel 
(nab-paclitaxel, Abraxane®, Celgene) and cabazitaxel (Jevtana®, Sanofi), or others that have 
entered clinical trials (e.g. Tesetaxel®, Opaxio®, Larotaxel®, Taxopresin® (Yared and Tkaczuk, 
2012, Muggia and Kudlowitz, 2014)) (Figure 1). 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of paclitaxel, docetaxel and cabazitaxel. Residues in black boxes differ between paclitaxel 
(R1=H, R2=Ac, R3=Ph), docetaxel (R1=R2=H, R3=O-t-Bu) and cabazitaxel (R1=R2=CH3, R3=O-t-Bu). 
 
These cytotoxic drugs bind with high affinity to the β-tubulin subunit on the inside surface 
of the microtubule leading to microtubule stabilization (Figure 2). This suppresses the 
microtubule dynamics required for accurate chromosome segregation, and results in mitotic arrest 
and finally, cell death through apoptosis (Rowinsky, 1997, Fauzee, 2011). In addition to the 
antimitotic role, taxanes have been shown to exert antiangiogenic effects (Wang et al., 2003, Guo 
et al., 2003) although the exact mechanisms are not well understood. Either as single agents or in 
combination with other chemotherapeutic or targeted agents, taxanes have demonstrated 
significant activity against many solid tumors and are among the standard first-line 
chemotherapeutic treatments (e.g. breast, ovarian, lung, pancreatic and prostate cancer). 
 
3. Paclitaxel 
Paclitaxel, a natural alkaloid derived from the bark of the Taxus Brevifolia (Pacific yew 
conifers), was the first taxane to be isolated and used in the clinic (Wani et al., 1971). It binds to 
a specific pocket in the β-tubulin subunit formed predominantly by hydrophobic residues. This 
binding induces a conformational change in the M-loop that leads to increased lateral interactions 
with H1-S2 loops of neighboring β-tubulin subunits (Nogales et al., 1998, Mitra and Sept, 2008) 
(Figure 2). This results in the inhibition of the normal dynamic reorganization of the microtubule 
network that is essential for vital interphase and mitotic cellular functions, and thus preventing 
proliferation of tumor cells (Schiff et al., 1979, Schiff and Horwitz, 1980, Jordan and Wilson, 
2004).  
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Figure 2. Taxanes binding site. A) Microtubules are made of α-β-tubulin dimers and taxanes bind to β-tubulin subunit 
on the inside surface of the microtubule. B) Paclitaxel binding site. 
 
The clinical use of this microtubule-binding drug is approved by the US Food and Drug 
Administration (FDA) and The European Medicines Agency (EMA) for the treatment of ovarian 
(McGuire et al., 1996), breast (Holmes et al., 1991), non-small-cell lung cancer (Murphy et al., 
1993) and AIDS-related Kaposi’s sarcoma (Fauzee, 2011), while nab-paclitaxel is approved for 
lung (Socinski et al., 2012), breast (Gradishar et al., 2005) and pancreatic cancer (Von Hoff et al., 
2011). Moreover, various studies have also reported antitumor activity against other tumors 
(Rowinsky 1997).  
Paclitaxel is administered intravenously and is largely distributed to all tissues except the 
testes and the central nervous system. Hepatic metabolism followed by biliary excretion is the 
major pathway of paclitaxel elimination (Rowinsky, 1997). The OATP1B3 and OATP1B1 
transporters are in charge of introducing paclitaxel into the hepatocytes (Smith et al., 2005, Gui 
et al., 2008, Nieuweboer et al., 2014, Svoboda et al., 2011, Marada et al., 2015) and there, it is 
metabolized by different cytochromes P450 (CYP2C8, CYP3A4 and CYP3A5) into 6α-
hydroxypaclitaxel, 3'-p-hydroxypaclitaxel and 6α, 3'-p-dihydroxypaclitaxel (Harris et al., 1994, 
Rahman et al., 1994, Sonnichsen et al., 1995). ABCB1, also known as P-glycoprotein, is in charge 
of the efflux transport into the bile canaliculi (Jang et al., 2001).  
 
3.1. Clinical problems associated with paclitaxel treatment 
Paclitaxel has been widely used since its approval in the 1990s as an effective 
antineoplasic agent. Unfortunately, intrinsic or acquired drug resistance and adverse effects are 
relevant clinical problems.  
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3.1.1. Paclitaxel resistance 
Many resistance mechanisms have been described including the up-regulation of the drug 
efflux transporter P-glycoprotein (Gottesman et al., 2002, Orr et al., 2003, Horwitz et al., 1993), 
alterations in the expression of β-tubulin isotypes (Kavallaris et al., 1997, Mozzetti et al., 2005, 
Sève and Dumontet, 2008) or in the microtubule assembly regulatory proteins (Larsson et al., 
1999, Balachandran et al., 2003, Zhang et al., 1998, Zhang et al., 1999), aberrant signal 
transduction pathways (Montgomery et al., 2000, Yu et al., 1998), and changes in proteins such 
as Bcl-2 (Gazitt et al., 1998, Panvichian et al., 1998), survivin (Zhou et al., 2004), TLR4 (Rajput 
et al., 2013), prohibitin1 (Patel et al., 2010) or BubR1 (Hu et al., 2013). In addition, altered 
expression of microRNAs has also been shown to contribute to paclitaxel resistance (Kim et al., 
2014, Cui et al., 2013). 
 
3.1.2. Paclitaxel toxicities 
Many adverse events have been associated with paclitaxel including bradycardia, 
hypotension, mucositis, vomiting, edema or alopecia among others (Rowinsky et al., 1993, 
Suffness, 1995). Nevertheless, the most critical toxicities are: 
 
a) Hypersensitivity reactions: Paclitaxel, due to its poor solubility in water, is marketed 
commercially in a formulation that contains a solvent system of Cremophor and dehydrated 
ethanol. Cremophor has been associated with severe, sometimes fatal, hypersensitivity 
reactions. However, premedication of cancer patients with steroids and antihistamines has 
greatly reduced the risk of such reactions (Gelderblom et al., 2001, Kloover et al., 2004, Weiss 
et al., 1990).  
 
b) Myelosuppression: Hematological toxicity is a common adverse event for many cytotoxic 
drugs. This toxicity derives from their effect on any highly proliferative cells, either tumor 
cells or normal host cells (e.g. bone marrow cells). Neutropenia is the most frequent 
hematological toxicity caused by paclitaxel (Rowinsky et al., 1993). It is dose and schedule 
dependent but not cumulative, suggesting that paclitaxel does not irreversibly affect immature 
hematopoietic cells (Eisenhauer et al., 1994, Perez, 1998). The incidence of neutropenia 
increases when prior myelotoxic therapy is used or when paclitaxel is given in combination 
schedules (Rowinsky et al., 1993, Albain et al., 2008). Fortunately, the implementation of 
granulocyte-colony stimulating factors (G-CSF) and the decrease of paclitaxel infusion times 
(e.g. from 24h to 3h), have diminished the clinical complications of this side effect. 
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c) Neuropathy: This is the current paclitaxel dose-limiting toxicity (Rowinsky et al., 1993). 
The incidence and severity of the neuropathic manifestations are related to the drug schedule 
and the cumulative dose (Postma et al., 1995, Argyriou et al., 2008). Paclitaxel affects 
predominantly large sensory nerves causing sensory symptoms although motor alterations can 
also be observed (Mielke et al., 2006, Scripture et al., 2006). Paclitaxel dose reductions and 
treatment discontinuations as a consequence of the neuropathy are common, and can 
compromise treatment success. Regarding the duration of the symptoms, in most patients they 
disappear months after finishing the treatment, but in severe cases the nerve damage can be 
irreversible affecting permanently the patients’ quality of life (Lipton et al., 1989). In addition, 
the lack of an effective preventive or symptomatic treatment (Wolf et al., 2008) makes 
neuropathy the most relevant toxicity of paclitaxel. 
 
4. Peripheral neuropathy 
The peripheral nervous system is a network of nerves that connect the brain and the spinal 
cord (the central nervous system) to the entire human body. These nerves control sensation, 
movement, motor coordination and involuntary functions. Peripheral neuropathy develops as a 
result of damage to these nerves. The incidence of peripheral neuropathy in the population has 
been estimated between 2% and 8% (Martyn and Hughes, 1997). The damage or dysfunction can 
affect the neuron cell body “neuronopathy”, the axons “axonopathy”, the myelin sheath 
“myelinopathy” or the neuromuscular junctions. Neuropathy can involve one nerve 
(mononeuropathy), two or more nerves in separate areas (multiple mononeuropathy) or many 
peripheral nerves in a generalized and homogenous manner (polyneuropathy), and it can affect 
different types of nerves (e.g. sensory or motor) (England and Asbury, 2004, Chamberlin and 
Narins, 2005). Peripheral neuropathy can be divided into: a) hereditary neuropathy, when it is 
caused by genetic defects (e.g. Charcot-Marie-Tooth disease); b) acquired neuropathy, when it is 
caused by environmental factors such as toxins, drugs, trauma, illness, dysmetabolic states or 
infection (e.g. diabetes, alcoholism, chemotherapy, AIDS) and c) idiopathic neuropathy, when 
the causes are not known (Barohn and Amato, 2013, Martyn and Hughes, 1997).  
 
4.1. Hereditary peripheral neuropathy 
Charcot-Marie-Tooth (CMT) diseases comprise a genetically heterogeneous group of 
disorders. The majority of CMT are transmitted in a monogenic (dominant, recessive, or X-
linked), highly penetrant mode and are one of the most common inherited disorders in humans, 
with an estimated prevalence of one case per 2,500 individuals (Skre, 1974).  
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CMT is characterized by a progressive and length-dependent degeneration of the 
peripheral nerves resulting in muscle weakness and wasting in distal limbs, feet and hands, 
sensory loss, decreased reflexes and foot deformities (Rossor et al., 2015, Klein et al., 2013). 
Approximately 80 genes representing key elements in biological mechanisms have been reported 
to cause CMT (Timmerman et al., 2014). 
 
4.2. Chemotherapy-induced peripheral neuropathy 
Chemotherapy-induced peripheral neuropathy (CIPN) is a type of acquired neuropathy, 
and is a major side effect of many commonly used chemotherapeutic agents (e.g. platinum drugs, 
taxanes, epothilones, vinca alkaloids, thalidomide, bortezomib) (Quasthoff and Hartung, 2002, 
Gutiérrez-Gutiérrez et al., 2010, Miltenburg and Boogerd, 2014). It is estimated to affect a high 
percentage of cancer treated patients (ranging from 12 to 96% depending on the drug), some of 
which will have dose reductions or treatment discontinuation, which can compromise drug 
efficacy (Speck et al., 2013, Bhatnagar et al., 2014). In addition, CIPN can lead to permanent 
symptoms and disabilities (Seretny et al., 2014) negatively altering daily life activities, in some 
cases greatly compromising the quality of life of the survivor (Ezendam et al., 2014). Nowadays 
with millions of cancer survivors worldwide, it is critical to prevent and to have effective 
treatments against CIPN.  
 
4.2.1. Chemotherapy-induced peripheral neuropathy symptoms and diagnosis 
In patients with CIPN, sensory nerves are commonly affected leading to paresthesia 
(abnormal sensation such as tingling, pricking, itching or burning), dysesthesia (unpleasant 
abnormal sensation such as hyperalgesia or allodynia), numbness and pain. The early symptoms 
usually affect the tips of the toes and/or fingers and progress with a “glove and stocking” 
distribution (Figure 3). Sensory loss in feet and legs can cause sensory ataxia and gait disorders. 
Moreover, motor and autonomic symptoms can also happen (Park et al., 2013b, Quasthoff and 
Hartung, 2002, Grisold et al., 2012).  
Figure 3. Sensory neurons and peripheral neuropathy. A) Representation of the parts of a sensory neuron. B) Glove 
and stocking distribution of peripheral neuropathy. 
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There is no gold standard to assess CIPN and therefore, the studies on CIPN are based on 
descriptions of this toxicity in medical records, clinical examinations of the patients or patient-
reported outcomes. Neurologists usually evaluate sensory perception (touch, vibration, and 
proprioception), coordination and deep tendon reflexes. Instrumental examinations including 
electromyography, nerve conduction studies and nerve biopsies are less frequently used in the 
diagnosis due to the limited usefulness in detecting early signs and the discomfort produced in 
patients (Cavaletti et al., 2010, Park et al., 2013b).  
Several grading scales are utilized to evaluate CIPN severity. However, when the scales 
include subjective items, they often lead to inter-observer inconsistencies (Postma et al., 1998) or 
to under-estimation and under-reporting of the neuropathy grade compared to patient self-reports 
(Fromme et al., 2004, Basch et al., 2006). Owing to these issues, scales based on clinical and 
instrumental examination, and patients’ questionnaires have been developed to improve the 
accuracy, reliability and effectiveness of neuropathy assessment. 
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-
CTCAE) (Trotti et al., 2003) and the Total Neuropathy Score (TNS) (Cornblath et al., 1999, 
Cavaletti et al., 2003) are among the most common clinical grading scales used (Table 1). Other 
scales such as the World Health Organization Scale (Miller et al., 1981), Eastern Cooperative 
Oncology Group Scale (Oken et al., 1982), Ajani Scale (Ajani et al., 1990) are also used. 
Moreover, drug specific scales as the Functional Assessment of Cancer Therapy-Taxane (Cella 
et al., 2003) or the Oxaliplatin-associated neuropathy questionnaire (Leonard et al., 2005) have 
been developed. 
In cancer patients, the most frequently used scale is the NCI-CTCAE, which includes 
neurosensory and neuromotor parameters. It is fast and easy to perform, however, it results in 
moderate inter-observer disagreement (45 to 81% of agreement between clinicians), although 
training the observers has been demonstrated to increase accuracy (Postma et al., 1998, Cavaletti 
et al., 2013). Regarding TNS, it combines symptom scores with objective measurements of 
sensory loss and neurophysiological parameters and it has been shown to be more sensitive and 
precise to detect neuropathy changes during chemotherapy than the NCI-CTCAE scale (Cavaletti 
et al., 2006, Cavaletti et al., 2007, Frigeni et al., 2011, Chaudhry et al., 2008). The development 
of faster and simpler versions of the TNS, such as the TNS clinical, based on clinical items (e.g. 
tendon reflexes, vibration perception) or the TNS reduced, without quantitative sensory testing, 
provides with additional resources for CIPN evaluation (Cavaletti et al., 2003, Cavaletti et al., 
2007). Despite the accuracy of the TNS, it is commonly perceived as complicated to perform in 
a routinely cancer consultation because it requires specific instrumentation to perform the clinical 
examination and because it is time consuming.  
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At any rate, it is relevant to highlight that many studies assessing the presence and severity 
of CIPN with different scales have showed a good correlation between TNS and NCI-CTCAE 
(Cavaletti et al., 2003, Cavaletti et al., 2006, Cavaletti et al., 2013). 
Recently, patient-reported toxicities have shown to detect higher neuropathy grades and 
at an earlier onset than those reported by clinicians (Sasane et al., 2010, Cirillo et al., 2009, Di 
Maio et al., 2016). This strongly supports the incorporation of patient-reported outcomes into 
toxicity reporting. Among the patient self-reported questionnaires, we can find the European 
Organization for Research and Treatment of Cancer QTQ-CIPN20 questionnaire (Postma et al., 
2005), the Functional Assessment of Cancer/Gynecologic Oncology Group-Neurotoxicity 
questionnaire (Calhoun et al., 2003) and the Patient Neurotoxicity Questionnaire (Hausheer et al., 
2006).  
Numerous initiatives are underway to identify the best approach to measure CIPN. 
Meanwhile, available data suggests that appropriate, standardized, and objective assessment tools 
joined with patient-reported symptoms would be needed to accurately assess CIPN.  
 
4.2.2. Chemotherapy-induced peripheral neuropathy prevention and treatment 
Another relevant factor regarding CIPN is the lack of neuroprotective and effective 
treatment despite the many trials performed with different drugs. Nowadays no agent can prevent 
CIPN and only few drugs are recommended to decrease pain and sensory symptoms (e.g. 
duloxetine or tricyclic antidepressants) (Hershman et al., 2014, Piccolo and Kolesar, 2014). Thus, 
the most successful approaches to prevent CIPN are dose modifications or treatment interruption. 
The understanding of the mechanisms by which chemotherapy drugs cause neuropathy will allow 
to developing neuroprotective strategies and valid treatments. 
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Table 1. Most common neuropathy grading scales used in the clinics 
 
 
 
 
 
 
 
 
In CTCAE, grade 5 is death. ADL= Activities of daily life; QST= Quantitative Sensory Test; ULN= Upper Limit of Normal; LLN= Lower Limit of Normal. Activities of daily living are basic 
tasks of everyday life (i.e. walking, eating, bathing) whereas instrumental activities of daily living capture a wide range of more complex activities (i.e. cooking, driving, shopping). 
* TNS has a total of 10 items each rated on a scale of 0-4, where 0 is normal and 4 is most severe, yielding a total possible score of 0-40. A higher total score indicates a more severe neuropathy. 
Scale Parameter Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Common 
Terminology 
Criteria for 
Adverse Events 
(CTCAE) v4.0 
Motor symptoms None 
Asymptomatic; clinical or 
diagnostic observations 
only; intervention not 
indicated 
Moderate symptoms; 
limiting instrumental ADL 
Severe symptoms; limiting 
self-care ADL; assistive 
device indicated 
Life-threatening consequences; 
urgent intervention indicated 
Sensory symptoms None 
Asymptomatic; loss of 
deep tendon reflexes or 
paresthesia 
Moderate symptoms; 
limiting instrumental ADL 
Severe symptoms; limiting 
self-care ADL 
Life-threatening consequences; 
urgent intervention indicated 
Scale Parameter Score 0 Score 1 Score 2 Score 3 Score 4 
Total 
Neuropathy 
Score (TNS)* 
Sensory symptoms None 
Symptoms limited to 
finger or toes 
Symptoms extend to ankle 
or wrist 
Symptoms extend to knee or 
elbow 
Symptoms above knees or 
elbows, or functionally 
disabling 
Motor symptoms None Slight difficulty Moderate difficulty Requires help/assistance Paralysis 
Autonomics 
symptoms 
0 1 2 3 4 o 5 
Pin sensibility Normal Reduced in finger/toes Reduced up to wrist/ankle Reduced up to elbow/knee Reduced above elbow/knee 
Vibration sensibility Normal Reduced in finger/toes Reduced up to wrist/ankle Reduced up to elbow/knee Reduced above elbow/knee 
Strength Normal Mild weakness Moderate weakness Severe weakness Paralysis 
Tendon reflex Normal Ankle reflex reduced Ankle reflex absent 
Ankle reflex absent, others 
reduced 
All reflexes absent 
Vibration sensation 
(QST vibration) 
Normal to 125% 
of ULN 
126-150% of ULN 151-200% of ULN 201-300% of ULN >300% of ULN 
Sural amplitude 
Normal/Reduced 
to <5% of LLN 
76-95% of LLN 51-75% of LLN 26-50% of LLN 0-25% of LLN 
Peroneal amplitude 
Normal/Reduced 
to <5% of LLN 
76-95% of LLN 51-75% of LLN 26-50% of LLN 0-25% of LLN 
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5. Paclitaxel-induced peripheral neuropathy 
In the specific case of paclitaxel, some patients treated with this drug will present a long-
lasting peripheral neuropathy. The incidence of peripheral neuropathy among patients treated with 
paclitaxel can be up to 70%, depending on the dose and schedule, with high grades occurring in 
up to 30% of patients (Rivera and Cianfrocca, 2015, Schneider et al., 2012, Pace et al., 2007). 
Peripheral neuropathy improves in most patients within 3-6 months after cessation of the 
treatment, but symptoms and disability can be permanent in a significant percentage of the 
patients (Tanabe et al., 2013, Scripture et al., 2006, Pignata et al., 2006). 
 
5.1. Paclitaxel-induced peripheral neuropathy pathophysiology 
Paclitaxel-induced peripheral neuropathy has been described as a symmetrical and distal 
sensory neuropathy with less prominent motor involvement. Reduction in motor skills and 
walking ability may occur in severe cases. Sensory symptoms include numbness, tingling and 
pain. There is also loss of proprioception, vibration, temperature and tendon reflexes (Argyriou 
et al., 2008). This phenomenon begins at the distal nerve endings of the longest nerves and then 
spreads centrally (Cavaletti et al., 1995, Cavaletti et al., 1997). The exact mechanism that 
underlies paclitaxel-induced neuropathy is not known although the inhibition of microtubule 
dynamics disrupting axonal transport is widely accepted (Gornstein and Schwarz, 2014, Cavaletti 
et al., 1995, Cavaletti et al., 1997, Peters et al., 2007). Increased axonal microtubule stability or 
polar reconfiguration (Shemesh and Spira, 2010) following paclitaxel treatment may alter axonal 
transport resulting in abnormal nerve physiology (Nakata and Yorifuji, 1999), and altered 
mitochondrial supply (Park et al., 2013a, Canta et al., 2015), leading to a loss of axonal integrity 
or axonal degeneration. The reason why paclitaxel produces preferentially impairment of sensory 
neurons over motor ones remains unclear (Gornstein and Schwarz, 2014). The morphological 
changes observed in neurons are axonopathy, severe nerve fiber loss, axonal atrophy and 
secondary demyelination with little axonal regeneration (Quasthoff and Hartung, 2002, 
Dougherty et al., 2004). 
An acute pain syndrome has also been found in up to 70% of paclitaxel-treated patients 
(Loprinzi et al., 2011). It is characterized by myalgia or arthralgia that usually develops within 1 
to 3 days of drug infusion and resolves in a week (Rowinsky et al., 1993, Saibil et al., 2010, 
Tofthagen et al., 2013). It is frequently observed with short and high-dose infusions (Moulder et 
al., 2010, Loprinzi et al., 2011) and has been reported to be predictive of sensory neuropathy 
(Reeves et al., 2012). The mechanism underlying this syndrome has been related with a 
sensitization of nociceptors and their fibers by pro-inflammatory cytokines (IL-6, IL-8, IL1β, 
TNF-α) (Loprinzi et al., 2007, Wang et al., 2012). 
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5.2. Paclitaxel-induced peripheral neuropathy risk factors 
Not all patients receiving paclitaxel will develop peripheral neuropathy, and among 
affected patients there is high inter-individual difference in the severity of the toxicity. There are 
many factors that can influence neuropathy risk and severity.  
Regarding treatment type, paclitaxel schedule and cumulative dose have been identified 
as risk factors. Patients with higher doses per cycle (≥250 mg/m2) and higher cumulative doses 
are at greater risk of neuropathy (Postma et al., 1995, Rowinsky et al., 1993). Drug infusion-time 
has also been associated with neuropathy incidence. In this case, shorter infusion times are 
associated with higher neuropathy risk (Moulder et al., 2010, Smith et al., 1999). Concerning the 
combination of paclitaxel with different drugs, the co-administration of paclitaxel with other 
neurotoxic drugs such as cisplatin has consistently been demonstrated to increase the development 
of neuropathy (Chaudhry et al., 1994, Kudlowitz and Muggia, 2013). It is also important to take 
into account that co-administered drugs inhibiting or inducing liver drug metabolizing enzymes 
may alter paclitaxel metabolism and alter the risk to suffer from neuropathy (Badyal and Dadhich, 
2001).  
Patient predisposing factors such as higher age (Tanabe et al., 2013, Chen et al., 2006, 
Akerley et al., 2003), hyperglycemia (Akerley et al., 2003) and non-European origin (Hertz et al., 
2013) have been associated with increased risk of neuropathy. Other conditions such as alcohol 
intake, diabetes, liver disease or previous neuropathy diseases (e.g. Charcot-Marie-Tooth) have 
been described to predispose to paclitaxel-induced neuropathy (Weimer and Podwall, 2006, 
Rowinsky et al., 1993, Lee and Swain, 2006, Chopra and Tiwari, 2012, de la Morena Barrio et 
al., 2015). Moreover, there are increasing amounts of evidence supporting that the patient genetic 
background can influence drug response. In a pharmacogenomic study analyzing 29 commonly 
prescribed cytotoxic drugs in vitro, estimated that a high proportion of the variability observed in 
paclitaxel response was inherited (Peters et al., 2011).  
 
6. Genetic variants associated with paclitaxel-induced peripheral neuropathy 
Genetic polymorphisms are a major source of individual differences in drug response. 
Therefore, the identification of genetic markers of paclitaxel-induced peripheral neuropathy could 
lead to an individualized neuropathy risk assessment and personalization of the treatment. As a 
result, many efforts have been done to accomplish this goal. 
 
6.1. Genotyping-based strategies  
Genotyping is performed to determine the genetic makeup of an individual (genotype), 
by examining the DNA sequence at a specific position and comparing it to a reference DNA 
sequence (Shi et al., 1999).   
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Genotyping methods can be carried out to evaluate a single variant (e.g. through gel 
electrophoresis-based or fluorescent dye-based techniques) or they can be applied simultaneously 
to hundreds of thousands of variants (e.g. through high-throughput technologies based on high-
density oligonucleotide SNP arrays). 
 
6.1.1. Genotyping-based candidate gene approaches  
Increased susceptibility to neuropathy can be caused by an alteration in the drug 
pharmacokinetic (drug absorption, distribution, metabolism and excretion) and/ or 
pharmacodynamic pathways (drug targets and mechanisms of drug action) (Pirmohamed and 
Park, 2001). Thus, several studies have studied common polymorphisms in genes encoding 
paclitaxel metabolizing enzymes (CYP2C8, CYP3A4 and CYP3A5), paclitaxel transporters 
(SLCO1B3, SLCO1B1 and ABCB1) and paclitaxel targets (tubulins and microtubule-associated 
proteins) in relation with the drug neuropathy.  
CYP2C8 
CYP2C8 is the major enzyme metabolizing paclitaxel to 6α-hydroxypaclitaxel, a process 
that occurs in the liver (Rahman et al., 1994, Sonnichsen et al., 1995). Coding polymorphisms in 
CYP2C8 include CYP2C8*2, CYP2C8*3 (rs11572080 plus rs10509681), CYP2C8*4 and 
CYP2C8*6 alleles, among others. CYP2C8*3 allele, with a frequency of 12% in the Caucasian 
population, encodes for a protein with Arg139Lys and Lys399Arg substitutions. Several in vitro 
studies have found that CYP2C8*3 exhibits an altered activity in the metabolism of several drugs 
(Dai et al., 2001, Soyama et al., 2001, Rowbotham et al., 2010, Bahadur et al., 2002), including 
paclitaxel (Dai et al., 2001). In addition, Gréen et al and Bergmann et al found that patients 
heterozygous for CYP2C8*3 had lower clearance of paclitaxel compared to patients homozygous 
for CYP2C8*1 (wild type) (Gréen et al., 2009, Bergmann et al., 2011a), although another 
pharmacokinetics study did not detect an effect (Henningsson et al., 2005). Leskela et al and Hertz 
et al found that CYP2C8*3 allele was associated with a high risk of neuropathy by analyzing the 
accumulated paclitaxel dose causing a grade 2 or higher neuropathy (HR=1.72, P=0.032; n=118 
patients) and (HR=1.93, P=0.006, n=209 Europeans, and P=0.043, n=107 African-Americans) 
(Leskelä et al., 2011, Hertz et al., 2013). The association was replicated in two independent studies 
(n=412, HR=1.72 (Hertz et al., 2014) and n=119, OR=1.49 (Boora et al., 2016)). However, other 
groups did not find an association (Abraham et al., 2014, Marsh et al., 2007, Baldwin et al., 2012, 
Ofverholm et al., 2010, Bergmann et al., 2011b, Rizzo et al., 2010). Potential factors that could 
account for these differences include: differences in neuropathy grade assessments, sample size, 
paclitaxel regimens and ethnicity. At any rate, an in depth characterization of CYP2C8*3 allele 
on paclitaxel metabolism and toxicity remains to be performed.  
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Additional variants with decreased in vitro enzyme activity have been described (e.g. 
CYP2C8*2 (Dai et al., 2001) and CYP2C8*4 (Singh et al., 2008)).  
One study found an association for CYP2C8*4 allele (rs1058930, Ile264Met) with 
neuropathy (HR= 1.38, 95%CI=1.03–1.86, P=0.04 (Abraham et al., 2014)) and this is supported 
by a CYP2C8.4 decreased paclitaxel metabolism detected in bacteria models  (Singh et al., 2008) 
and in patients (18% lower mean clearance; (Bergmann et al., 2011a)). However, the association 
between CYP2C8*4 and paclitaxel neuropathy has not been replicated in other studies (Hertz et 
al., 2014, Leskelä et al., 2011, Henningsson et al., 2005, Baldwin et al., 2012, Marsh et al., 2007, 
Rizzo et al., 2010). CYP2C8 haplotypes B and C with frequencies of 24 and 22% in Caucasians 
were associated with a significantly increased and reduced paclitaxel metabolism, respectively, 
in human liver samples (Rodríguez-Antona et al., 2008). Leskela et al detected an association 
between CYP2C8 haplotype C (rs1113129) with neuropathy protection (HR=0.55, 95%CI=0.34–
0.89, P=0.014, (Leskelä et al., 2011)) but follow up studies could not confirm this association 
(Abraham et al., 2014, Baldwin et al., 2012).  
CYP3A4 
CYP3A4 is another major paclitaxel metabolizing enzyme, and it catalyzes the 3’-p-
hydroxylation of the drug (Harris et al., 1994, Sonnichsen et al., 1995). It is encoded by a highly 
conserved gene. Unlike other cytochrome P450 enzymes, and despite the fact that it is suggested 
that up to 90% of CYP3A4 activity variability would have a genetic basis, no common coding 
polymorphisms have been described to date (Ozdemir et al., 2000, Lamba et al., 2002, Rahmioglu 
et al., 2011). Genetic databases include many coding variants in CYP3A4 but they all have a low 
frequency, there are rare premature stop codons producing truncated proteins (e.g. CYP3A4*6, 
CYP3A4*20 (Westlind-Johnsson et al., 2006) and CYP3A4*26 (Werk et al., 2014)) and missense 
variants, some of them conferring reduced CYP3A4 activity (e.g. CYP3A4*8).  
The most common CYP3A4 variant alleles proposed to have functional consequences are 
two noncoding SNPs with an allelic frequency of approximately 5% in the Caucasian population 
(CYP3A4*1B and CYP3A4*22). CYP3A4*1B is located in CYP3A4 promoter (rs2740574, -
392A>G) and carriers of this allele have been associated with lower enzymatic activity compared 
to those with CYP3A4*1 (wild type) (Rodríguez-Antona et al., 2005), but other studies did not 
detect an effect (Lamba et al., 2002, Ball et al., 1999). Concerning paclitaxel-induced neuropathy, 
only a trend towards higher risk of neuropathy has described for the variant allele in one study 
(P=0.057 (Leskelä et al., 2011)) (Marsh et al., 2007, Gréen et al., 2008, Bergmann et al., 2012, 
Ofverholm et al., 2010, Lambrechts et al., 2015, Abraham et al., 2014). CYP3A4*22 is located in 
intron 6 (rs35599367, C15389T) and it was first described to affect hepatic CYP3A4 expression 
and response to statin drugs (Wang et al., 2011).  
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The variant allele was associated with reduced mRNA levels when compared to wild type 
allele, accounting for around 10% of the variability observed in CYP3A4 mRNA expression and 
lower doses of statins and immunosuppressants were suggested for CYP3A4*22 carriers 
compared to CYP3A4 wild type individuals (Elens et al., 2011b, Elens et al., 2011c, Elens et al., 
2011a). Graan et al studied the role of CYP3A4*22 in paclitaxel-induced neuropathy finding that 
variant carriers had an increased risk of developing neurotoxicity and validated the findings in an 
independent series (P=0.043, n=262 and P=0.036, n=239; for combined analysis HR= 22.1, 
95%CI=4.7-105, P<0.001) (de Graan et al., 2013).  
CYP3A5 
CYP3A5 has similar substrate specificity than CYP3A4 (Williams et al., 2002, Zanger 
and Schwab, 2013). Unlike CYP3A4, CYP3A5 gene is very polymorphic and its activity in 
Caucasians is determined by CYP3A5*3 allele (rs776746, G6986A) (Kuehl et al., 2001). 
CYP3A5*3 introduces a splicing site in intron 3 resulting in an alternative spliced mRNA that 
encodes a nonfunctional truncated protein. As a consequence, homozygosity for the CYP3A5*3 
allele results in undetectable enzyme activity whereas the presence of the CYP3A5*1 allele in an 
individual is associated with high levels of functional protein. Leskela et al found that CYP3A5*3 
was associated with paclitaxel-induced neuropathy protection (OR=0.51, 95%CI=0.30–0.86, 
P=0.012, n=118, (Leskelä et al., 2011)), but others did not confirm the association (Bergmann et 
al., 2012, Lambrechts et al., 2015, Marsh et al., 2007, Abraham et al., 2014). 
SLCO1B3 and SLCO1B1 
Regarding the genes encoding for the transporters that introduce paclitaxel into the 
hepatocytes (i.e. OATP1B3 and OATP1B1), researchers studied missense SNPs with reported 
functional consequences: rs4149056 (p.V174A) in SLCO1B1, and rs4149117 and rs7311358 
(p.S112A and p.M233I, respectively) in SLCO1B3. However, no significant association for these 
SNPs has been detected when studying in vitro paclitaxel disposition (Smith et al., 2007) nor with 
paclitaxel-induced neuropathy in patients (Leskelä et al., 2011, Lambrechts et al., 2015). 
Conversely, the SNP rs3829306 in SLCO1B1 was significantly associated with neuropathy risk 
in one study (Leandro-García et al., 2013) but with protection in another (Abraham et al., 2014). 
ABCB1 
In ABCB1, the main protein mediating paclitaxel elimination through efflux transport into 
the bile canaliculi, three coding variants: rs2032582 (p.A893S), rs1128503 (p.G412G) and 
rs1045642 (p.I1145I), have been associated with altered drug transport (Leschziner et al., 2007); 
and a common missense polymorphism (rs9282564, p.N21D) has also been described (Chang et 
al., 2009).  
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Concerning paclitaxel pharmacokinetics, Gréen et al found that patients heterozygous for 
rs2032582 variant had a significantly higher clearance of paclitaxel than wild-type patients (Gréen 
et al., 2009). Henningsson et al studied rs1045642 but did not detect any association with 
paclitaxel pharmacokinetics (Henningsson et al., 2005). Regarding paclitaxel-induced 
neuropathy, rs2032582 allele has been associated with neuropathy risk in a large series of patients 
(HR=1.19, P=0.02, n=1303 (Abraham et al., 2014)) and rs1045642 allele with decreased risk of 
neuropathy (HR=0.71-0.83, (Leskelä et al., 2011, Gréen et al., 2008, Abraham et al., 2014)). 
In contrast, other groups have shown that rs1128503, rs2032582 or rs1045642 alleles did 
not correlate with the occurrence of neurotoxicity in their series of patients (Bergmann et al., 
2012, Bergmann et al., 2011b, Ofverholm et al., 2010, Lambrechts et al., 2015, Rizzo et al., 2010, 
Marsh et al., 2007). Additionally, a polymorphism located in the 5'UTR of ABCB1 (rs3213619) 
has been associated with protection against neuropathy (OR=0.12-0.51, (Leskelä et al., 2011, 
Abraham et al., 2014, Boora et al., 2016)).  
Pharmacodynamic genes 
In addition, variants in genes encoding paclitaxel target (β-tubulin) and microtubule 
related proteins have also been studied. Indeed, it has been found that paclitaxel-induced 
neuropathy has a heritable component driven in part by genes involved in axon outgrowth 
(Chhibber et al., 2014).  
As the cytotoxic effect of paclitaxel requires β-tubulin binding, genetic variants in β-
tubulin genes may influence neuropathy susceptibility. All β-tubulins, except for the hematologic-
specific β-tubulin VI (Leandro-García et al., 2012a), are highly conserved genes that lack 
polymorphisms leading to amino acid changes. However, variability in the expression of β-tubulin 
isotypes due to regulatory polymorphisms has been shown. Our group identified three 
polymorphisms located at -101 (rs909964), -112 (rs909965), and -157 (rs9501929) in the 
promoter of β-tubulin IIa gene (TUBB2A) that correlated with increased mRNA levels. The 
rs909964 and rs909965 variants, in total linkage disequilibrium, protected from paclitaxel-
induced peripheral neuropathy (HR=0.62, 95%CI=0.42-0.93, P=0.021 in multivariable analysis). 
This was further supported by the finding that higher TUBB2A gene expression correlated with 
lower levels of paclitaxel-induced apoptosis (P=0.001) in lymphoblastoid cell lines, leading to 
decreased paclitaxel sensitivity (Leandro-García et al., 2012b). Although Leandro-García et al 
did not find an association for rs9501929 allele, Abraham et al did detect it (OR=1.80; 
95%CI=1.20–2.72; P=0.005) (Abraham et al., 2014). 
Not only β-tubulins but also proteins such as microtubule-associated protein tau (MAPT) 
(Myers et al., 2007) or tau-related protein glycogen synthase kinase-3β (GSK3β) (Lovestone et 
al., 1994) are critical for microtubule function.  
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Given the possible role of microtubule dysfunction in neurotoxicity, Park and colleagues 
investigated the effects of genetic variation in MAPT and GSK3B on neurotoxicity in paclitaxel-
treated patients. They found a significant association between polymorphism rs6438552 in 
GSK3B and paclitaxel-induced neurotoxicity. The variant allele was associated with reduced 
neurotoxicity severity (P≤0.05) and increased tau phosphorylation, which resulted in a reduction 
of microtubule stabilization which may be beneficial to axonal integrity and thus protecting 
against neuropathy (Park et al., 2014). Lambrechts et al also studied SNPs in genes related to 
paclitaxel pharmacodynamics (e.g., MAPT, tubulins) in 322 patients treated with first-line 
paclitaxel-carboplatin but no association with neuropathy was found (Lambrechts et al., 2015).  
 
6.1.2. Genotyping-based genome-wide approaches 
With the progress of genotyping technology, genome-wide association studies (GWAS) 
have evolved into efficient and effective tools for mapping genes underlying human phenotypes. 
This approach allows genotyping simultaneously thousands of SNPs across the whole genome. 
Although successful candidate gene studies have been performed in pharmacogenetics, they 
cannot identify genes outside our current knowledge. GWAS allow such novel discovery in an 
unbiased way (Motsinger-Reif et al., 2013).  
Recent studies have demonstrated the utility of the GWAS approach for studying 
pharmacogenomic traits, including paclitaxel-induced neuropathy. The first CIPN GWAS 
included 855 subjects of European ancestry and the neuropathy was analyzed using both the 
cumulative dose analysis and the maximum peripheral neuropathy grade observed during 
treatment. They found a SNP in FGD4 associated with the onset of sensory peripheral neuropathy 
in the discovery cohort (rs10771973; HR=1.57, 95%CI=1.30-1.91, P=2.6 x 10-6) and was 
replicated in additional 154 Europeans (HR=1.72, 95%CI=1.06-2.80, P=0.013) and 117 African 
Americans (HR=1.93, 95% CI=1.13-3.28, P=6.7 x 10-3). There was also evidence of association 
with the onset or severity of paclitaxel-induced sensory for EPHA5 (rs7349683, HR=1.63, 
95%CI=1.34-1.98, P=9.6 x 10-7) and FZD3 genes ((rs7001034; OR=0.57, 95%CI=0.48-0.69, 
P=3.1x10-9). All these genes encode proteins that have been related with neuronal processes or 
diseases. FGD4 is involved in the regulation of actin cytoskeleton and cell shape, and mutations 
in the gen have been associated with Charcot-Marie-Tooth disease. EPHA5 is an ephrin receptor 
which plays crucial roles in several neuronal processes, and FZD3 has been associated with 
psychosis and congenital hydrocephalus (Baldwin et al., 2012). 
In our group, a GWAS was performed with 144 white European patients treated with 
paclitaxel/ carboplatin and using the cumulative dose of paclitaxel up to the development of grade 
2 sensory neuropathy.  
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We found a strong evidence of association for a gene encoding EPHA4 locus 
(rs17348202, P=1.0x10-6). Moreover, EPHA6 and EPHA5 were among the top hits (rs301927, 
P=3.4x10-5 and rs1159057, P=6.8x10-5, respectively). A meta-analysis performed for EPHA5-
rs7349683, the top marker for paclitaxel-induced neuropathy in Baldwin et al GWAS (in high 
linkage disequilibrium with rs1159057), was significant at genome wide level (HR=1.68, 
95%CI=1.42-1.99, P=1.4x10-9). This study provides independent confirmation of EPHA5-
rs7349683 and identifies for the first time, in an unbiased manner, a marker of risk of paclitaxel-
induced neuropathy with genome-wide significance. It also suggests that other EPHA genes may 
play an important role in the development of this toxicity (Leandro-García et al., 2013). Recently, 
Boora et al also were also able to replicate the association of EPHA5 in a genotyping study 
including 119 paclitaxel-treated patients (OR=2.07, P=0.02) (Boora et al., 2016). 
Another GWAS was conducted with 2,204 patients treated with paclitaxel with the aim 
of identifying SNPs associated with time to the first report of grade 2 to 4 neuropathy. Significant 
associations were found for RWDD3 gene (rs2296308) and TECTA gene (rs1829), both associated 
with increased risk of neuropathy (HR=1.5; P=8.5 ×10-8 and HR=2.1; P=3.2×10-7, respectively) 
(Schneider et al., 2011). However, another group failed to replicate these associations, and 
unexpectedly homozygous carriers of the variant allele in TECTA suggested protection rather than 
susceptibility to neuropathy (Bergmann et al., 2013). These contradictory results suggest 
important differences among the studies (e.g. different methodologies in the assessment of 
neuropathy or the use of paclitaxel alone versus paclitaxel plus carboplatin regimens). 
 
6.2. Next Generation Sequencing  
NGS has revolutionized the field of human genetics for both Mendelian disorders and 
complex traits (Ng et al., 2010, Panoutsopoulou et al., 2013). Nowadays, NGS is a feasible and 
cost-effective tool that allows the detection of both common variants and low-frequency/ rare 
variants associated with diseases (Cirulli and Goldstein, 2010, Shendure and Ji, 2008, Shendure, 
2011).  
 
6.2.1. NGS–based candidate gene approaches 
NGS can be used to perform candidate gene approaches by enrichment of a set of genes/ 
regions and exclusively performing sequencing in them. During the last part of the Thesis we 
adopted this technology to investigate candidate genes associated with paclitaxel-induced 
neuropathy. In addition to previously suggested candidates, we hypothesized that CMT genes 
may harbor non-pathogenic genetic variants that, while not being pathogenic, may predispose to 
acquired forms of polyneuropathies such as those caused by chemotherapeutic agents. 
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While performing this last project, Beutler et al published a study sequencing 49 CMT 
genes in 119 patients with different phenotype distribution (patients with high neuropathy vs. 
no/mild neuropathy). They identified an overrepresentation of rare non-synonymous coding 
variants in periaxin gene (PRX) in patients with high neuropathy but not in controls (P=8x10-3), 
and showed that ARHGEF10, encoding rho guanine nucleotide exchange factor 10, was 
associated with paclitaxel-induced neuropathy (P=5x10-4) due to the contribution of three 
common SNPs (i.e. rs9657362, rs2294039, and rs17683288). Of them, rs9657362 had the 
strongest effect (OR=4.8, P=4x10-4). Interestingly, the majority of the rare variants identified in 
PRX were in exon 7, where the majority of known CMT mutations are found. In another study by 
the same group, they validate the association of ARHGEF10 with paclitaxel-induced neuropathy 
(P=0.024). As in the original study, the strongest association was seen for rs9657362 (OR=3.56, 
P=0.018).  
Thus, only one NGS study, focused exclusively on CMT, has been published. However, 
the most relevant genes identified so far in relation with paclitaxel-induced neuropathy remained 
unexplored with this technique. 
 
6.2.2. NGS-based genome-wide approaches 
NGS offers the possibility to study not only candidate genes but also to sequence the 
entire genome (whole genome sequencing, WGS) or all protein coding genes (whole exome 
sequencing, WES). However, previous to this Thesis no article had used WGS or WES in relation 
with drug-induced neuropathy.  
 
6.3. Summary of genetic variants associated with CIPN 
Several markers have been associated with paclitaxel-induced peripheral neuropathy; 
however, the evidences supporting these associations vary and there are also contradictory results. 
Possible explanations for the discrepancies among studies and the lack of replication for the 
majority of the neuropathy markers identified so far include: inadequate sample sizes, dissimilar 
scales and methods used to assess neuropathy, and non-homogenous treatment regimens across 
cohorts. Moreover, only common polymorphisms have been studied so far and the role of low-
frequency variants in the susceptibility to suffer from neuropathy has not been explored, except 
for one study in which only CMT genes were sequenced (Beutler et al., 2014). 
Currently, the most consistent associations with paclitaxel-induced neuropathy 
correspond to CYP2C8*3 and EPHA5, based on evidences from several studies (Leskelä et al., 
2011, Hertz et al., 2013, Baldwin et al., 2012, Leandro-García et al., 2013), (Hertz et al., 2014, 
Boora et al., 2016) (Figure 4).  
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Therefore, further investigation is needed to identify reliable markers contributing to 
paclitaxel-induced peripheral neuropathy. This would aid in the development of personalized 
paclitaxel treatments reducing severe cases of neuropathy.  
 
 
In this Thesis we have identified and characterized genetic markers predictive of 
paclitaxel-induced peripheral neuropathy, using a variety of approaches: genotyping, whole 
exome sequencing and targeted next generation sequencing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Paclitaxel pharmacokinetics and pharmacodynamics. 6α-OH PAC, 3’-p-OH PAC and 6α,3’-p-diOH PAC 
represent 6α-hydroxypaclitaxel, 3′-hydroxypaclitaxel and 6α-p-3'-dihydroxypaclitaxel paclitaxel metabolites.  
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Although it has been proposed that there is a strong genetic component underlying the 
inter-individual variability in paclitaxel-induced neuropathy, currently, there are no markers used 
in the clinic that can identify, prior to the treatment, those patients with a high risk of this toxicity. 
Therefore, the main goal of this Thesis was to identify genetic markers predictive of peripheral 
neuropathy caused by paclitaxel, with the overall aim to provide with critical data that can help 
improve cancer therapy. The specific objectives of this Thesis are: 
 
1) To explore the association of common single nucleotide polymorphisms, previously 
proposed by our group, as predictive markers of paclitaxel-induced neuropathy. 
Specifically, to study in depth CYP2C8*3 variant and top signals identified in genome 
wide association studies (GWAS). 
 
2) To identify novel low frequency genetic markers associated with increased susceptibility 
of paclitaxel-induced peripheral neuropathy. For this purpose we will apply whole exome 
sequencing and targeted next generation sequencing using highly informative selected 
series of patients. In addition, we will characterize the functional impact and world-wide 
distribution of the newly identified genetic variants. 
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ARTICLE 1: Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism 
and paclitaxel-induced neurotoxicity. 
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Published in Pharmacogenomics. 2015;16(9):929-37 
 
Abstract:  
Chemotherapy-induced peripheral neuropathy is an important clinical problem. Several 
anticancer drugs such as taxanes cause a severe and disabling neuropathy in a high proportion of 
patients. Therefore, the identification and validation of markers predictive of this neuropathy are 
an urgent need. The genetic background has been suggested to account for a high percentage of 
the inter-individual variability observed in neuropathy risk among paclitaxel-treated patients. 
Previous studies have identified polymorphisms in genes encoding paclitaxel metabolizing 
enzymes (CYP3A4 and CYP2C8) as risk markers of the neuropathy.  
CYP2C8*3, a frequent allele in the Caucasian population that encodes for a protein with 
two amino acid substitutions (p.R139K, p.K399R), has been suggested to be associated with 
paclitaxel neuropathy. However, there is contradictory data in the literature regarding the effect 
of CYP2C8*3 on the metabolism of different substrates, in vitro and in vivo. We conducted a 
study in collaboration with Prof. Ingelman-Sundberg group at Karolinska Instituted to elucidate 
the implication of CYP2C8*3 in paclitaxel metabolism by using a heterologous human cell 
expression system (HEK293 cells). To investigate the association of this variant with paclitaxel-
induced neuropathy we used a large cohort of well-characterized cancer patients treated with this 
drug.  
Concerning paclitaxel metabolism, CYP2C8.3 had a similar catalytic activity as CYP2C8 
wild type when they were expressed in HEK293 cells for paclitaxel substrate. 
Regarding in vivo data, we did not find a significant association between CYP2C8*3 allele 
and maximum neuropathy grade in a cohort of 343 patients. However, a trend was observed when 
using the accumulated paclitaxel dose up to the development of grade 2 neuropathy, data available 
for 148 patients.  
In conclusion, these results suggest that CYP2C8*3 allele does not have a strong effect 
on paclitaxel metabolism in vitro neither on paclitaxel-induced neuropathy in vivo. Thus, 
CYP2C8*3 genotyping is expected to have limited clinical utility to identify patients at risk of 
developing paclitaxel-induced neuropathy.  
Article 1 
62 
 
Personal contribution: I extracted DNA from the blood samples of the Spanish patients, 
performed CYP2C8*3 genotyping and statistical analyses regarding in vivo data (logistic 
regression and Cox regression models). I contributed to the discussion of the results and helped 
drafting the paper. 
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Aim: The CYP2C8*3 allele has been suggested as a risk factor for paclitaxel-induced 
neuropathy but the data hitherto published are conflicting. Materials & methods: 
In total 435 patients were investigated with respect to maximum neuropathy grade 
and accumulated paclitaxel dose. The enzymatic properties of CYP2C8.3 variant were 
analyzed using heterologous mammalian HEK293 cell expression system. Results: No 
significant association between CYP2C8*3 allele and neuropathy was found, although 
a trend was observed. The paclitaxel and amodiaquine metabolism by CYP2C8.3 were 
found similar to CYP2C8.1, whereas CYP2C8.3 was more efficient in the metabolism 
of rosiglitazone. Conclusion: These results indicate a difference in substrate specificity 
between CYP2C8.1 and CYP2C8.3; however, the CYP2C8*3 allele has no major impact 
on paclitaxel metabolism in vitro or of paclitaxel-induced neuropathy in vivo.
Original submitted on 6 February 2015; revision submitted on 9 April 2015
Keywords:  amodiaquine • breast cancer • CYP2C8 • neuropathy • ovarian cancer  
• paclitaxel • rosiglitazone
Background
Paclitaxel is widely used alone or in combi-
nation with other cytotoxic drugs in breast, 
ovarian and lung cancers. Paclitaxel binds to 
β-tubulin and causes microtubule stabilization 
which impedes chromosome segregation, and 
results in cell apoptosis. Peripheral neuropathy 
and bone marrow suppression are the dose-
limiting toxicities of paclitaxel. The severity 
of paclitaxel-induced peripheral neuropathy 
appears to be dependent on age, accompany-
ing disorders, such as diabetes mellitus and 
alcoholism, but has also been suggested to be 
influenced by genetic factors, for example, by 
variability in genes encoding drug metaboliz-
ing enzymes [1–4]. Such polymorphisms are 
known to influence the pharmaco kinetics and 
efficacy of many different drugs (cf. Sim and 
Ingelman-Sundberg, 2011 [5]).
Paclitaxel has been shown to be metabo-
lized by two different cytochrome P450 
enzymes, CYP2C8 and CYP3A4. CYP3A4 
is a highly conserved gene, and there are few 
CYP3A4 alleles, including CYP3A4*22, *20, 
*25 and *27, associated with an increased 
risk of developing paclitaxel-induced 
peripheral neuropathy [6,7]. CYP2C8 poly-
morphisms include the CYP2C8*3 allele 
with an allele frequency of 10–13% in the 
Caucasian populations, encoding a variant 
enzyme (CYP2C8.3) with two amino acid 
substitutions, Arg139Lys and Lys399Arg [8]. 
Green et al. and Bergmann et al. showed 
lower clearance of paclitaxel in patients being 
heterozygotes for CYP2C8*3 (n = 23, n = 93, 
respectively) as compared with patients 
homozygous for CYP2C8*1 [9,10] suggesting 
reduced metabolism of paclitaxel in vivo by 
CYP2C8.3. Recently, Leskelä et al. (2011) 
and Hertz et al. (2013, 2014) reported an 
association between CYP2C8*3 and the 
accumulated dose of paclitaxel causing grade 
2 neuropathy, with hazard ratios of 1.72 
(p = 0.032; n = 118 patients), 1.93 (p = 0.006; 
n = 209) and 1.77 (p = 0.018; n = 412) [11–13], 
respectively. However, there are studies with 
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opposite results showing lack of association between 
CYP2C8*3 and taxane-induced neuropathy in large 
population studies [14–16].
From in vitro studies using other substrates, it has 
been suggested that CYP2C8.3 may cause reduced 
metabolism of the antimalarial drug amodiaquine [17], 
but increased metabolism of antidiabetic drug rosi-
glitazone [18]. However, Kaspera et al. showed that 
CYP2C8.3 metabolized these two substrates at higher 
rates as compared with CYP2C8.1 in an Escherichia 
coli system [19]. Due to such conflicting reports, the 
CYP2C8.3 enzymatic properties toward different 
substrates remain to be firmly established.
In order to shed more light on this controversial 
topic, we investigated the role of the CYP2C8*3 allele 
in paclitaxel-induced neuropathy in vivo studying max-
imum paclitaxel-induced neuropathy grade and accu-
mulated dose of paclitaxel until grade 2 neuro pathy in 
patient cohorts of 343 and 148 patients, respectively. 
Furthermore, due to the previous inconsistent results on 
CYP2C8.3 activity mainly derived from nonmamma-
lian systems, we have compared the enzymatic proper-
ties of CYP2C8.1 and CYP2C8.3 using a HEK293 cell 
expression system using paclitaxel, amodiaquine and 
rosiglitazone as substrates. The data indicate no major 
contribution of CYP2C8*3 allele to both paclitaxel-
induced neuropathy and CYP2C8.3 mediated pacli-
taxel metabolism in vitro. Similarly, CYP2C8.3 showed 
unaltered amodiaquine kinetics, but more efficient 
metabolism of rosiglitazone.
Materials & methods
Chemicals
Paclitaxel, rosiglitazone and NADPH were pur-
chased from Sigma-Aldrich (MO, USA). Human 
CYP2C8+P450 reductase supersomes and 6α-hydroxy-
paclitaxel were acquired from BD Gentest (BD Biosci-
ence, Franklin Lakes, NJ, USA). Anti-CYP2C8 puri-
fied MaxPab rabbit polyclonal (D01P) antibody was 
purchased from Abnova Taiwan Corporation (Tai-
pei, Taiwan). A goat antirabbit IgG antibody conju-
gated with the horseradish peroxidase was purchased 
from Dako (Glostrup, Denmark) and the plasmid 
pcDNATM5/FRT vector was purchased from Invitro-
gen (Life Technologies, Carlsbad, CA, USA). HPLC-
grade methanol was obtained from Merck (Darmstadt, 
 Germany).
Patients
Blood samples were collected from 304 breast (89%) 
and 39 ovarian (11%) cancer patients treated with 
paclitaxel in Spanish hospitals. Part of this series (236 
patients) has already been communicated and the 
clinical characteristics have already been presented 
in [7]. Full characteristics for the 343 patients are pre-
sented in Supplementary Table 1 (see online at: www.
futuremedicine.com/doi/suppl/10.2217/pgs.15.46). 
For each patient, the following information was col-
lected: demographics, tumor characteristics, maxi-
mum neuropathy grade during paclitaxel treatment, 
cumulative dose of paclitaxel and paclitaxel dose 
reductions/suspensions and their causes. A neuropathy 
assessment was conducted in each patient to evaluate 
the maximum peripheral neuropathy grade during 
paclitaxel treatment as previously described [7]. In addi-
tion to maximum neuropathy grade, during paclitaxel 
treatment, accumulated paclitaxel dose up to grade 
2 neuropathy was also available for 56 of the Span-
ish patients and also from 92 Danish patients previ-
ously published [10,20]. All cancer patients were at least 
18 years of age, and the clinical information had been 
documented including histological cancer neoplasia, a 
life expectancy of greater than or equal to 12 weeks and 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status smaller than or equal to two, adequate 
bone marrow, renal and hepatic function and no previ-
ous history of neuropathy, and usage of contraception. 
The recruitment of patients and collection of samples 
were approved by local internal ethical review com-
mittees (reference id: VF-20050083). All patients gave 
verbal and written informed consent to participate in 
the study.
DNA isolation & genotyping
FlexiGene DNA Kit (Qiagen, Germantown, MA, 
USA) was used to obtain genomic DNA from the 
blood samples of Spanish patients. Genotyping of 
CYP2C8*3 allele (rs11572080, R139K) was performed 
on 15 ng of gDNA using the KASPar SNP Geno typing 
System (LGC Genomics, Teddington, Middelsex, 
UK). All assays included DNA samples with known 
genotypes and negative controls. The Sequence Detec-
tion System ABI PRISM® 7900HT (Applied Biosys-
tems, Life Technologies, Carlsbad, CA, USA) was used 
to determine fluorescence and for allele assignment.
The frequency of CYP2C8*3 allele in the patients was 
similar to that previously reported in Caucasians [21] 
and the genotype distribution was in Hardy–Weinberg 
equilibrium.
Generation of CYP2C8 variants & 
overexpression of proteins in HEK293 cells
Human CYP2C8 cDNA was used to generate 
CYP2C8*3 (416G>A and 1196A>G) sequence by 
using a QuikChange Lightning Site-Directed Muta-
genesis kit (Stratagene, CA, USA). The cDNAs were 
subcloned between the KpnI and hoI restriction sites 
in the pCDNA5/FRT expression plasmid. Mutagen-
10.2217/PGS.15.46future science group
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esis was confirmed by DNA sequencing. HEK293 cells 
were transiently transfected with these recombinant 
plasmids using Lipofectamine LTX and PLUS accord-
ing to Invitrogen protocol in 150 mm culture dishes. 
HEK293 cells transfected with empty pcDNA5/FRT 
were used as a negative control.
Preparation of cell homogenates
Cell homogenates were prepared by resuspending pel-
leted cells in Tris-buffered saline (25 mM Tris base, 138 
mM NaCl, 2.7 mM KCl, pH 7.4) that were then dis-
rupted by 20 sonication ‘bursts’ each for 1 sec and cen-
trifuged at 800 × g for 20 min at 4°C. The supernatant 
(S800 fraction) was used for western blot and enzyme 
kinetic assay. Total protein amount was determined by 
Bradford method [22].
Western blot
5–20 μg of protein from S800 fractions was sepa-
rated by 12% SDS-polyacrylamide gel electrophoresis. 
Proteins were transferred onto Whatman® Optitran® 
reinforced nitrocellulose membranes (GE Healthcare, 
Uppsala, Sweden) and probed with the anti-CYP2C8 
purified MaxPab rabbit polyclonal antibody (Abnova, 
Taiwan) (1:200 dilution, incubated overnight at 4°C) 
or rabbit anti-ERp29 antibody (1:1000, incubated 1 h 
at room temperature). ERp29, an abundantly expressed 
endoplasmic reticulum escort chaperone was chosen as 
a loading control [23]. A goat antirabbit IgG antibody 
conjugated with the horseradish peroxidase was used as 
secondary antibody (1:5000, Dako Cytomation, Glos-
trup, Denmark) and incubated for 1 h at room tempera-
ture. The membranes were developed with SuperSignal 
West Pico Chemiluminescence kit (Pierce chemical, 
IL, US) and signals were visualized by the Fuji LAS-
1000 gel documentation system (FujiFilm, Tokyo, 
Japan) . The relative expression levels of the CYP2C8 
variant apoproteins were determined by densitomet-
ric analysis of protein bands using Image Gauge V4.0 
software (FujiFilm, Tokyo, Japan). Different amounts 
(0.025–0.08 pmol) of CYP2C8 recombinant protein 
(BD Supersomes) were used for plotting the calibration 
curve. Experiments were repeated for 3-times.
HPLC analysis
Paclitaxel
S800 fractions, corresponding to 300 μg protein, from 
the transfected HEK 293 cells were incubated in a 
final volume of 0.1 ml of 50 mM potassium phosphate 
buffer, pH 7.4 at 37°C using 0-40 μM paclitaxel. The 
reaction was initiated by adding 1 mM NADPH and 
it was linear for 90 min. The reaction was stopped by 
adding 200 μl of ice-cold 100% methanol and sam-
ples were stored at -80°C until further analysis. After 
centrifugation at 16,000 × g for 10 min in cold room, 
the supernatant was injected into the C18 Spherisorb 
ODS-2; 5μm, 150 × 4.6 mm column (Waters, Milford, 
MA, USA). Metabolite and parent compound were 
separated by reverse phase HPLC with 65% methanol 
in isocratic mode with flow of 1 ml/min in the Waters 
2690/996 and the signal was detected at UV 229 nm. 
Docetaxel was spiked in each sample (retention times 
of 6OH paclitaxel, paclitaxel and docetaxel = 13.9, 17.8 
and 20.5 min).
Amodiaquine
The enzyme assay was performed similar to that of 
paclitaxel. The hydroxylation reaction was linear for 
90 min. The catalytic reaction was stopped by add-
ing 100 μl of ice-cold 100% acetonitrile containing 
10 μM chloroquine. After centrifugation at 16,000 × g 
for 10 min at 4ºC, supernatant was injected into the 
Zorbax SB C18 125 × 4.6 mm, 3.5 μm column (Agi-
lent, Santa Clara, CA, USA). Metabolite and par-
ent compound were separated by Varian ProStar 310 
HPLC system using 16% methanol in 50 mM phos-
phate buffer, pH 2.1 as mobile phase with flow of 
1 ml/min. The compounds were detected using UV 
340 nm and the retention times of chloroquine, N-bis-
desethyl- amodiaquine and amodiaquine were 7.6, 9.9 
and 12.2 min, respectively.
Rosiglitazone
N-demethylation assay was performed in a final vol-
ume of 0.1 ml of 50 mM potassium phosphate at 37°C. 
The reaction was initiated by adding 1mM NADPH. 
N-demethylation was linear for 90 min. The reaction 
was stopped by adding 300 μl of ice-cold 100% metha-
nol and all the samples were stored in freezer (-20°C) 
until further analysis. After addition of 10 μl of internal 
standard (1.1 μg/ml venlafaxine), the sample was cen-
trifuged (2800 × g, 2°C, 5 min). 200 μl of the super-
natant was diluted with 100 μl 0.1% formic acid and 
20 μl of the solution analyzed on a Synergi 4μ MAX-
RP 80A-column 100 × 3 mm, 4 μm with a precolumn 
Gemini C18 4 × 2.0 mm (both from Phenomenex, Tor-
rance, CA, USA) with a flow rate of 0.9 ml/min at 9°C. 
The mobile phase consisted of acetonitrile : methanol : 
sodium acetate 0.01 M, pH 6 = 30:8:62 (V/V/V). Both 
N-demethyl-rosiglitazone (NDES) and rosiglitazone 
were detected using fluorescent detector with an excita-
tion wavelength of 250 nm and monitoring the emis-
sion wavelength at 390 nm. Venlafaxine was detected 
using 230 and 310 nm for excitation and emission.
Statistical analysis
The kinetic constants, K
m
 and V
max
 were estimated 
using nonlinear regression analysis of Michaelis–Men-
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ten model by GraphPad Prism version 5.0 software 
(GraphPad Software, Inc., CA, USA). Amodiaquine 
and paclitaxel concentration-velocity curves were fit-
ted by using nonlinear regression analysis of hill slope 
model by GraphPad Prism. Intrinsic clearance (CL
int
) 
values were determined as the ratio of V
max
/K
m
. All 
values are expressed as the mean ± standard deviation 
of triplicates. Student t test was used to evaluate the 
difference between two variants’ activities (GraphPad) 
indicating significance with p value (p < 0.05).
The association between maximum paclitaxel-
induced neuropathy grade (ranked 0 to 3) and 
CYP2C8*3 genotype was assessed using an ordinal 
logistic regression. Binary logistic regression was applied 
to evaluate the association between paclitaxel treat-
ment modifications (binary variable) and CYP2C8*3 
genotype. Tumor type, total number of chemotherapy 
cycles and potential confounders (diabetes mellitus and 
alcoholism) were included as covariates in the multi-
variable analysis. Association between CYP2C8*3 and 
neuropathy was also evaluated, analyzing the accumu-
lated dose of paclitaxel up to the development of grade 
2 neuropathy (cumulative dose analysis) using Cox 
regression analysis. Multivariable analysis included 
country of origin (in this analysis patients from both 
Spain and Denmark were included), tumor type and 
total number of chemotherapy cycles as covariates. 
SPSS software package v.19 (IBM Corp., Armonk, NY, 
USA) was used for these statistical analyses. p-values 
less than 0.05 were considered statistically significant.
Results
Influence of CYP2C8*3 on the  
paclitaxel-induced neuropathy
A total of 343 paclitaxel-treated Spanish patients were 
recruited and genotyped for CYP2C8*3. Demographic 
and clinical data of these patients are presented in 
Supplementary Table 1. We examined the distribution 
of CYP2C8*3 in the patients but did not find an asso-
ciation between the CYP2C8*3 allele and maximum 
paclitaxel-induced neuropathy grade (Figure 1A). By 
analyzing paclitaxel treatment modifications due to 
neuropathy, again we did not observe an association 
with CYP2C8*3 allele (Figure 1B). Multivariate analy-
sis including relevant covariates did not change these 
results.
Cumulative dose analysis is an alternative method to 
test for neuropathy risk factors. Neuropathy symptoms 
occur after multiple chemotherapy cycles and there-
fore the cumulative dose of paclitaxel is a significant 
risk factor in chemotherapy-induced neuropathy. The 
accumulated paclitaxel dose causing grade 2 neuropa-
thy was available from 56 of the 343 Spanish patients 
and similar data were also available from a previously 
published Danish study (n = 92) [10,20], resulting in a 
total of 148 patients that could be used for cumulative 
dose analysis (Figure 2). Cox regression analysis showed 
no statistically significant association between neu-
ropathy and CYP2C8*3 genotype, but a multi variate 
analysis including country of origin, tumor type and 
number of chemotherapy cycles as covariates, gave a 
trend toward higher neuropathy risk for carriers of 
the CYP2C8*3 allele (HR: 1.70; 95% CI: 0.94–3.05; 
p = 0.078; Figure 2).
Enzymatic activity of CYP2C8.1 & CYP2C8.3 
expressed in HEK293 cells
The capacity of the CYP2C8.1 and CYP2C8.3 enzyme 
variants to metabolize paclitaxel, amodiaquine and 
rosiglitazone was determined in a mammalian expres-
sion system using HEK293 cells. The apoprotein levels 
of recombinant CYP2C8 enzymes were determined 
using the densitometric quantification of immuno-
blots. As shown in Figure 3, the apoprotein levels of the 
two CYP2C8 variants were similar in the expression 
system used. The S800 fraction isolated from the trans-
fected cells was incubated with paclitaxel, amodiaquine 
and rosiglitazone and the corresponding metabolites, 
6 OH-paclitaxel, N-desethyl-amodiaquine and NDES 
were identified using substrate-specific HPLC assays.
As shown in Figure 4, the enzyme kinetic parameters 
for CYP2C8.1 and CYP2C8.3 dependent metabolism 
of paclitaxel and amodiaquine in this expression system 
were similar (no significant differences in K
m
 or CL
int
 for 
CYP2C8.1 and CYP2C8.3 for either paclitaxel or amo-
diaquine; p > 0.05). However, rosiglitazone was metab-
olized to NDES more extensively by CYP2C8.3 than 
by CYP2C8.1 (Figure 4 & Table 1). For rosiglitazone, 
the intrinsic clearance and the K
m
 by CYP2C8.3 were 
significantly different from that of CYP2C8.1 (1.8-fold 
higher and1.7-fold lower than CYP2C8.1, respectively), 
whereas both enzyme variants exhibited similar V
max
 
values.
Discussion
Genetic variations in paclitaxel metabolizing enzymes 
have been considered as risk factors for paclitaxel-
induced peripheral neuropathy. In particular, 
CYP2C8*3 has been suggested to be associated with 
paclitaxel-induced adverse effects. However, in the cur-
rent study encompassing a cohort of 343 patients, we 
did not detect an association between the CYP2C8*3 
allele and paclitaxel-induced neuropathy. In addi-
tion, the catalytic efficacy of CYP2C8.3 expressed in 
HEK293 cells did not differ from the one of CYP2C8.1 
with respect to paclitaxel metabolism.
As mentioned, the association of the CYP2C8*3 
allele with higher risk for neuropathy is debated and 
10.2217/PGS.15.46
Figure 1. Paclitaxel-induced neuropathy grade and treatment modifications grouped by CYP2C8*3 genotype. 
(A) Maximum neuropathy grade and (B) treatment modifications due to neuropathy were compared among 
patients with different CYP2C8*3 genotypes. As described in the ‘Materials & methods’ section, ordinal logistic 
regression or binary logistic regression, respectively, were performed. ‘Tx modif’ refers to treatment modifications 
due to peripheral neuropathy.
Figure 2. Kaplan–Meier curve comparing cumulative 
paclitaxel dose up to grade 2 neuropathy by CYP2C8*3 
genotype. A total of 148 paclitaxel-treated patients 
were grouped according to CYP2C8*3 genotype 
and compared with paclitaxel cumulative dose up to 
the development of grade 2 peripheral neuropathy. 
p-values correspond to multivariate Cox regression 
analysis, including country of origin, tumor type 
and number of chemotherapy cycles as covariates. 
The curves, HR, 95% CI and p-values presented 
correspond to the comparison between CYP2C8*1/*3 
and CYP2C8*1/*1 patients. Only two patients were 
CYP2C8*3/*3 and are not included in the graph. 
HR: Hazard ratio.
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constitutes a controversial issue. Some clinical inves-
tigations report such association [9,11–13,24] in line 
with other studies indicating lower paclitaxel clear-
ance [9–10,25]. However, here we did not observe higher 
neuropathy grades in CYP2C8*3 carriers (Figure 1) in 
agreement with other studies [6,14,26–30]. In the cumu-
lative dose analysis, we found a trend toward higher 
paclitaxel-induced neuropathy risk in CYP2C8*3 car-
riers (HR: 1.70, p = 0.078; Figure 2). In line with this 
result, recent large studies by Abraham et al.[15] and 
Baldwin et al.[16] (>800 patients), found no statisti-
cally significant association of CYP2C8*3 variant allele 
with taxanes related sensory neuropathy using cumula-
tive dose analysis (HR: 1.22; p = 0.14 and HR: 1.21; 
p = 0.23, respectively).
Although CYP2C8 constitutes a major meta-
bolic pathway of paclitaxel, CYP3A4 also contrib-
utes to its metabolism. In fact, in a recent study, 
defective CYP3A4 variants, including CYP3A4*20, 
CYP3A4*25 and CYP3A4*27 were found to be asso-
ciated with a higher risk of paclitaxel-induced neu-
ropathy [7]. Thus, carriers of these CYP3A4 variants 
had more severe neuropathy and higher probability 
of neuropathy-induced paclitaxel treatment modifi-
cations (2- to 7-fold higher risk) as compared with 
patients with wild-type CYP3A4 [7]. Increased pacli-
taxel neuropathy risk has also been reported for 
CYP3A4*22 allele, which causes decreased expres-
sion of the CYP3A4 enzyme [6,31]. The neuropathy 
risk (HR: 22.1, p < 0.001) [6] shown in this study for 
carriers of CYP3A4*22 allele is substantially higher 
than the HR value for CYP2C8*3 in the present study 
(HR: 1.70, p = 0.078) and also when compared with 
the risk for CYP2C8*3 reported in previous reports 
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Figure 3. Protein expression of CYP2C8.1 and CYP2C8.3. S800 fractions prepared from transiently transfected 
HEK293 cells were immunoblotted with antibodies for CYP2C8 and loading control, ERp29 [23]. A representative 
image is shown for CYP2C8 variants with samples loaded in two concentrations. 0.025–0.08 pmol of CYP2C8 
recombinant protein (BD Supersomes) was used for plotting the calibration curve. Densitometric analysis 
estimated 7.5 ± 0.5 pmol/mg protein for CYP2C8.1 and 7.8 ± 0.7 pmol/mg protein for CYP2C8.3.
Figure 4. Kinetic evaluation of CYP2C8.3 on paclitaxel 6α-hydroxylation, amodiaquine N-de-ethylation and rosiglitazone  
ρ-hydroxylation. The activity values were normalized by the corresponding amounts of CYP2C8 variant proteins as estimated by 
densitometry of western blot bands (Figure 1). Curve fitting was accomplished by GraphPad v. 5.0 using H-loop (paclitaxel and 
amodiaquine) and Michaelis–Menten plot (rosiglitazone).
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(HR between 1.72 and 1.93) [11–13]. These data may 
indicate a stronger effect of the identified CYP3A4 
defective variants than of CYP2C8*3 polymorphism 
in paclitaxel-induced neuropathy.
The reason for the conflicting data regarding cat-
alytic activity of CYP2C8.3 on the metabolism of 
paclitaxel might be associated with the type of expres-
sion system used. Heterologously expressed enzymes 
fold differently in different types of cells. Thus for 
example, CYP2D6.17 identified in a patient possess-
ing defective drug metabolism showed identical rate of 
metabolism as the CYP2D6.1 enzyme using bufuralol 
as a substrate when the enzyme was expressed in yeast 
cells but showed much reduced hydroxylation rate 
compared with CYP2D6.1 when expressed in COS-1 
cells in accordance with the in vivo data [32]. Similarly 
lower intrinsic paclitaxel clearance as compared with 
CYP2C8.1 has been observed when CYP2C8.3 was 
expressed in heterologous systems based on E. coli, 
yeast or insect cells [8,19,33,34], whereas when paclitaxel 
hydroxylation was evaluated in mammalian systems 
using transfected human hepatoma cells HepG2 [35] 
or in HEK293 cells, as reported here, the kinetics of 
paclitaxel metabolism by CYP2C8.3 and CYP2C8.1 
were similar. The differences above might thus be 
inherited in aberrant folding or interaction with redox 
partners in the heterologous expression systems used.
The enzymatic activity of CYP2C8.1 and 
CYP2C8.3 proteins was also tested using amodiaquine 
and rosiglitazone as substrates. For amodiaquine, we 
did not observe differences in kinetic parameters 
between the enzyme variants, although there are previ-
ous conflicting results for CYP2C8.3 in E. coli [17,19]. 
Concerning rosiglitazone, we found a higher clear-
ance for CYP2C8.3, which is in accordance with other 
in vitro [19] and in vivo studies [18,36].
The CYP2C8.3 variant enzyme contains two con-
served amino acid changes, R139K and K399R. There-
fore, it could a priori be suggested that the physico-
chemical properties of CYP2C8.3 should not differ 
much from CYP2C8.1, and in silico analysis using two 
online tools PolyPhen2 [37] and SIFT [38] support this 
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notion (results not shown). Such predictions are in 
good agreement with the experimental data showing 
no difference in catalytic activities of these two vari-
ant proteins toward paclitaxel and amodiaquine. Inter-
estingly, an in silico study based on the crystal struc-
ture of CYP2C8 complexed with troglitazone, a drug 
similar to rosiglitazone, predicts a missing salt bridge 
in R139K mutant whereas the salt bridge in K399R 
should remain intact. The authors conclude that this 
may affect the substrate specificity of the R139K pro-
tein [19], and this can be suggested as a possible expla-
nation for the different rosiglitazone conversion rates 
found in our study. Different enzyme kinetics for two 
different substrates has previously been shown for 
other P450s, for example for CYP2D6.17 variant for 
codeine and bufuralol [32].
Paclitaxel-induced neurotoxicity remains a major 
detrimental factor in ovarian/breast cancer chemo-
therapy and the mechanisms of such phenomenon 
are still unclear. Our study indicates that variations 
in the CYP2C8 gene do not affect the metabolism of 
paclitaxel. The impact of CYP2C8*3 allele seems to be 
moderate in neurotoxicity given that cumulative dose 
analysis only showed a weak nonsignificant trend.
Conclusion & future perspective
In conclusion, using two patient cohorts with a total of 
435 cases, we found no major impact of the CYP2C8*3 
allele on the risk of paclitaxel-induced neuropathy (HR: 
1.70, p = 0.078). This is supported by our in vitro find-
ings. Future work should be directed at revealing addi-
tional genetic factors associated with paclitaxel-induced 
neuropathy.
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Executive summary
Background
•	 Paclitaxel is a widely used anticancer drug that frequently causes peripheral neuropathy.
•	 CYP2C8 is the main paclitaxel metabolizing enzyme and CYP2C8*3 allele has been suggested as a risk factor 
for paclitaxel-induced neuropathy.
•	 However, the hitherto published in vivo and in vitro data are highly controversial with respect to the influence 
of CYP2C8*3.
Materials & methods
•	 Association between CYP2C8*3 genotype and paclitaxel-induced neuropathy was investigated in 435 cancer 
patients.
•	 The impact of CYP2C8.3 on paclitaxel metabolism was analyzed using a HEK293 cell expression system. Also 
amodiaquine and rosiglitazone were analyzed in the same manner.
Results
•	 No statistically significant association between CYP2C8*3 and paclitaxel-induced neuropathy was found.
•	 The CYP2C8.3 enzyme kinetics of paclitaxel and amodiaquine were similar to CYP2C8.1, whereas CYP2C8.3 
was more efficient in the conversion of rosiglitazone.
Conclusion
•	 No major impact of CYP2C8*3 allele on paclitaxel-induced neuropathy was found, consistently with no 
changes in in vitro activity of CYP2C8.3 toward paclitaxel as compared with CYP2C8.1.
  Km (μM) Vmax (pmol CYP2C8 
pmol-¹ min-¹)
CLint (Vmax/Km)
Paclitaxel CYP2C8.1 13.11 ± 2.01 1.17 ± 0.10 0.089 ± 0.005
 CYP2C8.3 11.87 ± 2.11 1.20 ± 0.12 0.101 ± 0.007
Amodiaquine CYP2C8.1 10.04 ± 1.11 9.08 ± 0.49 0.905 ± 0.046
 CYP2C8.3 9.67 ± 0.77 8.66 ± 0.32 0.896 ± 0.036
Rosiglitazone CYP2C8.1 12.75 ± 1.10 0.49 ± 0.02 0.039 ± 0.002
 CYP2C8.3 7.67 ± 0.47* 0.52 ± 0.01 0.067 ± 0.002*
All experiments were carried out in triplicates and the data are presented as mean ± standard error of the mean.
*p < 0.05 as compared with CYP2C8.1.
Table 1. Kinetic constants of reconstituted CYP2C8.1 and CYP2C8.3 with different substrates.
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SUPPLEMENTARY MATERIAL: 
Supplementary Table1. Characteristics of the 343 paclitaxel-treated patients  
 
Characteristics N (%)* 
Age (years)  
Median (min-max)  52 (30-82) 
Tumor type  
Breast 304 (89%) 
Ovary 39 (11%) 
Type of paclitaxel treatment  
First line 336 (98%) 
Second linea 7 (2%) 
Paclitaxel chemotherapy treatmentb  
FEC+Tc 146 (43%) 
AC+Td 70 (20%) 
T+FECe 51 (15%) 
C+Tf 40 (12%) 
T+ACg 17 (5%) 
Others 19 (5%) 
Number of paclitaxel cycles   
(min-max)  8 (3-44) 
Maximum sensory neuropathy gradeh  
G0 53 (16%) 
G1 38 (11%) 
G2 86 (25%) 
G3 166 (48%) 
Treatment modificationsi   
Due to neuropathy 50 (15%) 
Due to all causes 77 (22%) 
  
* Unless otherwise stated 
a Patients with second line paclitaxel treatment and no previous cytotoxic drugs in first line therapy. 
b Some patients receiving chemotherapeutic drugs in combination with targeted therapy (bevacizumab, 
trastuzumab, denosumab or pertuzumab) are included in the table according to the chemotherapy agents 
received. 
c FEC+T: 5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2, every 21 
days, followed by paclitaxel 80 or 100 mg/m2, every 7 days. 
d AC+T:  doxorubicin 60mg/m2 and cyclophosphamide 600 mg/m2, every 21 days, followed by paclitaxel 
80mg/m2, every 7 days. 
e T+FEC: paclitaxel 80 mg/m2, every 7 days, followed by 5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2 
and cyclophosphamide 600 mg/m2, every 21 days. 
f C+T: carboplatin AUC5-6 and paclitaxel 175mg/m2, every 21 days. 
g T+AC: paclitaxel 80mg/m2, every 7 days, followed by doxorubicin 60mg/m2 and cyclophosphamide 600 
mg/m2, every 21 days. 
h NCI-CTC v4.  
i Considering as treatment modifications paclitaxel dose reductions or treatment suspensions. 
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ARTICLE 2: Replication of Genetic Polymorphisms Reported to Be Associated with 
Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated 
with Paclitaxel—letter. 
 
Authors: Apellániz-Ruiz M, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Sereno M, García-
Donás J, Åvall-Lundqvist E, Gréen H, Brøsen K, Bergmann TK, Rodríguez-Antona C. 
 
Published in Clin Cancer Res. 2015 Jul 1;21(13):3092-3 
 
Abstract: 
Candidate gene approaches have allowed to identify common polymorphisms in genes 
involved in paclitaxel pharmacokinetics and pharmacodynamics; however, with the development 
of genome-wide association studies (GWAS) millions of SNPs across the whole genome can be 
genotyped simultaneously. GWAS allow to identify new genes explaining the basis of human 
traits such as drug-induced toxicity. Two previous GWAS carried out by us and by another group, 
suggested polymorphisms in ephrin type-A receptors (encoded by EPHA genes) as predictors of 
paclitaxel-induced neuropathy.  
In this study we evaluated the association of 4 common SNPs in EPHA4, EPHA5, EPHA6 
and EPHA8, with paclitaxel-induced peripheral neuropathy. To accomplish this goal, we collected 
a series of 146 patients treated with paclitaxel and with neuropathy data recorded cycle by cycle. 
We found that the SNPs in EPHA5, EPHA6 and EPHA8 genes were associated with a higher risk 
to suffer peripheral neuropathy. Regarding the SNP in EPHA4, we had low statistical power to 
detect an association due to the low frequency of the variant allele. 
Moreover, as EphA receptor tyrosine kinases are involved in a variety of neuronal-related 
functions, including neural repair after injury, the findings herein described not only validate the 
involvement of EphA receptors in paclitaxel-induced neuropathy but they also suggest their 
potential role as neuropathy risk markers for other neurotoxic drugs. 
 
Personal contribution: I participated in the design of the study. I performed the genotyping of 
all SNPs in the samples and carried out the subsequent statistical analyses using Kaplan–Meier 
and Cox regression models. Finally, I contributed to the discussion of the results and I was the 
principal author drafting the paper. 
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ARTICLE 3: Whole-exome sequencing reveals defective CYP3A4 variants predictive of 
paclitaxel dose-limiting neuropathy. 
 
Authors: Apellániz-Ruiz M, Lee MY, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, García-
Estévez L, Sereno M, García-Donás J, Castelo B, Guerra E, Leandro-García LJ, Cascón A, Johansson 
I, Robledo M, Ingelman-Sundberg M, Rodríguez-Antona C. 
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Abstract: 
The neuropathies triggered by the anticancer drug paclitaxel can lead to dose reductions or even 
treatment suspension and, in severe cases, it can cause irreversible nerve damage. In this regard, the 
selection of phenotypic outliers has been shown to be a powerful strategy to identify genetic variants 
associated with drug outcomes.  
In this study, we used an extreme phenotype approach coupled with whole exome sequencing 
(WES) to discover low-frequency variants associated with severe neuropathy. We selected for WES 8 
paclitaxel-treated patients with a long lasting severe neuropathy and with treatment modifications due 
to neuropathy. Analysis of key genes involved in paclitaxel pharmacokinetics unveiled two CYP3A4 
variants in different patients: a novel and a rare variant (CYP3A4*25 and CYP3A4*20, respectively). 
Further screening of the full CYP3A4 coding region in 228 paclitaxel-treated patients revealed five 
additional carriers of CYP3A4 rare variants, one not previously described (CYP3A4*27). Functional 
studies showed that the novel variants CYP3A4*25 and CYP3A4*27 exhibited decreased CYP3A4 
activity.  
Statistical analyses confirmed that defective CYP3A4 variants were overrepresented in 
paclitaxel-treated patients with severe neuropathy. Moreover, these variants were associated with a 7-
fold increased risk of having paclitaxel treatment modifications. 
On the whole, we identified for the first time a genetic marker associated with paclitaxel 
treatment modifications caused by neuropathy. These results support a role for CYP3A4 in paclitaxel-
induced neuropathy and provide a basis for paclitaxel treatment individualization.  
 
Personal contribution: I participated in the selection of the 8 patients with severe neuropathy and in 
the analysis of WES data. I validated the relevant variants by Sanger sequencing and performed in silico 
functional testing for the missense variants. In addition, I performed DHPLC screening of the 13 exons 
of CYP3A4 in the validation series and did the statistical analyses (Goodman and Kruskal Gamma test, 
Fisher exact test and Pearson correlation test). Finally, I contributed to the discussion of the results and 
I was one of the principal authors drafting the paper. 
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SUPPLEMENTARY MATERIAL 
 
Supplementary Table S1. Characteristics of the 228 prospectively recruited breast and ovarian cancer 
patients treated with paclitaxel and used for the detection of CYP3A4 coding variants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Unless otherwise stated 
a Patients with second line paclitaxel treatment and no previous cytotoxic drugs in first line therapy. 
b Some patients receiving chemotherapeutic drugs in combination with targeted therapy (bevacizumab, 
trastuzumab, denosumab or pertuzumab) are included in the table according to the chemotherapy agents received. 
c  FEC+T: 5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2, every 21 days, 
followed by paclitaxel 100 mg/m2, every 7 days. 
d AC+T:  doxorubicin 60mg/m2 and cyclophosphamide 600 mg/m2, every 21 days, followed by paclitaxel 
80mg/m2, every 7 days. 
e T+FEC: paclitaxel 80 mg/m2, every 7 days, followed by 5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2 and 
cyclophosphamide 600 mg/m2, every 21 days. 
f C+T: carboplatin AUC5-6 and paclitaxel 175mg/m2, every 21 days. 
g  NCI-CTC v4. 
h When in the same patient’s paclitaxel dose was reduced and then later suspended, the patient is included in the 
table as “treatment suspension”.  
Characteristics N (%)* 
Age (years)  
Median (min-max)  51 (30-81) 
Tumor type  
Breast 200 (88%) 
Ovary   28 (12%) 
Type of paclitaxel treatment  
First line 221 (97%) 
Second linea   7 (3%) 
Paclitaxel chemotherapy treatmentb  
FEC+Tc 111 (49%) 
AC+Td  35 (15%) 
T+FECe  29 (13%) 
C+Tf  27 (12%) 
Others  26 (11%) 
Number of paclitaxel cycles   
(min-max)  8 (3-12) 
Maximum sensory neuropathy gradeg  
G0  36 (16%) 
G1  25 (11%) 
G2  53 (23%) 
G3 114 (50%) 
Treatment modifications due to neuropathyh  
Dose reduction  5 (2%) 
Treatment suspension 16 (7%) 
All treatment modifications  
Dose reduction 21 (9%) 
Treatment suspension 21 (9%) 
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Supplementary Table S2. Primers used for CYP3A4 sequencing. 
 
Exon    Primer sequence         Fragment size (bp) 
E1 FW        5’ TTCTTTGCCAACTTCCAAGG3’  378 
E1 RV     5’AAGGGAAAGAGAGGCCTGA3’ 
E2 FW    5’TCGTTCTCTTGAGCATTCCA3’  247 
E2 RV     5’AAGCTGCTCTTGGCAATCAT3’ 
E3 FW     5’GGCTTCCACTGTTTTCATCC3’  221 
E3 RV     5’TTGGGCTGAGACTGTCCTCT3’ 
E4 FW     5’TTGGGCTCCAGCTGTAGAAT3’  582 
E4 RV     5’CCACATGGAGACAGAGTGGA3’ 
E5 FW   5’ CCATGGAGACCTCCACAACT3’  271 
E5 RV      5’ CAGTGGACTACCCCTTGGAA3’ 
E6 FW     5’TCACTTACTGCTCCATGCTG3’  546 
E6 RV     5’TGCCAACCAACAGATACCAA3’ 
E7 FW       5’ATGTGGGTTTCCTGTTGCAT3’  374 
E7 RV       5’TGATGGTCACACATATCTTCAAA3’ 
E8 FW        5’TGGCTTCCAGTTGAGAACCT3’  379 
E8 RV    5’GAGCAGTCTTCATGTTAAAAGCA3’ 
E9 FW     5’TCAGGAGCCACTTTCTGTCA3’  283 
E9 RV      5’GCCTGCATGCCTCTAGAAAG3’ 
E10 FW    5’AGGGATTTGAGGGCTTCACT3’  334 
E10 RV      5’TTCTCCTGGGAAGTGGTGAG3’ 
E11 FW      5’AAATGCTTCGATCCTTTACCA3’  415 
E11 RV      5’GGCAGAATATGCTTGAACCAG3’ 
 
Exon    Primer sequence         Fragment size (bp) 
E12 FW      5’GGGTGGCCCCTAAGTAAGAA3’  392 
E12 RV      5’TCACAGATGGGCCTAATTGA3’ 
E13 FW      5’GTCCCCTCAACACTGAAGGA3’  202 
E13 RV        5’GGAAAATTCAGGCTCCACTT3’ 
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Supplementary Table S3. Loss-of-function, missense and known regulatory variants in genes mediating paclitaxel pharmacokinetics in the eight patients with 
extreme paclitaxel-induced neuropathy studied by WES. 
 
Gene 
Variant ID/ common 
name 
Type  
of variant 
Protein  
change 
No variant  
carriers (het/hom) 
MAFa (%) Predicted  
effectb 
Obs Eur 
CYP3A4 c.1165C>T/ novel (*25) Missense P389S 1/0 6 NDc Altered function (4) 
 rs67666821/ *20 Frameshift P488Tfs*494 1/0 6 0.09 - d 
 rs35599367/ *22 Intronic - 1/0 6 5 - d 
CYP2C8 rs11572080/ *3 Missense R139K 2/0 12 12 Neutral (4) 
 rs10509681/ *3 Missense K399R 2/0 12 12 Neutral (4) 
 rs1058930/ *4 Missense I264M 1/0 6 6 Neutral (2) 
ABCB1 rs9282564 Missense N21D 1/0 6 10 Neutral (4) 
 rs60419673 Missense N183S 1/0 6 0.2 Neutral (3) 
 rs2032582/ 2677GT Missense A893S 5/1 43 43 Neutral (3) 
SLCO1B3 rs188817665 Missense G653E 1/0 6 1 Neutral (3) 
 
a Minor allele frequency observed in the eight patients studied by WES (Obs) and in European Americans (Eur) according to Exome Variant Server (ESP2), or 1000 Genomes 
Project for the intronic rs35599367. 
b The effect of the missense changes was predicted by using 4 algorithms: PolyPhen (Adzhubei et al., 2010), SIFT (Ng and Henikoff, 2003), MutPred (Li et al., 2009)and 
SNPs&Go (Calabrese et al., 2009). For MutPred a threshold score of 0.5 was used. The number of algorithms with consistent results is indicated in brackets. 
c Not described. 
d Predictions for frameshift and intronic variants are not performed by the algorithms. However, functional studies have shown that rs67666821 leads to a non-functional 
truncated protein (Westlind-Johnsson et al., 2006) and that rs35599367 decreases CYP3A4 expression (Elens et al., 2013a).  
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Supplementary Table S4. Genotype of variants previously associated with paclitaxel-induced neuropathy, in the patients with defective CYP3A4 coding 
variants. 
 
Gene 
Variant common 
name 
Variant ID 
Nr. of neuropathy risk alleles 
11S1213 11S919 13S812 13S120 11S872 12S513 11S918 
CYP3A4 
CYP3A4*20 rs67666821 (frameshift)   1 1 1 1 0 0 0 
CYP3A4*25 novel (P389S) 0 0 0 0 1 0 0 
CYP3A4*27 novel (L475V) 0 0 0 0 0 1 0 
CYP3A4*8 rs72552799 (R130Q) 0 0 0 0 0 0 1 
CYP3A4 CYP3A4*22 rs35599367  1 0 0 0 0 0 0 
CYP2C8 CYP2C8*3 rs11572080/ rs10509681 1 1 0 0 0 0 1 
EPHA5 - rs7349683 0 2 0 0 1 2 0 
XKR4 - rs4737264 1 1 0 0 1 0 1 
CYP3A4 coding variants Loss-of-function (no activity) Missense (decreased activity) 
Paclitaxel-induced neuropathy (grade/ dose modif.) a 3/ Red (2)  3/ Red 3/ Red 3/ - 3/ Susp 3/ - 1/ - 
 
a Dose modif, paclitaxel dose modifications; Red, paclitaxel dose reduction due to neuropathy; Susp, paclitaxel treatment suspension due to neuropathy. 
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Supplementary Figure S1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CYP3A4.25 protein stability assessment. Degradation rate of CYP3A4.25 protein compared to 
CYP3A4.1. 48 hour post-transfection HEK293 cells were exposed to 50 µM cycloheximide (CXM) or 
vehicle (0.06% DMSO) for 8 hours. Upper panel, relative protein levels estimated by densitometric analysis 
of western blot bands. Lower panel, western blot results. Each lane was loaded with the cell lysate 
containing equal amounts of total protein. Membranes were overexposed to visualize the protein bands after 
CXM treatment. 
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Supplementary Figure S2 
 
Neuropathy risk conditions confer an increased risk of paclitaxel-induced neuropathy and a trend 
towards treatment modifications. Neuropathy grade (A) and treatment modifications due to neuropathy 
(B), were compared between patients with neuropathy risk conditions (diabetes mellitus, high alcohol 
intake or restless-legs-syndrome) and patients without risk conditions. Two patients were excluded from 
the analysis due to lack of information regarding confounding factors. The median cumulative paclitaxel 
dose was used to group patients according to high or low paclitaxel exposure. Neuropathy grade (C) and 
treatment modifications due to neuropathy (D), were compared between patients with different cumulative 
paclitaxel doses. The Goodman and Kruskal's gamma test and Fisher exact test were used to assess 
associations with neuropathy grade (γ=1) and treatment modifications, respectively. Treatment modif PN, 
treatment modifications due to peripheral neuropathy. 
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Supplementary Figure S3 
 
CYP3A4*22 association with paclitaxel-induced neuropathy and paclitaxel dose modifications. 
Neuropathy grade (A), treatment modifications due to neuropathy (B) and treatment modifications due to 
any cause (C), were compared between CYP3A4*22 heterozygous carriers (CYP3A4*1/*22) and CYP3A4 
wild type patients (CYP3A4*1/*1). Five patients were excluded from the analysis due to missing 
CYP3A4*22 genotype. The Goodman and Kruskal's gamma test and Fisher exact test were used to assess 
associations with neuropathy grade (γ=1) and treatment modifications, respectively. Treatment modif PN, 
treatment modifications due to peripheral neuropathy. Treatment modif (any cause), treatment 
modifications due to neuropathy or to any other cause. 
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ARTICLE 4: High frequency and founder effect of the CYP3A4*20 loss-of-function allele 
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Abstract: 
Cytochrome P450 3A4 (CYP3A4) is a key drug metabolizing enzyme involved in the 
biotransformation of more than half of all clinically used drugs. Genetic factors have been estimated to 
account for a high percentage of the inter-individual variability observed in CYP3A4 expression. 
Despite these evidences, loss-of-function variants have only been reported as rare events.  
One of these rare loss-of-function alleles is CYP3A4*20. Interestingly, we found four carriers 
of this variant among Spanish patients with severe neuropathy. As no data was available regarding 
CYP3A4*20 allele origin, we characterized the world distribution and origin of CYP3A4*20 mutation.  
CYP3A4*20 was genotyped in more than 3750 individuals representing different populations 
and haplotype analysis was performed using CYP3A polymorphisms and microsatellite markers.  
We found that CYP3A4*20 allele was present in 1.2% of the Spanish population (up to 3.8% in 
specific regions), and that all CYP3A4*20 carriers shared a common haplotype. These results were 
compatible with a Spanish founder effect. In addition, it is the first description of a loss-of-function 
CYP3A4 allele with a relatively high frequency in a population, classifying CYP3A4 as a polymorphic 
enzyme.  
The key role of CYP3A4 in drug metabolism, together with evidences of increased risk of 
adverse drug reactions in CYP3A4*20 carriers, suggest the relevance of implementing CYP3A4*20 
screening in the Spanish population. 
 
Personal contribution: I participated in the design of the study, performed SNP genotyping and 
microsatellite testing through DNA fragment analysis. I performed haplotype analysis and participated 
in statistical analyses. Finally, I contributed to the discussion of the results and I was the principal author 
drafting the paper. 
  
ORIGINAL ARTICLE
High frequency and founder effect of the CYP3A4*20
loss-of-function allele in the Spanish population classiﬁes
CYP3A4 as a polymorphic enzyme
M Apellániz-Ruiz1, L Inglada-Pérez1,2, MEG Naranjo3, L Sánchez1, V Mancikova1, M Currás-Freixes1, AA de Cubas1, I Comino-Méndez1,
S Triki4, A Rebai4, M Rasool5, G Moya6, M Grazina7, G Opocher8, A Cascón1,2, P Taboada-Echalar9, M Ingelman-Sundberg10,
A Carracedo5,11, M Robledo1,2, A Llerena3 and C Rodríguez-Antona1,2
Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have been reported as rare events,
and the ﬁrst demonstration of a CYP3A4 protein lacking functional activity is caused by CYP3A4*20 allele. Here we characterized the
world distribution and origin of CYP3A4*20 mutation. CYP3A4*20 was determined in more than 4000 individuals representing
different populations, and haplotype analysis was performed using CYP3A polymorphisms and microsatellite markers. CYP3A4*20
allele was present in 1.2% of the Spanish population (up to 3.8% in speciﬁc regions), and all CYP3A4*20 carriers had a common
haplotype. This is compatible with a Spanish founder effect and classiﬁes CYP3A4 as a polymorphic enzyme. This constitutes the
ﬁrst description of a CYP3A4 loss-of-function variant with high frequency in a population. CYP3A4*20 results together with the key
role of CYP3A4 in drug metabolism support screening for rare CYP3A4 functional alleles among subjects with adverse drug events
in certain populations.
The Pharmacogenomics Journal advance online publication, 4 November 2014; doi:10.1038/tpj.2014.67
INTRODUCTION
Cytochromes P450 (CYPs) are the most important drug-metaboliz-
ing enzymes, being CYP1, 2 and 3 families responsible for the
biotransformation of ~ 70–80% of all therapeutic compounds.1,2
CYP 3A4 (CYP3A4) is the most abundant P450 enzyme in the
human liver and gastrointestinal tract and it is involved in the
biotransformation of more than half of all clinically used drugs.1–3
There is a high variability in CYP3A4 expression (4100-fold),1
caused by non-genetic and genetic factors, which contributes to
unpredictable drug responses and toxicities. Among environmental
factors, drug–drug interactions are one of the most studied causes
of variation, but gender, hormonal status and age also inﬂuence
CYP3A4 expression and activity.4,5 With respect to genetic factors,
twin studies and repeated drug administration approaches have
estimated a high degree of heritability in the CYP3A4 interindividual
variation.6–8 In this regard, the Human CYP Allele Nomenclature
Database includes 26 different CYP3A4 variant proteins. Three are
truncated proteins resulting from rare premature stop codons
(CYP3A4*6, CYP3A4*20 and CYP3A4*26 alleles),9,10,11 whereas the
rest are low-frequency/rare missense variants, some with reduced
enzymatic activity (e.g. CYP3A4*8, *11, *13, *16 and *17 alleles;
http://www.cypalleles.ki.se/). In addition, two noncoding SNPs have
been related to altered gene expression (e.g. CYP3A4*1B and
CYP3A4*22).12,13 On the whole, although several genetic
variants that affect CYP3A4 activity have been described, in general
these are rare or low-frequency alleles expected to explain only a
small fraction of CYP3A4 phenotypic variability.14
The CYP3A4*20 allele, a single base pair (A) insertion causing
a frameshift and premature stop codon in the protein
(c.1461_1462insA; p.P488Tfs*494), is one of the two CYP3A4 gene
variants in which lack of enzymatic activity has been demon-
strated. This allele was found in heterozygosity in an individual of
Brazilian descent with a sixfold increased exposure of a drug
metabolized by CYP3A4 and low systemic midazolam clearance,9
and classiﬁed as rare, as no CYP3A4*20 carriers were found in 428
Germans. This variant has not been described again, and there is
no data regarding its possible origin and distribution in different
populations. However, we found one CYP3A4*20 carrier upon
whole-exome sequencing of Spanish patients with severe
toxicity.15 This ﬁnding triggered this study investigating the
CYP3A4*20 allele distribution in Spain and worldwide. We ﬁnd that
1 in 82 Spanish individuals carries this allele, and haplotype
analyses suggest a Spanish founder effect. This is the ﬁrst
description of a loss-of-function CYP3A4 allele with a relatively
high frequency in a population, and demonstrates the poly-
morphic nature in this gene.
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MATERIALS AND METHODS
DNA from control individuals
DNA isolated from blood samples (FlexiGene DNA Kit; Qiagen, Hilden,
Germany) of 1977 Spanish, 450 Portuguese, 478 Italian, 240 Argentinean,
199 Bolivian, 29 Algerian, 95 Libyan, 117 Israeli, 133 Saudi Arabian, 83
Kuwaiti, 186 Pakistani and 108 Chinese controls were collected. All
individuals were over 18 years, the collection of samples was approved by
local internal ethical review committees and investigations were con-
ducted according to the principles expressed in the Declaration of Helsinki.
Genotyping of SNPs in CYP3A genes
In addition to CYP3A4*20 (rs67666821), the CYP3A single-nucleotide
polymorphisms (SNPs) CYP3A4*22 (rs35599367), CYP3A4*1B (rs2740574),
CYP3A5*3 (rs776746) and CYP3A7*2 (rs2257401) alleles were selected for
genotyping using the KASPar SNP Genotyping System (LGC Genomics,
Herts, UK) with 15 ng of genomic DNA. All assays included DNA control
samples with known genotypes and negative controls. The Sequence
Detection System ABI PRISM 7900HT (Applied Biosystems, Darmstadt,
Germany) was used for ﬂuorescence detection and allele assignment. The
accuracy of the genotyping was conﬁrmed by sequencing all CYP3A4*20
carriers, and a random selection of individuals with different CYP3A4*22,
CYP3A4*1B, CYP3A5*3 and CYP3A7*2 genotypes. PCR products were
puriﬁed and Sanger sequencing run on an ABI PRISM 3700 DNA Analyzer
capillary sequencer (Applied Biosystems).
Microsatellites markers
For haplotype analysis, a panel of four microsatellite markers on
chromosome 7q21-22 spanning an interval of 3.2 Mb was used: D7S651,
D7S2498, D7S2480 and D7S666 (Supplementary Figure 1). In brief, PCR was
carried out using speciﬁc primers, and with the forward primers labeled
with 6-Fam ﬂuorochrome. The diluted PCR products were mixed with Hi-Di
Formamide and LIZ-500 size standard (Applied Biosystems), separated and
detected using an ABI Prism 3100 automatic sequencer (Applied
Biosystems) and analyzed by Peak Scanner software version 1 (Applied
Biosystems).
Haplotype analysis and dating the origin of CYP3A4*20 allele
Haplotypes were identiﬁed using SNPs (CYP3A4*22, CYP3A4*1B, CYP3A5*3
and CYP3A7*2) and the four microsatellite markers in 20 CYP3A4*20 carriers
(19 Spanish and 1 Portuguese) and in 50 Spanish individuals wild type for
this variant, using PHASE software (University of Chicago, USA, http://c4c.
uwc4c.com/express_license_technologies/phase).16
The mutation origin of CYP3A4*20 variant was calculated using DMLE+
software version 2.3 developed by Reeve and Rannala17 (http://dmle.org/).
This program uses the Markov Chain Monte Carlo algorithm to allow
Bayesian estimation of the mutation age based on: the observed
haplotypes in variant carriers and unrelated normal individuals, map
distances between markers, the position of the mutation relative to the
markers and the estimated population growth rate.
Statistical analysis
Hardy–Weinberg equilibrium was tested for the SNPs genotyped and none
signiﬁcantly deviated from expected values.18 Fisher’s exact test was used
to examine the association between CYP3A4*20 allele frequency and
country of origin. P-values below 0.05 were considered statistically
signiﬁcant. SPSS version 19 was used for the statistical analysis.
RESULTS
CYP3A4*20 allele distribution in different populations
The Exome Variant Server (EVS) database (http://evs.gs.washing
ton.edu/EVS/) suggested that the loss-of-function CYP3A4*20 allele
is rare but detectable in some individuals, mainly of European
origin, and our ﬁnding of one carrier in a Spanish individual led us
to carry out a CYP3A4*20 allele frequency population study in
individuals from European, African and Asian descent (Table 1 and
Figure 1). As expected from previous data, no CYP3A4*20 carriers
were found in Italians, Argentineans, Bolivians and individuals
from different countries in Africa and Asia. However, the
CYP3A4*20 variant was detected in heterozygosity in 24 Spanish
individuals and in 1 Portuguese, revealing that 1.2% and 0.2%,
respectively, of these populations carried the variant (Table 1). The
unexpected high number of CYP3A4*20 allele carriers in the
Spanish individuals was signiﬁcantly different from the other
populations studied (Fisher's exact test Po0.0001).
Characterization of CYP3A4*20 allele frequency in different
Spanish regions
To determine CYP3A4*20 allele distribution within Spain, we
collected the place of birth of 1544 individuals among the 1953
genotyped Spanish controls. When comparing the CYP3A4*20
allele frequency with the region of birth, we found that the variant
had the highest frequency in individuals from Castilla y León,
Table 1. Distribution of CYP3A4*20 allele in different populations
Country Population CYP3A4 wild-type
homozygous (no.)
CYP3A4*20
heterozygous (no.)
CYP3A4*20
carriers (%)
Reference
Spain European 1953 24 1.21 This study
Portugal 449 1 0.22 This study
Italy 478 0 0 This study
Germany 428 0 0 Westlind-Johnsson et al.9
Argentinaa 240 0 0 This study
Boliviab 199 0 0 This study
European Americans 4119 8 0.19 EVSc
Libya African 95 0 0 This study
Algeria 29 0 0 This study
African Americans 2131 1 0.05 EVSc
Israel Asian 117 0 0 This study
Saudi Arabia 133 0 0 This study
Kuwait 83 0 0 This study
Pakistan 186 0 0 This study
China 108 0 0 This study
Abbreviations: CYP3A4, cytochrome P450 3A4; EVS, Exome Variant Server. aClassiﬁed as an European population because of the high number of Argentinians
of European origin. bIn Bolivian population, the European ancestry is 13–21% and the Native American component 77–86%. cData from EVS (http://evs.gs.
washington.edu/EVS/).
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Comunidad Valenciana and Extremadura, where we found one
heterozygous every 26, 33 and 48 individuals, respectively,
resulting in 3.8%, 3.0% and 2.1% CYP3A4*20 carriers (Figure 1
and Supplementary Table 1). In other Spanish regions, the
proportion of variant carriers ranged from 1.6 to 0.8%, with the
exception of Galicia, where no variant carriers were found
(Figure 1 and Supplementary Table 1).
CYP3A4*20 ancestral haplotype
To investigate whether all occurrences of CYP3A4*20 allele
descended from a single ancestral mutation event or arisen
independently, we constructed haplotypes with CYP3A4*20, four
SNPs in CYP3A locus and four microsatellite markers
(Supplementary Figure 1). Haplotype reconstruction in 20
CYP3A4*20 allele carriers suggested that all carriers showed a
common haplotype (282, 172, A, C, InsA, C, G) that contained this
variant and spanned ~ 700 kb (from microsatellite D7S2480 to SNP
CYP3A5*3; Figure 2 and Supplementary Figure 2). The CYP3A4*20
haplotype contained wild-type alleles for CYP3A4*22, CYP3A4*1B
and CYP3A7*2, and carried CYP3A5*3, the most common variant in
Caucasians. In 50 individuals wild type for CYP3A4*20, represent-
ing the control Spanish population, 27 different haplotypes
existed with frequencies ranging from 18 to 1% (Figure 2). Further-
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Figure 1. Geographical distribution of CYP3A4*20 allele. World map showing the percentage of CYP3A4*20 allele carriers in different
populations. The Spanish peninsula is shown in greater detail. Number of carriers and individuals studied are presented in Table 1 and in
Supplementary Table 1. *Concerning United States of America, the data corresponds to the EVS, the ﬁrst number refers to African Americans
and the second to European Americans.
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x 270 180 A C - C G x 1
x 284 180 A C - C G x 1
x 290 181 A C - C G x 1
x 286 182 A C - C G x 1
x 286 180 A C - C G x 11
x 290 180 A C - C G x 10
x 288 180 A C - C G x 4
x 288 182 A C - C G x 3
x 290 176 A C - C G x 2
x 286 180 A T - C G x 3
x 270 180 A T - C G x 1
x 288 180 A T - C G x 2
x 270 166 A C - G G x 1
x 270 172 A C - G G x 2
x 270 172 A C - G A x 3
x 288 180 A C - G A x 1
x 288 180 G C - G A x 1
Indiv
CYP3A4*20
(n=20)
Indiv
not CYP3A4*20
(n=50)
Figure 2. CYP3A4*20 haplotype analysis. Haplotypes were identiﬁed using PHASE in 20 CYP3A4*20 carriers and 50 Spanish control individuals
with 5 SNPs (CYP3A4*1B, CYP3A4*22, CYP3A4*20, CYP3A7*2 and CYP3A5*3) and 4 microsatellite markers at 7q (D7S666, D7S2480, D7S2498 and
D7S651), spanning an interval of 3.2 Mb. For the 20 CYP3A4*20 carriers only the haplotype containing the mutation is shown; for the 50 non-
carriers the 100 haplotypes are shown. D7S666 and D7S651 showed variability within the CYP3A4*20 haplotype, this is indicated as “x”.
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more, 4 out of the 100 chromosomes analyzed were predicted to
carry the same haplotype as CYP3A4*20 but without this mutation
(282, 172, A, C, –, C, G). This result suggests a single ancestral allele
in which the variant was likely originated.
Age of CYP3A4*20 variant
The decay of linkage disequilibrium due to recombination can be
used to date the age of a mutation. We used the DMLE+ software
to estimate the age of CYP3A4*20 variant using the haplotype data
from the 20 CYP3A4*20 carriers and 50 Spanish controls previously
studied. The mutation age was estimated to be 51 generations
(95% credible interval of 43–60) using an average growth rate of
0.25. Assuming 20 years for a generation, the age of the variant
was estimated to be 1020 years old. For growth rates of 0.15 and
0.35, mutation age was estimated to be 82 and 38 generations,
respectively.
DISCUSSION
In contrast to the high polymorphic nature of most drug-
metabolizing enzymes, CYP3A4 gene exhibits little genetic
variability. The Human CYP Allele Nomenclature Database
(http://www.cypalleles.ki.se/) includes only three loss-of-function
CYP3A4 alleles (CYP3A4*6, CYP3A4*20 and CYP3A4*26) and the EVS
database (http://evs.gs.washington.edu/EVS/) suggests that only
0.2% of Americans carry CYP3A4-defective variants and 2%
missense variants, many of which have unknown functional
signiﬁcance. The CYP3A4*20 allele, which encodes a truncated
protein devoid of catalytic activity,9 is the most common CYP3A4-
defective allele in the EVS database with 0.2% and 0.05% of
European Americans and African Americans carriers, respectively
(i.e. 8 carriers out of 4127 and 1 carrier out of 2132 individuals),
whereas it was not detected in 428 German individuals.9 In the
present study, we found that 1.2% of the Spanish population (24
out of 1977 individuals) carry the CYP3A4*20 allele, compared with
0.2% in Portugal (1 out of 450) and no carriers in Italy, Argentina,
Bolivia, Libya, Algeria, Israel, Kuwait, Saudi Arabia, Pakistan and
China (Figure 1). On the whole, one in 82 Spanish carried this
variant. Within Spain, this ﬁgure increased to one CYP3A4*20
carrier every 26 individuals in Castilla y León, one in 33 in
Comunidad Valenciana one in 48 individuals in Extremadura.
These results constitute the ﬁrst proof that CYP3A4 loss-of-function
alleles can be classiﬁed as polymorphisms (i.e. with allele
frequencies above 1%) and affect a substantial number of
individuals, in speciﬁc populations/regions.
Haplotype analysis suggested that CYP3A4*20 appeared in a
haplotype present in only 4% of chromosomes of the Spanish
population, and containing the most common Caucasian variants
for the CYP3A SNPs genotyped (i.e. wild-type CYP3A4*22,
CYP3A4*1B and CYP3A7*2, and variant CYP3A5*3 allele; see
Figure 2).19 The highest frequency of CYP3A4*20 in Spain and
the infrequent detection outside the Spanish peninsula, together
with a 700 kb haplotype common to all mutation carriers
(Supplementary Figure 2), suggests a recent occurrence of the
mutation. In agreement with this, dating of CYP3A4*20 mutation
suggested that it appeared about 1000 years ago. Altogether,
these data are compatible with a single origin of the mutation in
Spain, and then spreading to different geographical areas in
recent times.
CYP3A4 has a prominent role in the biotransformation of a
broad range of xenobiotics, including many clinical drugs,14 and
contributes to the metabolism of endogenous substrates such as
vitamine D3, arachidonic acid, bile acids and steroid hormones.2,20
It has been suggested that the CYP3A4 gene allows little variation
owing to this fact and only one individual being homozygous for
defective CYP3A4 alleles has been described.11 With the exception
of drug metabolism impairment, no other major phenotype could
be detected in Cyp3a knockout mice.21,22 Alternative enzymes
may have compensated the effect on the metabolism of
endogenous compounds, whereas the prominent decrease in
xenobiotic biotransformation would only manifest after xenobiotic
exposure. In contrast, in a human CYP3A4-transgenic mouse line,
the females were found to be deﬁcient in lactation, leading to a
markedly lower pup survival, and the mammary glands of the
Tg-CYP3A4 lactating mothers had underdeveloped alveoli with
low milk content.23 Because of the absence of a null phenotype in
mice, the small number of individuals expected to be homozygous
for CYP3A4*20 (i.e. one in 4100 individuals in Castilla y León) might
not have any clinical manifestation, although a very severe toxicity
proﬁle would be expected when exposed to drugs metabolized by
this enzyme.11 CYP3A4*20 heterozygous carriers, with decreased
CYP3A4 activity, may not show an effect when treated with single
doses of wide therapeutic index drugs, but may show altered
response upon treatment with narrow therapeutic index drugs.
This is supported by Westlind-Johnsson et al.9 who described a
sixfold higher exposure to a drug metabolized by CYP3A4 and low
systemic midazolam clearance in an individual heterozygous for
the CYP3A4*20 allele9 and by a sevenfold higher risk of paclitaxel
dose reductions because of peripheral neuropathy in the
CYP3A4*20 carriers as described by us.15 We also found that
CYP3A4*20 is independent of CYP3A4*22, an intronic polymorph-
ism robustly associated with a decreased elimination of CYP3A4
substrates and carried by about 5–7% of Caucasians.13,24 Thus, a
highly reduced CYP3A4 activity would be expected in individuals
carrying both of these two alleles.
In conclusion, this is the ﬁrst demonstration of a polymorphic
nature of CYP3A4 gene, with 1.2% of Spanish individuals carrying
CYP3A4*20 allele, likely due to a founder effect. Furthermore, the
key role of CYP3A4 in drug metabolism and in preliminary clinical
evidences support an increased risk of unexpected drug responses
in CYP3A4*20 carriers and suggest the importance of implement-
ing CYP3A4*20 genotyping in the clinic, at least in the Spanish
population.
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SUPPLEMENTARY MATERIAL 
 
Supplementary Table 1. Distribution of CYP3A4*20 allele in Spain. 
 
Region in Spain 
CYP3A4 wild type 
homozygous (Nr) 
CYP3A4*20 
heterozygous (Nr) 
CYP3A4*20  
carriers (%) 
Castilla León 151 6 3.8 
Comunidad Valenciana 129 4 3.0 
Extremadura 142 3 2.1 
Castilla la Mancha 62 1 1.6 
Andalucia 113 1 0.9 
Cataluña 126 1 0.8 
Comunidad Madrid 508 4 0.8 
Galicia 153 0 0.0 
Other Spanish regions* 78 1 0.4 
No birth place data 491 3 0.6 
TOTAL 1953 24 1.2 
 
*Other Spanish regions: 57 from Murcia, 5 from Asturias, 4 from Navarra  (1 of them CYP3A4*20 carrier), 4 from País 
Vasco, 3 from Cantabria, 2 from Aragón, 2 from Ceuta y Melilla, 1 from Canarias and 1 from Islas Baleares. 
 
 
Supplementary Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representation of the microsatellites and SNPs used for haplotype analysis. Graph indicates the location of 
microsatellites (D7S651, D7S2498, D7S2480 and D7S666) and SNPs (CYP3A4*22, CYP3A4*1B, CYP3A7*2 and 
CYP3A5*3) used for haplotype analysis. Microsatellites location is indicated with respect to CYP3A4*20. CYP3A 
locus is magnified indicating the orientation of the genes. Sanger sequencing of a CYP3A4*20 (c.1461_1462insA) 
heterozygous variant is shown.  
Article 4 
103 
 
Supplementary Figure 2 
 
 
Haplotypes of CYP3A4*20 carriers. PHASE was used to determine the common haplotype in the 20 CYP3A4*20 
carriers used in the analysis. D7S651 and D7S666 were not amplified for samples 222 and 260. Recurring 
haplotypes are color shaded. 
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ARTICLE 5: Targeted exome sequencing identifies markers of chemotherapy-induced 
peripheral neuropathy 
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Romero-Laorden, María Sereno, María Merino, María Currás, Cristina Montero-Conde, Veronika 
Mancikova, Elisabeth Åvall-Lundqvist, Henrik Green, Fátima Al-Shahrour, Alberto Cascón, Mercedes 
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Under review in Clinical Cancer Research 
 
Abstract: 
As previously mentioned, paclitaxel is a microtubule stabilizing agent widely used to treat solid 
tumors. However, paclitaxel-induced neuropathy can limit treatment success and importantly reduce the 
quality of life of the patients. Although polymorphisms in paclitaxel metabolizing enzymes, in paclitaxel 
targets and in EPHA genes have been associated with neuropathy, they only show moderate effects. In 
this study we proposed that low-frequency variants with strong effects, may also contribute to the 
variability in neuropathy susceptibility observed among patients. To test this hypothesis, we designed 
and performed a targeted exon sequencing analysis of 39 genes including EPHA family genes, genes 
involved in paclitaxel pharmacokinetics and genes causative of familial neuropathies (Charcot-Marie-
Tooth). In total 228 patients with high or no/low paclitaxel-induced neuropathy were analyzed. 
In the discovery series, EPHA6 was the gene most significantly associated with paclitaxel-
induced neuropathy (P=0.041). Interestingly, low frequency non-synonymous variants in EPHA6 were 
present exclusively in patients with high neuropathy and all affected the ephrin receptor ligand binding 
domain. In addition, using cumulative paclitaxel dose analysis we observed a significantly higher 
neuropathy risk for carriers of EPHA5/6/8 low-frequency non-synonymous variants. This association 
was further confirmed in an independent cohort of 202 patients treated with paclitaxel.  
In conclusion, this is the first study identifying low-frequency variants in EPHA6, EPHA5 and 
EPHA8 as markers of paclitaxel-induced neuropathy susceptibility. This further support that these genes 
are relevant neuropathy markers for other neurotoxic agents. 
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Personal contribution: I participated in the selection of the patients, I processed the DNAs to create 
the next generation sequencing libraries and performed the targeted NGS using a MiSeq Illumina 
sequencer. I validated selected variants through Sanger sequencing. Moreover, I collaborated in the 
variant analyses (SKAT and Chi square tests). I generated the graphs to represent EPHA variants using 
Illustrator for Biological Sequences. Finally, I contributed to the discussion of the results and I was the 
principal author drafting the paper. 
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Translational Relevance  
Paclitaxel treatment frequently causes peripheral neuropathy, an adverse event that can limit treatment 
course and lead to permanent symptoms drastically decreasing quality of life. Our group has contributed 
to the identification and validation of common polymorphisms in EPHA genes associated with paclitaxel 
neuropathy, but a large part of the inter-individual variation in neuropathy remains unexplained. We 
hypothesized that low-frequency variants with strong effects may contribute to the neuropathy 
variability in patients. By performing targeted exon sequencing of candidate genes we found that 
patients carrying low-frequency non-synonymous coding variants in EPHA5/6/8 contribute to 
paclitaxel-induced neuropathy susceptibility. Furthermore, these genes might also be relevant 
neuropathy markers for other neurotoxic drugs due to the involvement of Eph receptors in neuronal 
functions.  
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ABSTRACT 
 
Purpose: Neuropathy is the dose limiting toxicity of paclitaxel and a major cause for decreased quality 
of life. Genetic factors have been shown to contribute to paclitaxel neuropathy susceptibility; however, 
the major causes for inter-individual differences remain unexplained. In this study we identified genetic 
markers associated with paclitaxel-induced neuropathy through massive sequencing of candidate genes.  
 
Experimental Design: We sequenced the coding region of 4 EPHA genes, 5 genes involved in 
paclitaxel pharmacokinetics and 30 Charcot-Marie-Tooth genes, in 228 cancer patients with no/low 
neuropathy or high grade neuropathy during paclitaxel treatment. An independent validation series 
included 202 paclitaxel-treated patients. Variation-/ gene-based analyses were used to compare variant 
frequencies among neuropathy groups and Cox regression models were used to analyze neuropathy 
evolution along treatment. 
 
Results: Gene-based analysis identified EPHA6 as the gene most significantly associated with 
paclitaxel-induced neuropathy. Low frequency non-synonymous variants in EPHA6 were present 
exclusively in patients with high neuropathy and all affected the ligand binding domain. Accumulated 
dose analysis in the discovery series showed a significantly higher neuropathy risk for EPHA5/6/8 low-
frequency non-synonymous variant carriers (HR=18.04, 95%CI=2.87-113.36, P=0.0020) and an 
independent cohort confirmed an increased neuropathy risk (HR=1.96, 95%CI=1.08-3.56; P=0.028). 
Combining the series gave an estimated 2.81- fold higher risk of neuropathy (95%CI=1.63-4.86; 
P=2.1x10-4). 
 
Conclusion: This first study sequencing EPHA genes revealed that low frequency variants in EPHA6, 
EPHA5 and EPHA8 contribute to the susceptibility to paclitaxel-induced neuropathy. Furthermore, 
EPHAs neuronal injury repair function suggests that these genes might constitute important neuropathy 
markers for many neurotoxic drugs.  
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INTRODUCTION  
The anticancer agent paclitaxel is a microtubule inhibitor widely used in the treatment of many 
solid tumors (1). Peripheral neuropathy is its dose-limiting toxicity (2), and severe neuropathy cases 
with an important reduction in the quality of life of the patients are not rare (3, 4). The lack of effective 
treatments for the neuropathy creates an urgent need to identify markers that can help to personalize 
treatment and avoid severe neuropathy events. The patient genetic background has been proposed to 
play a relevant role in the susceptibility for suffering neuropathy (5). In this regard, paclitaxel 
pharmacokinetic (6, 7) and pharmacodynamic (8, 9) pathways have been included in studies of candidate 
genes and, more recently genome-wide association studies (GWAS) have been performed (10, 11).  
Candidate gene studies, by us and other groups, have demonstrated that common variants in 
paclitaxel metabolizing enzymes and paclitaxel target (i.e. CYP2C8*3 (12-14), CYP3A4*22 (7), 
TUBB2A rs909964 and rs909965 (8, 9)) influence neuropathy risk, while genome wide genotyping has 
uncovered novel genes (10, 11). A GWAS by our group (11) suggested that the EPHA gene family, 
which plays a key role in the development of nervous system and in nerve injury repair (15-17), was a 
key player for paclitaxel neuropathy susceptibility. Meta-analysis of GWAS top hits showed that 
EPHA5 rs7349683 reached genome-wide significance (11), and follow-up studies further supported that 
this variant (18), EPHA6 rs301927 (9, 18) and EPHA8 rs209709 (18) moderately increased paclitaxel-
induced neuropathy risk. However, large part of the variation in paclitaxel-induced neuropathy remains 
unexplained.  
Low-frequency variants with strong effects may contribute to the neuropathy variability 
observed in patients. To investigate this hypothesis sequencing technologies are required and, so far, 
only two exploratory studies following different strategies have been performed. In one we applied 
whole exome sequencing to few extreme neuropathy patients, and identified defective CYP3A4 variants 
associated with the neuropathy (19). The second study sequenced genes causative of familial 
polyneuropathies (Charcot-Marie-Tooth, CMT), and suggested ARHGEF10 and PRX as chemotherapy-
induced neuropathy markers (20). These initial studies are promising, however, the statistical power for 
a whole exome sequencing study is low and in the CMT analysis key genes were excluded.  
Here, we performed targeted exome sequencing of genes with common variants associated with 
paclitaxel-induced neuropathy (EPHA4, EPHA5, EPHA6 and EPHA8) plus genes involved in paclitaxel 
pharmacokinetics and in CMT. In total we sequenced 39 genes in 228 selected patients with high or 
no/low paclitaxel-induced neuropathy. The strongest association corresponded to EPHA6, and the 
relevance of low frequency EPHA5/6/8 non-synonymous coding variants was validated in an 
independent cohort of 202 paclitaxel-treated patients. These results reveal EPHA genes as key players 
in chemotherapy-induced neuropathy and stress the importance of gene sequencing for identifying 
genetic risk factors of neuropathy. 
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PATIENTS AND METHODS 
Patients  
The discovery series was derived from a set of 449 breast or ovarian cancer patients treated with 
paclitaxel (97% in first line), with DNA available, no previous neurotoxic drug treatments and with 
clinical data and neuropathy assessment; some have already been reported (18, 19, 21). In these patients 
the neuropathy was homogenously graded (19), and 228 were selected for whole or targeted exon deep-
sequencing, based on extreme-neuropathy phenotype. Among them, 131 were high-neuropathy patients 
that fulfilled the following criteria: grade 3 or 2 neuropathy (NCI-CTC v4) during paclitaxel treatment, 
no neuropathy risk factors (diabetes, alcoholism, AIDS or previous neuropathies), and treatment 
modifications due to neuropathy (dose reduction or treatment suspension) or neuropathy that lasted >6 
months after paclitaxel treatment finished. The remaining 97 patients were no/low-neuropathy patients 
with no neuropathy signs or grade 1 neuropathy after receiving paclitaxel (Table 1).  
The validation of results was performed in an independent series of 202 paclitaxel-treated 
patients with neuropathy data recorded cycle by cycle. Most patients had breast or ovarian tumors, 109 
were Spanish (54%) and 93 Swedish (46%). 129 samples corresponded to a previous GWAS study (11), 
37 to Spanish patients already described (18) and 36 samples were new cases collected in Spain. From 
all patients cumulative paclitaxel dose up to grade 2 (NCI_CTC v2/4) neuropathy was available (Table 
1).  
All individuals participating in the study were over 18 years of age, had been diagnosed of 
cancer with histological confirmation, a life expectancy of ≥12 weeks and ECOG performance status 
≤2, adequate bone marrow and renal and hepatic function. The recruitment of patients and collection of 
samples was approved by local internal ethical review committees and all patients gave written informed 
consent to participate in the study.  
 
Next generation sequencing (NGS) 
From the 228 patients used in the discovery series, 196 samples were processed using the TruSeq 
Custom Amplicon Kit (Illumina) covering the coding plus 25 bp intronic flanking region of 39 genes 
that included: EPHA4, EPHA5, EPHA6 and EPHA8 (10, 11) plus additional genes involved in paclitaxel 
metabolism and transport (ABCB1, CYP2C8, CYP3A4, SLCO1B1, SLCO1B3) and a selection of 30 
genes associated with CMT hereditary peripheral neuropathies (Fig. 1). Very conserved CMT genes 
with no/very few variants reported were not selected for sequencing (e.g. ATL1, EGR2, GDAP1, GJB1, 
LMNA, PRPS1, RAB7A, YARS). In brief, 150 ng of DNA extracted from peripheral blood (FlexiGene 
DNA Kit, Qiagen) was used to construct libraries and sequenced in a MiSeq sequencer (Illumina, Spain) 
with a paired-end mode using MiSeq Reagent Kit V3 (Illumina, Spain) and 600 cycles. In addition, 
whole exome sequencing was performed on the remaining 32 patients (16 with high neuropathy (8 have 
been reported (19)) and 16 patients with no neuropathy), as previously described (19).  
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For the validation of the results, a TruSeq Custom Amplicon Kit (Illumina) including the coding 
and intronic flanking region of EPHA5, EPHA6 and EPHA8 was used. 
 
Variant identification  
Targeted NGS data was demultiplexed with MiSeq Reporter (Illumina). Alignment was 
performed using Smith-Waterman algorithm (22) using GRCh37/hg19 assembly as reference and 
Genome Analysis Toolkit v2 (GATK, (23)) was used for raw variant calling. For the 32 samples with 
whole exome sequencing data, alignment and variant calling were performed by RUbioSeq software 
v3.7 (24). In this software the alignment was performed using Burrows-Wheeler alignment (25), 
unmapped reads are realigned using BFAST (26) and for variant calling, GATK v2 was used (23). 
Variants were annotated with Snp Eff (http://snpeff.sourceforge.net/) and Variant Effect Predictor 
(http://www.ensembl.org/info/docs/tools/vep/index.html), and only non-synonymous coding variants 
and those altering canonical splice sites, with P>0.001 for Hardy Weinberg Equilibrium were considered 
in subsequent steps. Supplementary Table 1 indicates gene and transcript references. 
Variants included in the analysis were: i) those previously described in public databases 
(dbSNP, http://www.ncbi.nlm.nih.gov/SNP/; Exome Aggregation Consortium (ExAC), 
http://exac.broadinstitute.org), and ii) variants not previously described with: high variant call quality 
(Q>30), read depth >10X and alternative variant frequency higher than 0.3 in at least one individual. 
Sequencing artefacts, defined as nucleotide changes detected in >20 samples in the sequencing panel 
but never described in ExAC, were omitted from the analysis. We defined loss of function (LOF) 
variants as those introducing stop codons (nonsense), variants disrupting canonical splice sites and 
indels disrupting the reading frame. Template and configuration files for alignment and scripts are 
available at https://github.com/htejero/PaclitaxelNeuropathy. 
Validation of variants was performed by Sanger sequencing with an ABI PRISM 3700 DNA 
Analyzer capillary sequencer (Applied Biosystems) on 3% of the LOF and missense variants included 
in the analysis. 
 
Data analysis 
Variants were classified as “common variants” if they had a minor allele frequency (MAF) 
≥0.5% in the more than 30.000 sequenced non-Finnish Europeans from ExAC. Variants were classified 
as “low frequency variants” if they had a MAF <0.5% in the non-Finnish Europeans from ExAC and 
MAF <1% in 578 Spanish exomes from the CIBERER Spanish Variant Server 
(http://csvs.babelomics.org/). The purpose of including the Spanish data was to detect population 
specific variants, because of the small sample size (n<600) the MAF threshold in this population was 
less stringent. For common variants, the frequency of each variant in the high versus no/low neuropathy 
group was compared with a Chi2 or Fisher test.  
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For low frequency variants, the association with paclitaxel-induced neuropathy was assessed 
with the gene-based Burden test (27) using the SKAT package and R statistical software (http://www.R-
project.org/). Scripts are available at https://github.com/htejero/PaclitaxelNeuropathy. Based on 
statistical power calculations, only genes with ≥ four rare variants were included in the analysis.  
For samples with cycle by cycle neuropathy data, association between EPHA variants and 
paclitaxel neuropathy risk was tested using Kaplan-Meier analysis, modelling the cumulative dose of 
paclitaxel up to the development of grade 2 neurotoxicity. Patients with no or low neuropathy (grade 
0/1) were censored at total cumulative dose. We also evaluated the association using univariate and 
multivariable Cox regression analysis (14), the latter including country of origin as covariate. SPSS 
software package v.19 was used for these analyses. P values less than 0.05 were considered statistically 
significant. 
 
RESULTS 
Study population and NGS 
NGS was performed on selected cases: 131 patients with high neuropathy (grades 2/3 that lasted 
a mean of 55 months) despite low accumulated paclitaxel dose (median= 1295 mg) and 97 patients with 
no/low neuropathy (grades 0/1) despite high accumulated paclitaxel dose (median= 1485 mg) (Table 1). 
In addition, 33% of patients in the high neuropathy group had paclitaxel dose reductions or treatment 
suspensions caused by the neuropathy.  
Sequencing of 39 candidate genes in the 228 patients identified 277 coding non-synonymous or 
canonical splice site variants (266 missense, 3 in-frame deletions, 8 LOF; Suppl. Table 1). From these, 
86 were common variants present in all genes except for CYP3A4, EPHA4, HSPB1, HSPB8, NDRG1 
and SPTLC2 (which only had low frequency variants) and NEFL (with no variants detected). When the 
presence of these common variants was compared among the neuropathy groups, association with 
paclitaxel neuropathy was found for only 2 SNPs located in CYP2C8 and PRX (P<0.05; Suppl. Table 
2).  
The remaining 191 variants were low frequency variants and were present in all genes except 
for NGF (with only common variants) and NEFL (with no variants). Among these, 3 altered canonical 
splice sites, 2 were nonsense variants and 3 were indels causing frameshifts leading to premature stop 
codons (Table 2). 
 
Gene-based analysis of paclitaxel-induced neuropathy 
Analysis of the low frequency variants identified EPHA6 as the gene most significantly 
associated with paclitaxel-induced neuropathy (Table 3). The 5 carriers of these variants were all high 
neuropathy patients with an amino acid change in the ephrin receptor ligand binding domain of the 
protein. Remarkably, no EPHA6 variant carriers were present in the no/low-neuropathy group, 
suggesting a strong effect on neuropathy.  
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One additional gene had this characteristic (SEPT9), but results did not reach statistical 
significance level. The other two EPHA genes analyzed, EPHA5 and EPHA8, have a similar biological 
function as EPHA6 (15-17) and also belonged to the high-neuropathy risk group of genes (Table 3). In 
EPHA5, 5 carriers had high neuropathy versus 1 with low neuropathy; and in EPHA8, 9 carriers were 
in the high neuropathy and 6 in the no/low neuropathy group (Fig. 2; Suppl. Table 1). The highly 
conserved EPHA4, with only 2 carriers, one in each group, could not be analyzed. 
Some of the discovery series patients had cycle by cycle neuropathy data available and among 
these, 3 were carriers of low-frequency variants in EPHA5/6/8 genes (one variant in each gene). 
Accumulated paclitaxel dose analysis revealed that these patients had a significantly higher risk to suffer 
from neuropathy than patients without EPHA low frequency variants (HR=18.04, 95%CI=2.87-113.36, 
P=0.0020; Fig. 3A). 
 
Low frequency variants in EPHA6, EPHA5 and EPHA8 confirmed as neuropathy risk factor 
Sequencing EPHA5/6/8 in an independent cohort of 202 patients treated with paclitaxel and 
detailed cycle by cycle neuropathy data (Table 1), revealed 15 carriers of low frequency missense 
variants in these genes (one corresponded to EPHA6, one to EPHA5 and 13 to EPHA8). These variants 
were combined and an accumulated paclitaxel dose analysis revealed that low frequency EPHA5/6/8 
variants conferred increased risk of neuropathy (HR=1.96, 95%CI=1.08-3.56, P=0.028; Fig. 3B). 
Combining discovery and validation series, resulted in a HR of 2.81 (95%CI=1.63-4.86) with a P value 
of 2.11x10-4 (Fig. 3C). 
 
DISCUSSION 
Paclitaxel induced-neuropathy is a clinically relevant toxicity affecting large number of cancer 
patients. Genetic variation has been shown to influence susceptibility to paclitaxel-induced neuropathy, 
however, a large part of the variation remains unexplained. Low-frequency variants with strong effects 
may explain part of the variability. To investigate this hypothesis, we performed massive sequencing of 
candidate genes in patients selected based on extreme-neuropathy phenotype. Gene-based analysis 
identified, for the first time, low frequency genetic variants in EPHA5/6/8 as risk factors of 
chemotherapy induced neuropathy. These results may provide a basis for personalizing paclitaxel 
treatment and decreasing the incidence of severe chemotherapy-induced neuropathies. 
GWAS studies have identified common variants in EPHA genes with moderate effects on 
paclitaxel-induced neuropathy (EPHA5-rs7349683, EPHA6-rs301927, EPHA8-rs209709 and EPHA4-
rs17348202) (10, 11) and subsequent studies further supported the association of EPHA5, EPHA6 and 
EPHA8 polymorphisms (9, 18). Non-synonymous coding variants, potentially affecting protein 
function, are expected to have stronger effects on neuropathy than common regulatory variants (28). 
Following this idea, we performed a NGS study in EPHA genes, together with paclitaxel 
pharmacokinetics and hereditary peripheral neuropathy related genes.  
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Gene-based analysis of our data revealed that low frequency missense variants in EPHA6 
increased paclitaxel-induced neuropathy risk. All these variants were located in the ephrin receptor 
ligand binding domain, suggesting an alteration of the protein function and further supporting the 
association. EPHA5 and EPHA8 followed a similar trend (Fig. 2). In total, 15% (19 of 131) of patients 
in the high neuropathy group carried low frequency non-synonymous coding variants in EPHA5/6/8 
genes. In the 202 patients of the validation series, 13 EPHA8 variant carriers were identified but only 
one EPHA6 and one EPHA5 carriers were detected, suggesting that EPHA6 and EPHA5 variants 
(present in 5 out of the 131 patients with high-neuropathy of the discovery) are less frequent in an 
unselected patient population, including many moderate-neuropathy patients (not represented in the 
discovery set). Thus, EPHA6 and EPHA5 variant carriers were scarce in the validation series, and the 
calculated EPHA-effect mainly derived from EPHA8. Despite this, the accumulated dose analysis is a 
sensitive approach (18, 21) and was able to detect a statistically significant association. Altogether, these 
data suggest a relevant role for EPHA5/6/8 genes in paclitaxel-induced neuropathy and indicates a high 
impact of low frequency variants missed in GWAS.  
Eph receptors are tyrosine kinases involved in neural development (15) and nerve regeneration 
after damage (17, 29) among other functions: EphA4 controls axon sprouting/ nerve regeneration after 
spinal cord injury (30-32); EphA5 plays an important role in the initiation of the early phases of 
synaptogenesis (33) and it has been found upregulated in mice with injured sciatic nerve (34); EphA6 is 
involved in neural circuits underlying aspects of learning and memory (35); and EphA8 induces neurite 
outgrowth through induction of sustained MAPK activity (36) while lack of this gene produces aberrant 
axonal projections (37). Knocking out EphA4, EphA5, Eph6 and EphA8 genes in mice, results in viable 
and fertile animals with different neurological phenotypes. EphA4 knockout mice have gross motor 
dysfunction (38-40) and altered axonal regeneration and functional recovery following spinal cord 
injury (41). Knocking-out the tyrosine kinase domain of EphA5 results in axon aberrations in 
topographic mapping and altered behavioral patterns (42, 43). EphA8 knockout mice have abnormal 
axonal projections in the spinal cord (37) and EphA6 knockout mice experienced behavioral deficits in 
learning and memory tests (35). Thus, these are crucial genes for neural development and nerve 
regeneration with a plausible link for the association found with paclitaxel-induced neuropathy. 
In ExAC database 0.1% of the European non-Finish population are carriers of LOF variants in 
either EPHA5, EPHA6 or EPHA8, and on >100,000 Islandic individuals, two complete human 
knockouts for EPHA5 and one for EPHA6 were identified (44). So far, no phenotype has been assigned 
to these individuals who are apparently healthy subjects. However, based on the literature and on our 
results, a high susceptibility to drug-induced neuropathy would be expected.  
Concerning other genes potentially associated with the neuropathy, in line with Beutler et al 
(20) we postulated that variants moderately affecting the function of CMT genes, while not being 
pathogenic, may increase the susceptibility to drug-induced neuropathy.  
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We did not find low frequency variants in PRX and common variants in ARHGEF10 associated 
with paclitaxel-induced neuropathy, although the 2nd and 3rd top protective genes were these two, 
similarly to Beutler et al. For the ARHGEF10 common variant rs9657362 we also found a trend towards 
protection (20, 45). We also observed a trend towards increased neuropathy risk for other CMT genes 
(SEPT9 and SH3TC2). Variability in results among studies may be related to differences in neuropathy 
definitions/ assessments, in tumor types and patient treatments, or in the distribution of low-frequency 
variants, which have shown to be population-specific. Thus, results need to be further explored and 
validated in large independent series. 
With regards to the LOF variants detected in this study, three occurred in CMT genes 
(ARGHEF10, IKBAP and DHTKD1). The patients with variants in ARGHEF10 and IKBAP belonged to 
the no/low neuropathy group, in agreement with the fact that activating rather than LOF mutations in 
ARGHEF10 cause CMT (46) and that no phenotype is observed for IKBAP heterozygous individuals 
(47). The variant in DHTKD1 was present in two patients with different neuropathy, but recent data 
question the role of this gene in CMT disease (48, 49). Among the remaining LOF variants, two affected 
EPHA genes (EPHA5 and EPHA8) and corresponded to high-neuropathy patients. One LOF occurred 
in the paclitaxel uptake transporter SLCO1B1, in a high neuropathy patient. Two occurred in CYP3A4, 
a gene in which we have demonstrated that defective variants increased neuropathy risk (19). Two 
patients were carriers of the CYP3A4*20 frameshift allele and belonged to the high-neuropathy group, 
but one patient with a splicing defect affecting the last exon belonged to the no/low neuropathy group. 
The effect of this latter variant on the splicing of the gene and how it affects function remains to be 
studied.  
Limitations of this study include gene selection, since relevant genes not yet connected with 
neuropathy susceptibility may have been excluded. There are also differences in the selection of patients 
in the discovery and validation series and, as mentioned before, although the number of patients in the 
study is substantial and the neuropathy assessment was homogenously performed to reduce subjectivity 
(11, 19), detection of low/ moderate effects on neuropathy may require even larger samples sets. 
In conclusion, this study proves a relevant role of EPHA5, EPHA6 and EPHA8 genes in 
paclitaxel-induced neuropathy susceptibility and suggests that sequencing studies, rather genotyping, 
would be adequate approaches to study genetic markers of neuropathy. Moreover, taking into account 
the role of these proteins in neural development and injury repair, EPHA variants may also confer 
increased neuropathy risk to many additional neurotoxic drugs. The final goal is to identify genetic risk 
factors that can help to personalize neurotoxic drug treatments and avoid severe chemotherapy-induced 
neuropathies that can seriously affect patients’ quality of life. 
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TABLES 
 
Table 1. Characteristics of the patients in the discovery (n=228) and validation (n=202) series. 
Characteristics 
Discovery series Validation series 
High 
neuropathy  
No/ low 
neuropathy  
Cycle by cycle 
neuropathy data 
Number of patients 131 97 202 
Age (years)    
Median (min-max) 54 (35-82) 48 (32-73) 60 (34-82) 
Gender    
Female 131 (100%) 97 (100%) 187 (93%) 
Male 0 (0%) 0 (0%) 15 (7%) 
Tumor type    
Breast 121 (92%) 82 (85%) 47 (23%) 
Ovary 10 (8%) 15 (15%) 120 (60%) 
Others 0 (0%) 0 (0%) 35 (17%) 
Type of paclitaxel treatment    
First line 129 (99%) 95 (98%) 192 (95%) 
Second linea 2 (1%) 2 (2%) 10 (5%) 
Paclitaxel treatmentb    
FEC+T 81 (62%) 23 (24%) 0 (0%) 
AC+T 18 (14%) 18 (19%) 35 (17%) 
T+FEC 14 (11%) 29 (30%) 0 (0%) 
C+T 10 (7%) 15 (15%) 156 (77%) 
Others 8 (6%) 12 (12%) 11 (6%) 
Number of paclitaxel cycles    
Median (min-max) 8 (3-13) 10 (6-27) 7 (2-44) 
Paclitaxel accumulated total dose (mg)    
Median (min-max) 1295 (450-1600) 1485 (900-4059) 1225 (114-3150) 
Maximum sensory neuropathy gradec    
Grade 0 0 (0%) 56 (58%) 32 (16%) 
Grade 1 0 (0%) 41 (42%) 42 (21%) 
Grade 2 30 (23%) 0 (0%) 78 (38%) 
Grade 3 101 (77%) 0 (0%) 50 (25%) 
Dose modifications due to neuropathyd   
Paclitaxel dose reduction 14 (11%) 0 (0%) 21 (10%) 
Paclitaxel treatment suspension 29 (22%) 0 (0%) 23 (11%) 
a Patients with second line paclitaxel treatment and no previous neurotoxic drugs in first line therapy. 
b Some patients receiving chemotherapeutic drugs in combination with targeted therapy (bevacizumab,  
trastuzumab, denosumab or pertuzumab) are included in the table according to the chemotherapy agents received. 
FEC+T: 5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2, every 21 days, 
followed by paclitaxel 100 mg/m2, every 7 days. AC+T: doxorubicin 60mg/m2 and cyclophosphamide 600 mg/m2, 
every 21 days, followed by paclitaxel 80mg/m2, every 7 days. T+FEC: paclitaxel 80 mg/m2, every 7 days, followed 
by 5-fluorouracil 600 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2, every 21 days. C+T: 
carboplatin AUC5-6 and paclitaxel 175mg/m2, every 21 days.  
c NCI-CTC v2/4. 
d When in the same patient paclitaxel dose was first reduced and later on paclitaxel treatment was suspended, the 
patient is included in the table as “treatment suspension”. 
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Table 2. Loss of function variants in the discovery series. 
 
Gene 
Type of 
gene 
Varianta Protein change 
Nr individuals, 
Status 
Discovery series 
group 
Variant ID b 
ExAC browser 
MAF b 
ARHGEF10 
CMT 
c.1521_1522delATc p.Ala509His fs*515 1, Heterozygous No/low NP rs765378810 0.000066 
IKBKAP c.150+1G>Ac Splicing defect 1, Heterozygous No/low NP -  -  
DHTKD1 c.1160-1G>Cc Splicing defect 2, Heterozygous Both rs760767010  0.000017 
EPHA5 
GWAS 
c.2722dupT p.Tyr908Leu fs*921 1, Heterozygous High NP - -  
EPHA8 c.1822C>T p.Gln608* 1, Heterozygous High NP - -  
CYP3A4 
PK 
c.1461_1462insA p.Pro488Thr fs*494 2, Heterozygous High NP rs67666821 0.00028 
CYP3A4 c.1417-1G>C Splicing defect 1, Heterozygous No/low NP rs141749477 0.0000083 
SLCO1B1 c.1738C>T p.Arg580* 1, Heterozygous High NP rs71581941 0.0016 
 
a Genomic position and reference transcript are indicated in Supplemental Table 1. 
b Variants not present in ExAC browser are indicated by “-“.  
c Variants not present in CMT databases (Inherited Peripheral Neuropathies Mutation Database http://www.molgen.vib-ua.be/CMTMutations/Mutations/MutByGene.cfm and 
OMIM http://www.omim.org/). 
CMT: Charcot-Marie-Tooth; GWAS: Genome Wide Association Study; PK: pharmacokinetics; NP: neuropathy; MAF: minor allele frequency. 
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Table 3. Genes associated with paclitaxel-induced neuropathy using the gene-based burden test. 
 
 
a Genomic position and reference transcript are indicated in Supplemental Table 1. 
Gene  
P-
value  
Number of variants carriers (variants)a 
High neuropathy group, n=131 No/ low neuropathy group, n=97 
Neuropathy risk 
EPHA6 0.041 5 (T72A,N127H,R162T,V196L) 0 
SEPT9 0.072 4 (S96L,T235I,D348N,R355W) 0 
SH3TC2 0.081 14 (T27A,V230A,T366A,S433L,Y510S,A590T,R658H,H696R,T755I,S831N,T1098P,D1229V)  4 (V230A,P251S,T1098P,D1229V) 
EPHA5 0.219 5 (A49S,R494C,A611T,E678V,Y908fs)  1 (R238Q) 
DHTKD1 0.271 9 (E42G,N107I,S114P,Q138K,A210S,c.1160-1G>C,T461K,I762del) 3 (I386V,c.1160-1G>C,G729R) 
MFN2 0.323 6 (N63H,G298R,T423A,R468H,R663C) 2 (R468H,R707W) 
LRSAM1 0.596 6 (I228M,F253V,Q409E,L500F,Q573K,L639P) 3 (S183L,R594C,Q697R) 
SLCO1B3 0.737 5 (R23C,S64T,N145S,V235M) 3 (F36L,N145S,T414I) 
ABCB1 0.752 5 (N183S,I261V,K624R,V835L)  3 (I261V,S1141T,R1225P) 
EPHA8 0.785 9 (P321L,V365M,V444M,E462G,E464G,L559F,Q608*,A791V,D940H) 6 (G160S,I360V,V365M,E462G,Q525R,R679Q) 
SBF2 0.787 7 (E304K,P339L,S730A,G775S,R890G,E1401K,K1672del) 3 (D289E,T1253S,A1849V) 
SLCO1B1 0.800 4 (T10I,L193I,R580*,I656V) 3 (L193I,G210V) 
Neuropathy protection 
TRPV4 0.082 1 (A293D) 4 (R160Q,R391W,T504A,S824L)  
PRX 0.138 3 (M670V,P756L,D1013N)  6 (M670V,S751P K1062N,G1257R,E1360del,E1394D) 
ARHGEF10 0.154 4 (S688N,H733Y,T811N,H1197Y) 7 (A509Hfs,S688N,H733Y,H834R,P956L,A960P) 
NTRK1 0.261 2 (L79Q,G192A) 4 (L247P,Q570R,G714S,A779G) 
SCN9A 0.456 4 (K40E,K655R,V1428I,L1916F) 5 (P74H,T152N,K655R,D1219E,L1267V)  
IKBKAP 0.571 3 (M182K,R629H,G1013S) 4 (c.150+1G>A,M182K,S339R,R629H)  
GARS 0.654 4 (C41R,R101H,S470F,T587M) 5 (T268I) 
FAM134B 0.701 3 (P6L,V156F,S382T) 4 (M185V,V203M,Q379E,S382T) 
 Equal risk and protection 
AARS 0.650 5 (P234S,G275D,I579M) 5 (K81E,P234S,G275D,I579M)  
FIG4 0.693 3 (I41T,K278N) 3 (I51V,A397P,E734K) 
FGD4 0.712 3 (T79I,S392T,V717M) 3 (R275Q,V461A,D521G) 
CYP3A4 0.795 4 (T185S,P389S,P488fs) 4 (R130Q,R162Q,T363M,c.1417-1G>C) 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes selected for targeted NGS. The NGS panel included 39 genes classified into two categories: 1) four 
EPHA genes involved in neural processes and found to be associated with taxane-induced neuropathy 
through GWAS; 2) 35 additional genes selected for an exploratory study, involved in paclitaxel 
pharmacokinetic (PK) or causative of Charcot-Marie-Tooth. Variants previously described to be associated 
with paclitaxel-induced neuropathy are included in the graph and the corresponding references provided. 
 
 
 
 
 
Non synonymous EPHA coding variants in the discovery series. The low frequency variants in EPHA6, 
EPHA5 and EPHA8 are represented along the protein sequences. In red variants in the high neuropathy 
group; in green variants in the no/low neuropathy group of patients. Protein domains are depicted according 
to Pfam database. Illustrator for Biological Sequences was used to create the graphs 
(http://ibs.biocuckoo.org/). 
Figure 2 
Figure 1 
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Figure 3 
 
Kaplan-Meier analysis of paclitaxel-induced neuropathy. Patients were grouped according to the 
absence (Without) or presence (With) of low-frequency variants in EPHA5, EPHA6, and EPHA8, and the 
cumulative dose of paclitaxel up to the development of grade 2 peripheral sensory neuropathy was 
compared. A) Discovery series (n=25). B) Validation series (n=202). C) Analysis combining patients from 
discovery and validation series (n=227). P values correspond to multivariable Cox regression analyses 
including country of origin as covariate. 
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SUPPLEMENTARY MATERIAL 
Supplementary Table 1. Non synonymous coding and splicing site variants in the discovery series targeted sequencing.  
Gene 
(Gene ID) 
Chr:position Variant ID Ref Alt Transcript ID Consequence 
Protein 
change 
MAF 
ExACa 
MAF 
Spanishb 
High 
Neuropathy 
group (nr.) 
No/Low 
Neuropathy 
group (nr.) 
HWE 
(Yes 
/No) a wt 
wt 
wt 
var 
var 
var 
wt 
wt 
wt 
var 
var 
var 
AARS 
(ENSG0000009
0861) 
16:70286631 rs35744709 T A 
ENST0000026
1772 
missense Lys967Met 0.01467 0.014 124 7 0 93 4 0 Yes 
16:70286740 rs149377346 C T missense Gly931Ser 0.01102 0.010 128 3 0 94 3 0 Yes 
16:70287883 rs147319762 T C missense Lys820Arg 0.00182 0.014 129 2 0 94 3 0 Yes 
16:70294995 rs144323646 G C missense Ile579Met 0.00009 0.004 130 1 0 96 1 0 Yes 
16:70303659 rs11537667 C T missense Gly275Asp 0.00038 0.004 130 1 0 96 1 0 Yes 
16:70304215 rs141840552 G A missense Pro234Ser 0.00171 0.007 128 3 0 95 2 0 Yes 
16:70310961 - T C missense Lys81Glu - - 131 0 0 96 1 0 Yes 
ABCB1 
(ENSG0000008
5563) 
7:87133728 rs779103120 C G 
ENST0000026
5724 
missense Arg1225Pro - - 131 0 0 96 1 0 Yes 
7:87138659 rs2229107 A T missense Ser1141Thr 0.00009 - 131 0 0 96 1 0 Yes 
7:87138760 rs55852620 T G missense Gln1107Pro 0.00582 0.002 129 2 0 97 0 0 Yes 
7:87160792 - C G missense Val835Leu - - 130 1 0 97 0 0 Yes 
7:87175195 rs141018820 T C missense Lys624Arg 0.00007 0.001 130 1 0 97 0 0 Yes 
7:87179809 rs2229109 C T missense Ser400Asn 0.04316 0.023 124 7 0 87 10 0 Yes 
7:87190625 rs36008564 T C missense Ile261Val 0.00120 0.002 129 2 0 96 1 0 Yes 
7:87195540 rs60419673 T C missense Asn183Ser 0.00167 0.002 130 1 0 97 0 0 Yes 
7:87229440 rs9282564 T C missense Asn21Asp 0.11199 0.053 112 19 0 80 16 1 Yes 
ARHGEF10 
(ENSG0000010
4728) 
8:1833801 rs9657362 G C 
ENST0000034
9830 
missense Leu370Phe 0.13846 0.119 110 19 2 71 26 0 Yes 
8:1844578 rs765378810 CAT C frameshift Ala509Hisfs 0.00000 - 131 0 0 96 1 0 Yes 
8:1857556 rs143290224 G A missense Ser688Asn 0.00105 0.007 130 1 0 96 1 0 Yes 
8:1857591 rs2294039 G A missense Val700Ile 0.04063 0.055 123 7 1 88 8 1 Yes 
8:1871183 rs147531758 C T missense His733Tyr 0.00176 0.003 130 1 0 96 1 0 Yes 
8:1871984 - C A missense Thr811Asn 0.00000 - 130 1 0 97 0 0 Yes 
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8:1873461 rs142973221 A G missense His834Arg 0.00006 - 131 0 0 95 2 0 Yes 
8:1876707 rs61752020 G A missense Val938Ile 0.00817 0.011 129 2 0 94 3 0 Yes 
8:1876762 rs201570359 C T missense Pro956Leu 0.00000 - 131 0 0 96 1 0 Yes 
8:1876773 - G C missense Ala960Pro 0.00003 - 131 0 0 96 1 0 Yes 
8:1877480 rs17683288 T G missense Ser984Ala 0.07288 0.057 111 20 0 87 10 0 Yes 
8:1904983 rs200779877 C T missense His1197Tyr 0.00055 - 130 1 0 97 0 0 Yes 
CCT5 
(ENSG0000015
0753) 
5:10256172 rs11557652 A T 
ENST0000028
0326 
missense Glu146Val 0.02393 0.012 128 3 0 95 2 0 Yes 
5:10256175 rs118203986 A G missense His147Arg 0.00002 - 131 0 0 96 1 0 Yes 
5:10256192 rs563305570 G A missense Asp153Asn 0.00002 - 130 1 0 97 0 0 Yes 
5:10261764 rs141675330 C G missense Ile362Met 0.00511 0.004 130 1 0 96 1 0 Yes 
CYP2C8 
(ENSG0000013
8115) 
10:96797034 rs143038562 G A 
ENST0000037
1270 
missense Arg442Cys 0.00008 - 130 1 0 97 0 0 Yes 
10:96798749 rs10509681 T C missense Lys399Arg 0.11299 0.152 87 39 5 64 29 4 Yes 
10:96818106 rs11572103 T A missense Ile269Phe 0.00397 0.003 129 2 0 97 0 0 Yes 
10:96818119 rs1058930 G C missense Ile264Met 0.05429 0.059 116 15 0 76 19 2 Yes 
10:96824658 rs41286886 C T missense Val181Ile 0.00762 0.001 130 1 0 96 1 0 Yes 
10:96827030 rs11572080 C T missense Arg139Lys 0.11287 0.137 92 35 4 67 27 3 Yes 
CYP3A4 
(ENSG0000016
0868) 
7:99355806 rs67666821 G GT 
ENST0000033
6411 
frameshift Pro488fs 0.00034 - 129 2 0 97 0 0 Yes 
7:99355852 rs141749477 C G splice accept c.1417-1G>C 0.00000 - 131 0 0 96 1 0 Yes 
7:99359752 rs749459749 G A missense Pro389Ser 0.00002 - 130 1 0 97 0 0 Yes 
7:99359829 rs67784355 G A missense Thr363Met 0.00022 - 131 0 0 96 1 0 Yes 
7:99366093 rs12721627 G C missense Thr185Ser 0.00000 - 130 0 1 97 0 0 Yes 
7:99367427 rs4986907 C T missense Arg162Gln 0.00019 0.002 131 0 0 96 1 0 Yes 
7:99367788 rs72552799 C T missense Arg130Gln 0.00164 0.001 131 0 0 96 1 0 Yes 
DHTKD1 
(ENSG0000018
1192) 
10:12111090 rs1279138 T C 
ENST0000026
3035 
missense Phe20Leu 0.00020 0.363 18 0 113 10 0 87 No 
10:12111157 - A G missense Glu42Gly - - 130 1 0 97 0 0 Yes 
10:12123525 rs34644609 C G missense Ala70Gly 0.00684 0.008 128 3 0 96 1 0 Yes 
10:12126548 - A T missense Asn107Ile - - 130 1 0 97 0 0 Yes 
10:12126568 - T C missense Ser114Pro - - 130 1 0 97 0 0 Yes 
10:12126640 - C A missense Gln138Lys - - 130 1 0 97 0 0 Yes 
10:12129639 rs146741810 G T missense Ala210Ser 0.00403 - 129 2 0 97 0 0 Yes 
10:12131081 rs3740015 T G missense Tyr272Asp 0.59906 0.427 23 53 55 14 56 27 Yes 
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10:12133603 rs147571909 T C missense Val360Ala 0.00558 0.003 130 1 0 96 1 0 Yes 
10:12133680 - A G missense Ile386Val - - 131 0 0 96 1 0 Yes 
10:12136071 rs760767010 G C splice accept c.1160-1G>C 0.00002 - 130 1 0 96 1 0 Yes 
10:12139706 rs201559023 C A missense Thr461Lys 0.00005 0.001 130 1 0 97 0 0 Yes 
10:12143105 rs2062988 C G missense Ile607Met 0.81243 0.168 5 41 85 3 31 63 Yes 
10:12154929 rs117225135 G A missense Gly729Arg 0.00233 0.004 131 0 0 96 1 0 Yes 
10:12155027 - CATT C inframe del Ile762del - - 130 1 0 97 0 0 Yes 
EPHA4 
(ENSG0000011
6106) 
2:222294690 rs142860268 G A ENST0000028
1821 
missense Thr893Met 0.00007 0.003 131 0 0 96 1 0 Yes 
2:222365859 rs200225096 G A missense Thr286Met 0.00010 - 130 1 0 97 0 0 Yes 
EPHA5 
(ENSG0000014
5242) 
4:66201779 - T TA 
ENST0000027
3854 
frameshift Tyr908fs - - 130 1 0 97 0 0 Yes 
4:66231667 - T A missense Glu678Val - - 130 1 0 97 0 0 Yes 
4:66231686 rs36050417 C T missense Ala672Thr 0.02758 0.038 124 7 0 91 6 0 Yes 
4:66242741 rs777294375 C T missense Ala611Thr 0.00002 - 130 1 0 97 0 0 Yes 
4:66286206 rs138678484 G A missense Arg494Cys 0.00034 0.004 130 1 0 97 0 0 Yes 
4:66467556 rs147719164 C T missense Arg238Gln 0.00016 - 131 0 0 96 1 0 Yes 
4:66509085 rs33932471 T G missense Asn81Thr 0.06647 0.065 115 16 0 88 9 0 Yes 
4:66535316 rs138631715 C A missense Ala49Ser 0.00033 0.001 130 1 0 97 0 0 Yes 
EPHA6 
(ENSG0000008
0224) 
3:96533681 rs373432052 A G 
ENST0000038
9672 
missense Thr72Ala 0.00015 - 130 1 0 97 0 0 Yes 
3:96533846 rs200313366 A C missense Asn127His 0.00037 - 130 1 0 97 0 0 Yes 
3:96706208 rs192891419 G C missense Arg162Thr 0.00319 0.003 129 2 0 97 0 0 Yes 
3:96706309 - G T missense Val196Leu - - 130 1 0 97 0 0 Yes 
3:97311483 rs4857276 C T missense Ala805Val 0.00742 0.011 129 2 0 97 0 0 Yes 
EPHA8 
(ENSG0000007
0886) 
1:22895820 rs45498698 G A 
ENST0000016
6244 
missense Gly45Ser 0.00821 0.004 126 5 0 95 2 0 Yes 
1:22903028 rs370843084 G A missense Gly160Ser 0.00003 - 131 0 0 96 1 0 Yes 
1:22913111 rs56656925 C T missense Pro321Leu 0.00035 0.003 130 1 0 97 0 0 Yes 
1:22915462 rs762631777 A G missense Ile360Val 0.00002 - 131 0 0 96 1 0 Yes 
1:22915477 rs369589341 G A missense Val365Met 0.00011 - 130 1 0 96 1 0 Yes 
1:22919833 rs2295021 G A missense Val444Met 0.00000 - 130 1 0 97 0 0 Yes 
1:22919888 rs77608596 A G missense Glu462Gly 0.00150 - 130 1 0 96 1 0 Yes 
1:22919894 rs777499719 A G missense Glu464Gly 0.00000 - 130 1 0 97 0 0 Yes 
1:22920150 rs149084883 A G missense Gln525Arg 0.00308 0.002 131 0 0 96 1 0 Yes 
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1:22921794 rs200214765 C T missense Leu559Phe 0.00088 0.001 130 1 0 97 0 0 Yes 
1:22923859 rs144329757 C A missense Pro607His 0.00844 0.004 128 3 0 97 0 0 Yes 
1:22923861 - C T stop gained Gln608* - - 130 1 0 97 0 0 Yes 
1:22923873 rs999765 G C missense Glu612Gln 0.10359 0.078 109 20 2 82 11 4 Yes 
1:22924274 rs562829959 G A missense Arg679Gln 0.00000 - 131 0 0 96 1 0 Yes 
1:22925524 - C T missense Ala791Val - - 130 1 0 97 0 0 Yes 
1:22927503 rs62618734 G A missense Arg884His 0.00930 0.006 129 2 0 95 2 0 Yes 
1:22927881 rs374945795 G C missense Asp940His 0.00000 - 130 1 0 97 0 0 Yes 
FAM134B 
(ENSG0000015
4153) 
5:16475199 rs61733811 C G 
ENST0000030
6320 
missense Ser382Thr 0.00070 0.004 130 1 0 96 1 0 Yes 
5:16475209 rs34432513 G C missense Gln379Glu 0.00015 0.004 131 0 0 96 1 0 Yes 
5:16481181 rs143878016 C T missense Val203Met 0.00425 - 131 0 0 96 1 0 Yes 
5:16483487 rs756538225 T C missense Met185Val 0.00002 - 131 0 0 96 1 0 Yes 
5:16483574 rs758377163 C A missense Val156Phe 0.00002 - 130 1 0 97 0 0 Yes 
5:16572153 rs78314670 G A missense Arg127Cys 0.01020 0.004 130 1 0 93 4 0 Yes 
5:16617064 - G A missense Pro6Leu - - 130 0 1 97 0 0 Yes 
FGD4 
(ENSG0000013
9132) 
12:32735037 rs145115430 C T 
ENST0000042
7716 
missense Thr79Ile 0.00006 0.002 130 1 0 97 0 0 Yes 
12:32754345 rs756169087 G A missense Arg275Gln 0.00002 - 131 0 0 96 1 0 Yes 
12:32763752 rs781528826 G C missense Ser392Thr - - 130 1 0 97 0 0 Yes 
12:32772675 - T C missense Val461Ala - - 131 0 0 96 1 0 Yes 
12:32777929 rs141237776 A G missense Asp521Gly 0.00013 - 131 0 0 96 1 0 Yes 
12:32778663 rs144693221 C A missense Pro571Thr 0.00619 0.002 130 1 0 96 1 0 Yes 
12:32793315 rs61753359 G A missense Val717Met 0.00189 0.001 130 1 0 97 0 0 Yes 
FIG4 
(ENSG0000011
2367) 
6:110036336 rs121908287 T C 
ENST0000023
0124 
missense Ile41Thr 0.00155 0.001 129 2 0 97 0 0 Yes 
6:110036365 - A G missense Ile51Val - - 131 0 0 96 1 0 Yes 
6:110062705 rs138048706 A T missense Lys278Asn 0.00049 0.001 130 1 0 97 0 0 Yes 
6:110064928 rs2295837 A T missense Met364Leu 0.03636 0.038 123 8 0 92 5 0 Yes 
6:110081504 - G C missense Ala397Pro - - 131 0 0 96 1 0 Yes 
6:110107517 rs9885672 T C missense Val654Ala 0.15789 0.148 92 34 5 74 23 0 Yes 
6:110112598 rs372846619 G A missense Glu734Lys 0.00014 - 131 0 0 96 1 0 Yes 
GARS 
(ENSG0000010
6105) 
7:30634548 rs62636572 C T 
ENST0000038
9266 
missense Pro4Leu 0.02812 0.003 126 5 0 94 2 1 Yes 
7:30634658 rs762605231 T C missense Cys41Arg 0.00000 - 130 1 0 97 0 0 Yes 
7:30634661 rs1049402 C G missense Pro42Ala 0.76849 0.261 25 31 75 20 21 56 No 
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7:30638491 rs200887429 G A missense Arg101His 0.00061 0.001 130 1 0 97 0 0 Yes 
7:30649268 rs2230310 C T missense Thr268Ile 0.00475 0.005 131 0 0 92 5 0 Yes 
7:30661058 - C T missense Ser470Phe - - 130 1 0 97 0 0 Yes 
7:30668236 rs750292154 C T missense Thr587Met 0.00002 - 130 1 0 97 0 0 Yes 
HSPB1 
(ENSG0000010
6211) 
7:75932237 - G A 
ENST0000024
8553 
missense Ala70Thr - - 131 0 0 96 1 0 Yes 
HSPB8 
(ENSG0000015
2137) 
12:119617202 rs748320300 C T 
ENST0000028
1938 
missense Arg29Cys 0.00002 - 131 0 0 96 1 0 Yes 
IKBKAP 
(ENSG0000007
0061) 
9:111641825 rs1538660 G A 
ENST0000037
4647 
missense Pro1158Leu 0.17074 0.166 101 28 2 68 26 3 Yes 
9:111651620 rs3204145 A T missense Cys1072Ser 0.17022 0.181 96 33 2 65 29 3 Yes 
9:111653606 rs2230795 C T missense Gly1013Ser 0.00013 0.001 130 1 0 97 0 0 Yes 
9:111656228 rs2230798 T A missense Lys952Ile 0.01692 0.008 130 1 0 95 2 0 Yes 
9:111659439 rs2230794 T C missense Ile830Met 0.04604 0.057 114 17 0 91 6 0 Yes 
9:111659483 rs2230793 T G missense Ile816Leu 0.18077 0.211 81 42 8 60 34 3 Yes 
9:111660851 rs2230792 C T missense Gly765Glu 0.18670 0.207 81 42 8 60 34 3 Yes 
9:111663930 rs148378319 C T missense Arg629His 0.00277 0.002 130 1 0 96 1 0 Yes 
9:111668652 rs838827 C T missense Arg525Gln 0.06139 0.089 113 14 4 84 12 1 Yes 
9:111674716 rs56053149 G T missense Ser339Arg 0.00004 - 131 0 0 96 1 0 Yes 
9:111678508 rs1140064 C T missense Glu312Lys 0.02805 0.017 128 3 0 95 2 0 Yes 
9:111679940 rs17853166 T C missense Ser251Gly 0.02803 0.016 129 2 0 95 2 0 Yes 
9:111685129 rs10521092 A T missense Met182Lys 0.00018 0.002 130 1 0 96 1 0 Yes 
9:111693276 - C T splice donor c.150+1G>A - - 131 0 0 96 1 0 Yes 
KIF1B 
(ENSG0000005
4523) 
1:10292415 - T C 
ENST0000026
3934 
missense Val10Ala - - 130 1 0 97 0 0 Yes 
1:10381802 rs551543997 T C missense Trp703Arg 0.00009 - 131 0 0 96 1 0 Yes 
1:10397567 rs2297881 A G missense Tyr1087Cys 0.02518 - 121 10 0 87 10 0 Yes 
1:10425683 rs779756425 C G missense Arg1531Gly 0.00000 - 130 1 0 97 0 0 Yes 
1:10428570 rs77172218 G A missense Val1554Met 0.01600 - 129 2 0 96 1 0 Yes 
LITAF 
(ENSG0000018
9067) 
16:11643394 rs149712652 G A 
ENST0000057
1688 
missense Pro196Ser 0.01258 0.011 128 3 0 96 1 0 Yes 
16:11647492 rs4280262 T C missense Ile92Val 0.20581 0.164 83 43 5 61 31 5 Yes 
16:11650441 rs141862602 G A missense Thr49Met 0.00077 0.003 130 1 0 96 1 0 Yes 
16:11650487 rs759905004 G T missense Pro34Thr 0.00002 - 130 1 0 97 0 0 Yes 
Article 5 
130 
LRSAM1 
(ENSG0000014
8356) 
9:130230038 rs75690855 C T 
ENST0000032
3301 
missense Ser183Leu 0.00047 0.001 131 0 0 96 1 0 Yes 
9:130236144 rs376671005 C G missense Ile228Met 0.00002 - 130 1 0 97 0 0 Yes 
9:130241219 rs762870327 T G missense Phe253Val - 0.001 130 1 0 97 0 0 Yes 
9:130242166 rs1539567 A G missense Asn318Asp 0.78166 0.343 18 47 66 10 37 50 Yes 
9:130248080 rs149540339 C G missense Gln409Glu 0.00078 - 130 1 0 97 0 0 Yes 
9:130253569 rs749192098 C T missense Leu500Phe 0.00006 - 130 1 0 97 0 0 Yes 
9:130258261 rs150882646 C A missense Gln573Lys 0.00017 - 130 1 0 97 0 0 Yes 
9:130258324 rs150062009 C T missense Arg594Cys 0.00033 - 131 0 0 96 1 0 Yes 
9:130263292 rs745672498 T C missense Leu639Pro 0.00002 - 130 1 0 97 0 0 Yes 
9:130265096 - A G missense Gln697Arg - - 131 0 0 96 1 0 Yes 
MED25 
(ENSG0000010
4973) 
19:50321695 - G C 
ENST0000031
2865 
missense Glu33Gln - - 131 0 0 96 1 0 Yes 
19:50334047 rs145770066 C T missense Ala335Val 0.00604 - 131 0 0 95 2 0 Yes 
19:50338843 rs193291405 C G missense Ala576Gly 0.02446 0.002 130 1 0 96 1 0 Yes 
MFN2 
(ENSG0000011
6688) 
1:12052623 rs761216583 A C 
ENST0000023
5329 
missense Asn63His 0.00003 - 130 1 0 97 0 0 Yes 
1:12061533 rs41278630 G A missense Gly298Arg 0.00316 0.005 130 1 0 97 0 0 Yes 
1:12064155 rs765921889 A G missense Thr423Ala 0.00000 - 130 1 0 97 0 0 Yes 
1:12064892 rs138382758 G A missense Arg468His 0.00325 0.009 129 2 0 96 1 0 Yes 
1:12067224 rs369762154   C T missense Arg663Cys 0.00012 - 130 1 0 97 0 0 Yes 
1:12069692 rs142271930 G A missense Val705Ile 0.00628 0.002 130 1 0 96 1 0 Yes 
1:12069698 rs119103267 C T missense Arg707Trp 0.00055 0.001 131 0 0 96 1 0 Yes 
MTMR2 
(ENSG0000008
7053) 
11:95568531 rs116750638 A G 
ENST0000034
6299 
missense Ser619Pro 0.00255 0.002 130 1 0 96 1 0 Yes 
11:95571347 rs61735578 C G missense Glu502Gln 0.02432 0.023 127 4 0 95 2 0 Yes 
11:95578167 rs146572467 C T missense Glu446Lys 0.00055 0.002 130 1 0 97 0 0 Yes 
11:95590766 rs186380748 G C missense Pro202Ala 0.00047 0.002 129 2 0 97 0 0 Yes 
11:95657111 rs3824874 T G missense Lys3Thr 0.42441 0.222 53 51 27 49 30 18 No 
NDRG1 
(ENSG0000010
4419) 
8:134251197 rs367925853 G A 
ENST0000041
4097 
missense Ala370Val 0.00052 - 131 0 0 96 1 0 Yes 
8:134251215 rs767058269 G C missense Ser364Trp - - 131 0 0 96 1 0 Yes 
8:134296524 rs145871479 C T missense Ala11Thr 0.00139 0.004 131 0 0 94 3 0 Yes 
NGF 
(ENSG0000013
4259) 
1:115829178 rs11466111 C T ENST0000036
9512 
missense Arg80Gln 0.01634 0.008 127 4 0 95 2 0 Yes 
1:115829313 rs6330 G A missense Ala35Val 0.44519 0.443 47 62 22 32 44 21 Yes 
1:156830779 rs1007211 G A ENST0000052
4377 
missense Gly18Glu 0.01562 0.002 130 1 0 96 1 0 Yes 
1:156834169 rs139140006 T A missense Leu79Gln 0.00006 - 130 1 0 97 0 0 Yes 
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NTRK1 
(ENSG0000019
8400) 
1:156838297 rs201185829 G C missense Gly192Ala 0.00133 - 130 1 0 97 0 0 Yes 
1:156841437 - T C missense Leu247Pro - - 131 0 0 96 1 0 Yes 
1:156846268 - A G missense Gln570Arg - - 131 0 0 96 1 0 Yes 
1:156848918 rs6336 C T missense His604Tyr 0.05491 0.046 120 10 1 89 8 0 Yes 
1:156848946 rs6339 G T missense Gly613Val 0.05483 0.047 120 10 1 89 8 0 Yes 
1:156849884 rs770727871 G A missense Gly714Ser 0.00002 - 131 0 0 96 1 0 Yes 
1:156851379 - C G missense Ala779Gly - - 131 0 0 96 1 0 Yes 
1:156851382 rs35669708 G A missense Arg780Gln 0.00722 0.003 129 2 0 93 4 0 Yes 
PMP22 
(ENSG0000010
9099) 
17:15134308 rs755551524 T C ENST0000039
5938 
missense Ile137Val 0.00000 - 130 1 0 96 1 0 Yes 
17:15134364 rs104894619 G A missense Thr118Met 0.00736 0.003 123 0 0 83 1 0 Yes 
PRX 
(ENSG0000010
5227) 
19:40900077 - C A 
ENST0000032
4001 
missense Glu1394Asp - - 131 0 0 96 1 0 Yes 
19:40900179 - TTCC T inframe del Glu1360del - - 131 0 0 96 1 0 Yes 
19:40900490 rs200332462 C T missense Gly1257Arg 0.00002 0.002 131 0 0 96 1 0 Yes 
19:40900865 rs268674 C T missense Gly1132Arg 0.94233 0.279 2 16 113 0 4 93 Yes 
19:40901011 rs3745202 G C missense Pro1083Arg 0.17537 0.160 124 4 3 89 6 2 No 
19:40901073 rs139188673 C A missense Lys1062Asn 0.00152 0.006 131 0 0 96 1 0 Yes 
19:40901222 rs548086012 C T missense Asp1013Asn 0.00003 0.001 130 1 0 97 0 0 Yes 
19:40901496 rs268673 T C missense Ile921Met 0.39123 0.350 46 61 24 33 49 15 Yes 
19:40901614 rs268671 A G missense Val882Ala 0.51248 0.379 28 63 40 27 48 22 Yes 
19:40901647 rs201389706 A G missense Val871Ala 0.04189 0.003 116 15 0 87 10 0 Yes 
19:40901992 rs749585237 G A missense Pro756Leu 0.00006 - 130 1 0 97 0 0 Yes 
19:40902008 - A G missense Ser751Pro - - 131 0 0 96 1 0 Yes 
19:40902251 rs757467172 T C missense Met670Val - - 130 1 0 96 1 0 Yes 
19:40902776 rs146789340 C G missense Glu495Gln 0.00393 0.011 130 1 0 97 0 0 Yes 
19:40903528 rs118071705 G A missense Ala244Val 0.03438 0.004 129 2 0 94 3 0 Yes 
SBF2 
(ENSG0000013
3812) 
11:9801969 - G A 
ENST0000025
6190 
missense Ala1849Val - - 131 0 0 96 1 0 Yes 
11:9809201 - CTTT C inframe del Lys1672del 0.00061 - 130 1 0 97 0 0 Yes 
11:9830504 rs758191255 C T missense Glu1401Lys - - 130 1 0 97 0 0 Yes 
11:9850939 - T A missense Thr1253Ser - - 131 0 0 96 1 0 Yes 
11:9853777 rs12574508 G C missense Gln1216Glu 0.10937 0.086 106 23 2 76 18 3 Yes 
11:9861208 rs117957652 G C missense Leu1098Val 0.02703 0.025 128 3 0 92 5 0 Yes 
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11:9871708 - G C missense Arg890Gly - - 130 1 0 97 0 0 Yes 
11:9878045 rs141330687 C T missense Gly775Ser 0.00409 0.002 130 1 0 97 0 0 Yes 
11:9878180 - A C missense Ser730Ala - - 130 1 0 97 0 0 Yes 
11:9879838 rs7102464 C T missense Glu679Lys 0.10425 0.102 107 24 0 78 19 0 Yes 
11:10015505 rs149794117 G A missense Pro339Leu 0.00003 - 130 1 0 97 0 0 Yes 
11:10019878 - C T missense Glu304Lys 0.00002 - 130 1 0 97 0 0 Yes 
11:10019921 rs775319050 A C missense Asp289Glu 0.00000 - 131 0 0 96 1 0 Yes 
SCN9A 
(ENSG0000016
9432) 
2:167055370 rs111558968 G A 
ENST0000040
9672 
missense Leu1916Phe 0.00015 0.002 130 1 0 97 0 0 Yes 
2:167055393 rs3750904 T C missense Asp1908Gly 0.00320 0.011 131 0 0 96 1 0 Yes 
2:167083160 rs149346064 C T missense Val1428Ile 0.00286 0.001 130 1 0 97 0 0 Yes 
2:167089942 rs180922748 G C missense Leu1267Val 0.00220 0.006 131 0 0 96 1 0 Yes 
2:167094638 rs141268327 T C missense Asn1245Ser 0.00809 0.012 127 4 0 95 2 0 Yes 
2:167094715 rs750397053 G C missense Asp1219Glu 0.00000 0.002 131 0 0 96 1 0 Yes 
2:167099158 rs6746030 A G missense Trp1150Arg 0.87293 0.215 19 17 95 17 22 58 No 
2:167108385 rs74401238 C T missense Arg1110Gln 0.02084 0.012 130 1 0 95 2 0 Yes 
2:167136962 rs182650126 T C missense Ile739Val 0.00626 0.004 130 1 0 96 1 0 Yes 
2:167138296 rs121908919 T C missense Lys655Arg 0.00290 0.008 130 1 0 96 1 0 Yes 
2:167141109 rs41268673 G T missense Pro610Thr 0.03443 0.029 119 12 0 91 6 0 Yes 
2:167142979 rs58022607 C T missense Ser490Asn 0.00546 0.008 130 1 0 94 3 0 Yes 
2:167163032 rs761441210 G T missense Thr152Asn - - 131 0 0 96 1 0 Yes 
2:167168046 rs201992546 G T missense Pro74His - - 131 0 0 96 1 0 Yes 
2:167168149 rs371565974 T C missense Lys40Glu 0.00004 0.001 130 1 0 97 0 0 Yes 
SEPT9 
(ENSG0000018
4640) 
17:75398351 - C T 
ENST0000042
7177 
missense Ser96Leu - - 130 1 0 97 0 0 Yes 
17:75398498 rs34587622 C T missense Pro145Leu 0.12237 0.130 90 33 8 71 26 0 Yes 
17:75398768 rs528907798 C T missense Thr235Ile 0.00000 - 130 1 0 97 0 0 Yes 
17:75483634 rs201560726 G A missense Asp348Asn 0.00021 - 130 1 0 97 0 0 Yes 
17:75484342 rs199557573 C T missense Arg355Trp 0.00055 - 130 1 0 97 0 0 Yes 
17:75494705 rs2627223 A G missense Met576Val 0.93855 0.215 38 8 85 21 3 73 No 
SH3TC2 
(ENSG0000016
9247) 
5:148384455 rs146920285 T A 
ENST0000051
5425 
missense Asp1229Val 0.00367 0.006 128 3 0 96 1 0 Yes 
5:148388420 rs55853803 C T missense Val1158Ile 0.03139 0.029 123 8 0 93 4 0 Yes 
5:148389868 rs77636085 T G missense Thr1098Pro 0.00188 - 130 1 0 96 1 0 Yes 
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5:148406803 rs375034766 C T missense Ser831Asn 0.00007 - 130 1 0 97 0 0 Yes 
5:148407031 - G A missense Thr755Ile - - 130 1 0 97 0 0 Yes 
5:148407208 rs17109261 T C missense His696Arg 0.00013 0.003 130 1 0 97 0 0 Yes 
5:148407322 rs138040787 C T missense Arg658His 0.00009 - 130 1 0 97 0 0 Yes 
5:148407527 rs149244124 C T missense Ala590Thr 0.00004 - 130 1 0 97 0 0 Yes 
5:148407766 rs757294130 T G missense Tyr510Ser 0.00000 - 130 1 0 97 0 0 Yes 
5:148407893 rs6875902 C A missense Ala468Ser 0.21292 0.210 78 49 4 67 27 3 Yes 
5:148407997 rs200967041 G A missense Ser433Leu 0.00074 - 130 1 0 97 0 0 Yes 
5:148411156 rs772832716 T C missense Thr366Ala 0.00003 - 130 1 0 97 0 0 Yes 
5:148420221 rs144963732 G A missense Pro251Ser 0.00027 - 131 0 0 96 1 0 Yes 
5:148421021 rs148634904 A G missense Val230Ala 0.00081 0.003 130 1 0 96 1 0 Yes 
5:148422274 rs17722293 C T missense Gly171Glu 0.01443 0.020 128 3 0 95 2 0 Yes 
5:148431777 rs141649676 T C missense Thr27Ala 0.00167 - 130 1 0 97 0 0 Yes 
SLCO1B1 
(ENSG0000013
4538) 
12:21294537 rs766950888 C T 
ENST0000025
6958 
missense Thr10Ile 0.00002 - 130 1 0 97 0 0 Yes 
12:21329738 rs2306283 A G missense Asn130Asp 0.41084 0.384 49 60 22 33 40 24 Yes 
12:21329813 rs11045819 C A missense Pro155Thr 0.16647 0.142 102 27 2 68 27 2 Yes 
12:21331549 rs4149056 T C missense Val174Ala 0.16052 0.124 96 29 6 70 27 0 Yes 
12:21331605 rs376996580 C A missense Leu193Ile 0.00000 - 130 1 0 95 2 0 Yes 
12:21331856 rs766417954 G T missense Gly210Val 0.00000 - 131 0 0 96 1 0 Yes 
12:21375289 rs71581941 C T stop gained Arg580* 0.00141 0.002 130 1 0 97 0 0 Yes 
12:21391976 rs34671512 A C missense Leu643Phe 0.05201 0.054 119 11 1 84 12 1 Yes 
12:21392013 rs757219127 A G missense Ile656Val 0.00002 - 130 1 0 97 0 0 Yes 
SLCO1B3 
(ENSG0000011
1700) 
12:20968739 rs369736559 C T 
ENST0000038
1545 
missense Arg23Cys 0.00011 - 130 1 0 97 0 0 Yes 
12:21007985 rs79042365 C G missense Phe36Leu 0.00000 - 131 0 0 96 1 0 Yes 
12:21008067 rs151295214 T A missense Ser64Thr 0.00000 - 130 1 0 97 0 0 Yes 
12:21011480 rs4149117 T G missense Ser112Ala 0.85331 0.190 6 27 98 4 20 73 Yes 
12:21014025 rs146623116 A G missense Asn145Ser 0.00248 0.002 129 2 0 96 1 0 Yes 
12:21015760 rs7311358 G A missense Met233Ile 0.85329 0.104 2 27 102 1 22 74 Yes 
12:21015764 - G A missense Val235Met - - 130 1 0 97 0 0 Yes 
12:21028208 rs60140950 G C missense Gly256Ala 0.16225 0.170 101 27 3 69 25 3 Yes 
12:21032475 rs146940490 C T missense Thr414Ile 0.00045 0.001 131 0 0 96 1 0 Yes 
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SPTLC1 
(ENSG0000009
0054) 
9:94800624 rs119482084 C G 
ENST0000026
2554 
missense Gly387Ala 0.00050 0.004 129 2 0 97 0 0 Yes 
9:94830356 rs45461899 C A missense Arg151Leu 0.03106 0.021 127 4 0 94 3 0 Yes 
9:94830357 rs146548058 G A missense Arg151Cys 0.00003 - 130 1 0 97 0 0 Yes 
9:94843240 rs76962472 G T missense Pro89Gln 0.00063 - 131 0 0 96 1 0 Yes 
SPTLC2 
(ENSG0000010
0596) 
14:77987874 rs747168398 G A 
ENST0000021
6484 
missense Arg452Cys 0.00002 - 131 0 0 96 1 0 Yes 
TRPV4 
(ENSG0000011
1199) 
12:110221524 rs55728855 C T 
ENST0000041
8703 
missense Glu840Lys 0.00885 0.004 129 2 0 97 0 0 Yes 
12:110221571 rs764622721 G A missense Ser824Leu 0.00005 - 131 0 0 96 1 0 Yes 
12:110230597 rs56177950 C T missense Val562Ile 0.01019 0.015 128 3 0 93 4 0 Yes 
12:110231809 rs762000967 T C missense Thr504Ala 0.00000 - 131 0 0 96 1 0 Yes 
12:110234491 rs775385702 G A missense Arg391Trp 0.00000 - 131 0 0 96 1 0 Yes 
12:110236693 - G T missense Ala293Asp - - 130 1 0 97 0 0 Yes 
12:110246181 rs139300843 C T missense Arg160Gln 0.00003 - 131 0 0 96 1 0 Yes 
12:110252547 rs3742030 G A missense Pro19Ser 0.03914 0.023 127 4 0 89 7 1 Yes 
 
aMAF in ExAC for Europeans non-Finish (>33.000 indiv). 
bMAF in Spanish population (578 indiv). 
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Supplementary Table 2. Association of common non-synonymous coding variants with paclitaxel-induced neuropathy. 
Gene Variant ID Protein change 
MAF 
ExACa 
MAF 
Spanishb 
Nr carriers 
OR, 95% CI 
(inf-sup) 
P value High 
neuropathy 
No/low 
neuropathy 
AARS 
 
rs35744709 Lys967Met 0.01467 0.014 7 4 1.30 (0.33-6.16) 0.766 
rs149377346 Gly931Ser 0.01102 0.010 3 3 0.74 (0.10-5.57) 0.703 
rs147319762 Lys820Arg 0.00182 0.014 2 3 0.49 (0.04-4.33) 0.655 
ABCB1 
 
rs55852620 Gln1107Pro 0.00582 0.002 2 0 1.01 (0.99-1.02) 0.510 
rs2229109 Ser400Asn 0.04316 0.023 7 10 0.51 (0.16-1.50) 0.257 
rs9282564 Asn21Asp 0.11199 0.053 19 17 0.76 (0.37-1.59) 0.542 
ARHGEF10 
 
rs9657362 Leu370Phe 0.13846 0.119 21 26 0.62 (0.33-1.18) 0.155 
rs2294039 Val700Ile 0.04063 0.055 8 9 0.66 (0.23-1.83) 0.502 
rs61752020 Val938Ile 0.00817 0.011 2 3 0.49 (0.04-4.33) 0.655 
rs17683288 Ser984Ala 0.07288 0.057 20 10 1.52 (0.66-3.73) 0.387 
CCT5 
rs11557652 Glu146Val 0.02393 0.012 3 2 1.11 (0.13-13.44) 1.000 
rs141675330 Ile362Met 0.00511 0.004 1 1 0.74 (0.01-58.32) 1.000 
CYP2C8 
 
rs10509681 Lys399Arg 0.11299 0.152 44 33 0.98 (0.59-1.62) 1.000 
rs1058930 Ile264Met 0.05429 0.059 15 21 0.45 (0.21-0.93) 0.030 
rs41286886 Val181Ile 0.00762 0.001 1 1 0.74 (0.01-58.32) 1.000 
rs11572080 Arg139Lys 0.11287 0.137 39 30 0.96 (0.57-1.63) 0.966 
DHTKD1 
 
rs34644609 Ala70Gly 0.00684 0.008 3 1 2.23 (0.18-117.89) 0.640 
rs3740015 Tyr272Asp 0.59906 0.427 76 70 0.80 (0.54-1.18) 0.275 
rs147571909 Val360Ala 0.00558 0.003 1 1 0.74 (0.01-58.32) 1.000 
rs2062988 Ile607Met 0.81243 0.168 46 34 1.03 (0.62-1.70) 1.000 
EPHA5 
rs36050417 Ala672Thr 0.02758 0.038 7 6 0.86 (0.24-3.15) 1.000 
rs33932471 Asn81Thr 0.06647 0.065 16 9 1.34 (0.54-3.51) 0.636 
EPHA6 rs4857276 Ala805Val 0.00742 0.011 2 0 1.01 (0.99-1.02) 0.510 
EPHA8 
 
rs45498698 Gly45Ser 0.00821 0.004 5 2 1.87 (0.30-19.78) 0.704 
rs144329757 Pro607His 0.00844 0.004 3 0 1.01 (0.99-1.03) 0.265 
rs999765 Glu612Gln 0.10359 0.078 22 15 0.93 (0.47-1.85) 0.947 
rs62618734 Arg884His 0.00930 0.006 2 2 0.74 (0.05-10.28) 1.000 
FAM134B rs78314670 Arg127Cys 0.01020 0.004 1 4 0.18 (0.00-1.86) 0.168 
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FGD4 rs144693221 Pro571Thr 0.00619 0.002 1 1 0.74 (0.01-58.32) 1.000 
FIG4 
rs2295837 Met364Leu 0.03636 0.038 8 5 1.19 (0.34-4.70) 0.986 
rs9885672 Val654Ala 0.15789 0.148 39 23 1.50 (0.85-2.71) 0.181 
GARS rs62636572 Pro4Leu 0.02812 0.003 5 3 0.92 (0.20-4.72) 1.000 
IKBKAP 
 
rs1538660 Pro1158Leu 0.17074 0.166 30 29 0.70 (0.40-1.24) 0.244 
rs3204145 Cys1072Ser 0.17022 0.181 35 32 0.75 (0.44-1.28) 0.315 
rs2230798 Lys952Ile 0.01692 0.008 1 2 0.37 (0.01-7.13) 0.577 
rs2230794 Ile830Met 0.04604 0.057 17 6 2.17 (0.80-6.86) 0.155 
rs2230793 Ile816Leu 0.18077 0.211 50 37 1.09 (0.68-1.77) 0.783 
rs2230792 Gly765Glu 0.18670 0.207 50 37 1.09 (0.68-1.77) 0.783 
rs838827 Arg525Gln 0.06139 0.089 18 13 1.18 (0.56-2.56) 0.774 
rs1140064 Glu312Lys 0.02805 0.017 3 2 1.11 (0.13-13.44) 1.000 
rs17853166 Ser251Gly 0.02803 0.016 2 2 0.74 (0.05-10.28) 1.000 
KIF1B 
rs2297881 Tyr1087Cys 0.02518 - 10 10 0.73 (0.27-2.00) 0.647 
rs77172218 Val1554Met 0.01600 - 2 1 1.48 (0.08-87.99) 1.000 
LITAF 
rs149712652 Pro196Ser 0.01258 0.011 3 1 2.23 (0.18-117.89) 0.640 
rs4280262 Ile92Val 0.20581 0.164 48 36 0.95 (0.58-1.54) 0.905 
LRSAM1 rs1539567 Asn318Asp 0.78166 0.343 65 47 1.11 (0.73-1.71) 0.672 
MED25 
rs145770066 Ala335Val 0.00604 - 0 2 0.00 (0.00-3.94) 0.180 
rs193291405 Ala576Gly 0.02446 0.002 1 1 0.74 (0.01-58.32) 1.000 
MFN2 rs142271930 Val705Ile 0.00628 0.002 1 1 0.74 (0.01-58.32) 1.000 
MTMR2 rs61735578 Glu502Gln 0.02432 0.023 4 2 1.49 (0.21-16.61) 1.000 
NGF 
rs11466111 Arg80Gln 0.01634 0.008 4 2 1.49 (0.21-16.61) 1.000 
rs6330 Ala35Val 0.44519 0.443 84 65 0.85 (0.58-1.26) 0.464 
NTRK1 
rs1007211 Gly18Glu 0.01562 0.002 1 1 0.74 (0.01-58.32) 1.000 
rs6336 His604Tyr 0.05491 0.046 11 8 1.12 (0.41-3.21) 0.997 
rs6339 Gly613Val 0.05483 0.047 11 8 1.12 (0.41-3.21) 0.997 
rs35669708 Arg780Gln 0.00722 0.003 2 4 0.37 (0.03-2.58) 0.409 
PMP22 rs104894619 Thr118Met 0.00736 0.003 0 1 0.00 (0.00-28.88) 0.425 
PRX 
rs268674 Gly1132Arg 0.94233 0.279 18 4 3.92 (1.28-16.01) 0.015 
rs268673 Ile921Met 0.39123 0.350 85 64 1.04 (0.70-1.54) 0.926 
rs268671 Val882Ala 0.51248 0.379 103 70 1.33 (0.90-1.97) 0.156 
rs201389706 Val871Ala 0.04189 0.003 15 10 1.12 (0.46-2.85) 0.955 
rs146789340 Glu495Gln 0.00393 0.011 1 0 1.00(0.99-1.01) 1.000 
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rs118071705 Ala244Val 0.03438 0.004 2 3 0.49 (0.04-4.33) 0.655 
SBF2 
rs12574508 Gln1216Glu 0.10937 0.086 25 21 0.81 (0.44-1.53) 0.588 
rs117957652 Leu1098Val 0.02703 0.025 3 5 0.44 (0.07-2.29) 0.294 
rs7102464 Glu679Lys 0.10425 0.102 24 19 0.93 (0.47-1.85) 0.947 
SCN9A 
rs141268327 Asn1245Ser 0.00809 0.012 4 2 1.49 (0.21-16.61) 1.000 
rs74401238 Arg1110Gln 0.02084 0.012 1 2 0.37 (0.01-7.13) 0.577 
rs182650126 Ile739Val 0.00626 0.004 1 1 0.74 (0.01-58.32) 1.000 
rs41268673 Pro610Thr 0.03443 0.029 12 6 1.50 (0.51-4.97) 0.573 
rs58022607 Ser490Asn 0.00546 0.008 1 3 0.24 (0.00-3.07) 0.317 
SEPT9 rs34587622 Pro145Leu 0.12237 0.130 41 26 1.49 (0.86-2.60) 0.167 
SH3TC2 
rs55853803 Val1158Ile 0.03139 0.029 8 4 1.49 (0.39-6.88) 0.720 
rs6875902 Ala468Ser 0.21292 0.210 53 30 1.36 (0.82-2.26) 0.254 
rs17722293 Gly171Glu 0.01443 0.020 3 2 1.11 (0.13-13.44) 1.000 
SLCO1B1 
rs2306283 Asn130Asp 0.41084 0.384 82 64 0.79 (0.54-1.18) 0.265 
rs11045819 Pro155Thr 0.16647 0.142 29 29 0.71 (0.40-1.25) 0.255 
rs4149056 Val174Ala 0.16052 0.124 35 27 1.15 (0.66-2.02) 0.704 
rs34671512 Leu643Phe 0.05201 0.054 12 13 0.67 (0.28-1.58) 0.419 
SLCO1B3 
rs4149117 Ser112Ala 0.85331 0.190 33 24 1.04 (0.59-1.83) 0.999 
rs7311358 Met233Ile 0.85329 0.104 29 23 0.95 (0.52-1.76) 0.977 
rs60140950 Gly256Ala 0.16225 0.170 30 28 0.76 (0.43-1.34) 0.372 
SPTLC1 rs45461899 Arg151Leu 0.03106 0.021 4 3 0.99 (0.16-6.82) 1.000 
TRPV4 
rs55728855 Glu840Lys 0.00885 0.004 2 0 1.01 (0.99-1.02) 0.510 
rs56177950 Val562Ile 0.01019 0.015 3 4 0.55 (0.08-3.30) 0.465 
rs3742030 Pro19Ser 0.03914 0.023 4 8 0.32 (0.07-1.17) 0.091 
 
aMAF in ExAC for Europeans non-Finish (>33.000 indiv). 
bMAF in Spanish population (578 indiv). 
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Thanks to the advances in oncology treatment, the number of cancer survivors is 
increasing. Despite this, anticancer therapy causes a high number of serious ADRs, some of which 
can have a great impact on the quality of life of the cancer patients. One example is the antimitotic 
agent paclitaxel (Wani et al., 1971, Rowinsky, 1997), widely used since the late twentieth century. 
It produces peripheral neuropathy (Rowinsky et al., 1993) in a large number of patients and, in 
some cases, with long-term nerve damage and long-life disabilities (Postma et al., 1995, Lipton 
et al., 1989). There is a lack of preventive or effective treatments (Wolf et al., 2008) and, therefore, 
the identification of neuropathy markers is an urgent need, to guide taxanes treatment and avoid 
serious and potentially permanent neurotoxicity.  
The individual genetic background has been shown to explain a great proportion of the 
inter-individual variability observed in the response to many different drugs; however, the 
majority of genetic factors related to paclitaxel-induced neuropathy remain undetermined. 
Although several groups have evaluated the role of common polymorphisms in genes involved in 
paclitaxel metabolism and transport (e.g. CYP2C8*3), their contribution to neuropathy is unclear. 
Moreover, only a few studies have been conducted to analyze the relevance of variants across the 
whole genome or to detect low-frequency variants associated with the neuropathy.  
Owing to these, the purpose of this Thesis was to identify genetic variants associated with 
increased susceptibility of peripheral neuropathy caused by paclitaxel. To accomplish this goal, 
series of hundreds of patients treated with paclitaxel and with complete neuropathy data were 
collected. To ensure homogeneity and objectivity in neuropathy grading, all patients were 
interviewed by telephone by one qualified nurse trained by a neurologist to determine the severity 
of symptoms and impairment in the activities of daily living during paclitaxel treatment and after 
finishing therapy. The neuropathy assessment was performed according to NCI-CTCAE v4. In 
addition, part of the patients also filled in a questionnaire after each paclitaxel dose and thus, cycle 
by cycle neuropathy data was available. In addition, neuropathy risk factors such as previous 
neurotoxic treatments, presence of diabetes or alcoholism were also recorded. 
In the first part of this Thesis we performed a comprehensive study of common single 
nucleotide polymorphisms previously associated with paclitaxel-induced neuropathy by our 
group, and investigated their role as potential predictive markers of this toxicity (Article 1 and 
Article 2). 
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1. Role of CYP2C8*3 in paclitaxel metabolism and paclitaxel-induced neurotoxicity 
(Article 1) 
 
Paclitaxel exposure has been associated with the severity of the neuropathy (de Graan et 
al., 2013, Mielke et al., 2005), suggesting that alterations in the activity of paclitaxel metabolizing 
enzymes and transporters (e.g. CYP2C8, CYP3A4, OATP1B3, OATP1B1 and P-glycoprotein) 
that result in decreased drug elimination could increase toxicity risk (Rodriguez-Antona, 2010, 
van de Steeg et al., 2013, Sparreboom et al., 1997). Indeed, the associations between 
polymorphisms in taxane pharmacokinetic pathways and the development of peripheral 
neuropathy were the first to be studied.  
Concerning CYP2C8, CYP2C8*2, CYP2C8*3 and CYP2C8*4 have been shown to 
produce different proteins with altered enzyme activity (Singh et al., 2008, Dai et al., 2001). 
CYP2C8*3 (rs11572080 and rs10509681, in total linkage disequilibrium (LD)) is a frequent allele 
in the Caucasian population (12%) that encodes for a protein with Arg139Lys and Lys399Arg 
substitutions (CYP2C8.3). The association of CYP2C8*3 allele with the risk of paclitaxel-induced 
neuropathy has been previously evaluated. Heterologous expression of CYP2C8.3 in bacteria and 
human cell lines indicated a decreased paclitaxel metabolism (Soyama et al., 2001, Dai et al., 
2001, Rowbotham et al., 2010, Bahadur et al., 2002). In patients, CYP2C8*3 allele has been 
associated with high risk of paclitaxel induced neuropathy in some studies (Leskelä et al., 2011, 
Hertz et al., 2013, Hertz et al., 2014, Green et al., 2009), but not in others (Abraham et al., 2014, 
Marsh et al., 2007, Ofverholm et al., 2010, Bergmann et al., 2012, Bergmann et al., 2011b). Owing 
to these conflicting data, we designed a comprehensive study in collaboration with Dr. Magnus 
Ingelman-Sundberg group at Karolinska Institute to in depth characterize the effect of CYP2C8*3 
on paclitaxel both in vitro and in vivo. 
Regarding the in vitro experiments, the type of expression system used can affect enzyme 
activity. In line with this, lower intrinsic paclitaxel clearance was observed when CYP2C8.3 was 
expressed in E. coli, yeast or insect cells systems (Dai et al., 2001, Kaspera et al., 2011, Gao et 
al., 2010, Yu et al., 2013) compared to CYP2C8.1 (wild type protein). However, in mammalian 
systems (i.e. human hepatoma cells) CYP2C8.3 and CYP2C8.1 kinetics were similar (Soyama et 
al., 2001). In our study we used mammalian human embryonic kidney cells and found no 
differences in paclitaxel metabolism between CYP2C8.1 and CYP2C8.3. The differences found 
among the heterologous expression systems might be due to dissimilar protein folding or 
interaction with other proteins that may alter substrate metabolism.  
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We also tested the enzymatic activity of CYP2C8.3 using an antimalarial agent 
(amodiaquine) and an antidiabetic drug (rosiglitazone) as substrates. As for paclitaxel, with 
amodiaquine we did not observe differences in kinetic parameters between wild type CYP2C8.1 
and CYP2C8.3 enzymes, although previous in vitro studies suggested altered metabolic activity 
(Kaspera et al., 2011, Parikh et al., 2007).  
Concerning rosiglitazone, we found a higher clearance for CYP2C8.3, in agreement with 
other in vitro (Kaspera et al., 2011) and in vivo studies (Kirchheiner et al., 2006, Aquilante et al., 
2008). These differences in enzyme kinetics depending on the substrate have also been shown for 
other cytochrome P450s (Oscarson et al., 1997), suggesting that the same allele may have 
different effects among different drugs.  
With reference to human data, a cohort of 343 paclitaxel-treated patients was genotyped 
for CYP2C8*3 allele. No association was found for CYP2C8*3 variant and the risk of neuropathy 
caused by paclitaxel when the maximum neuropathy grade developed during the treatment was 
analyzed, in agreement with previous studies (Marsh et al., 2007, Ofverholm et al., 2010, 
Bergmann et al., 2012, Bergmann et al., 2011b). Nevertheless, as paclitaxel neurotoxicity is dose-
dependent, we also analyzed the accumulated paclitaxel dose that produced a clinically relevant 
neurotoxicity (i.e. grade ≥2), rather than just evaluating the presence or lack of neurotoxicity at 
the end of the treatment. Cycle by cycle neuropathy data was obtained for 148 patients (56 Spanish 
from our series and 92 additional Danish individuals (Bergmann et al., 2011a)) and the cumulative 
dose analysis gave a trend towards increased neuropathy risk for CYP2C8*3 carriers (HR=1.70, 
P=0.078). This is in agreement with to the increased risk detected in three independent studies 
using this analysis (Leskelä et al., 2011, Hertz et al., 2013, Hertz et al., 2014). Conversely, 
Abraham et al (Abraham et al., 2014) when performing the same analyses in larger series of 
patients detected no significant association for CYP2C8*3 with taxane-related sensory neuropathy 
(P=0.14 and P=0.27, for maximum neuropathy and cumulative dose analysis, respectively). These 
discordances may be due to differences in neuropathy assessment or to the different chemotherapy 
regimens among the studies. Altogether, these data rule out a strong effect of CYP2C8*3 on 
paclitaxel-induced neuropathy, but suggest a low/moderate effect on the toxicity. 
To sum up, this work indicates that CYP2C8*3 allele has a low/moderate effect on 
neuropathy risk through a mechanism that is not detectable in mammalian heterologous 
expression systems we used. The low/moderate effect could explain the differences found among 
the different association studies performed, since a moderate effect could only be detected in well-
powered studies (e.g. with large sample size, objective neuropathy assessment, cycle by cycle 
neuropathy analyses).  
 
Discussion 
144 
2. Follow up study of GWAS top hits and characterization of EPHA polymorphisms 
as neuropathy risk markers (Article 2) 
 
Candidate gene approaches have allowed identifying common polymorphisms associated 
with paclitaxel neuropathy in genes involved in paclitaxel pharmacokinetic and 
pharmacodynamic pathways.  
However, a large part of the inter-individual variation remains to be explained. Genome-
wide studies have recently been used to identify novel genes associated with drug-induced 
neuropathy. In GWAS, hundreds of thousands of SNPs across the whole genome are genotyped 
simultaneously, allowing to identify new genes that contribute to the basis of human traits such 
as drug-induced toxicity (Low et al., 2014, Motsinger-Reif et al., 2013). In a GWAS performed 
by our group, a strong evidence of association with higher neuropathy was found for several 
ephrin type-A receptors (EPHA): EPHA4 (rs17348202, P=1.0x10-6), top hit of the analysis; 
EPHA6 (rs301927, P=3.4x10-5) and EPHA5 (rs1159057, P=6.8x10-5), among the 50 top hits 
(Leandro-Garcia et al., 2013). Interestingly, in a meta-analysis with the GWAS performed by 
Baldwin et al, a SNP in EPHA5 (rs7349683), in high LD with rs1159057, passed genome wide 
significance (P=1.4x10-9) and was suggested as a neuropathy risk marker (Baldwin et al., 2012).  
We followed up these initial findings in “Article 2” of the Thesis. In this study we used a 
series of 146 paclitaxel-treated patients with neuropathy graded cycle by cycle (57 from Spain 
and 89 from a previously described Danish cohort (Bergmann et al., 2011a)), to evaluate the role 
of SNPs detected as top signals in Leandro-Garcia et al GWAS as potential neuropathy markers. 
SNPs in EPHAs, in XKR4, in PIK3IP1 and in SGCG were selected for genotyping (Leandro-
Garcia et al., 2013). We used the cumulative paclitaxel dose analysis to increase the power to 
detect effects on neuropathy.  
We validated the association of EPHA5, EPHA6 and EPHA8 variant alleles with high risk 
of neuropathy, in agreement with the GWAS studies (Baldwin et al., 2012, Leandro-Garcia et al., 
2013), with the work from Abraham et al, in which a large series of patients was used to evaluate 
several candidate SNPs (Abraham et al., 2014) and with the recent work by Boora et al (Boora et 
al., 2016). In addition, we also studied the effect of the SNPs when using maximum neuropathy 
grade analysis. With this approach we were only able to detect a trend for EPHA6, meaning that 
the cumulative dose to grade 2 neuropathy is a more sensitive analysis. Regarding the SNP in 
EPHA4, no significant association was found with neither of the analyses. A possible explanation 
to this is that with a low allele frequency (5%) we do not have enough statistical power to detect 
the association.  
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In conclusion, this study provided an independent confirmation of EPHA5-rs7349683, 
EPHA6-rs301927 and EPHA8-rs209709 as markers of paclitaxel-induced neuropathy, 
emphasizing the power of genome-wide techniques to detect new pharmacogenetic markers. 
These results highlight ephrin receptors as key players in paclitaxel-induced peripheral 
neuropathy. It is also important to mention that as ephrin receptors are involved in several 
neuronal functions and in neuronal regeneration after injury repair, they may also be relevant 
markers of neuropathy for other neurotoxic agents (e.g. bortezomib, vinca alkaloids or cisplatin).  
Our next goal was to identify novel genetic factors, and potentially with stronger impact, 
associated with the neuropathy caused by paclitaxel treatment. To achieve this, we designed next 
generation sequencing approaches (Article 3 and Article 5). 
 
3. Whole-exome sequencing identifies rare defective variants of paclitaxel dose-
limiting neuropathy (Article 3) 
 
Despite the significant progress made by GWAS in the identification of loci that 
contribute to complex traits, for several phenotypes only a small fraction of the observed 
heritability is explained by the common variants so far identified (Manolio et al., 2009). The 
development of massively parallel sequencing technologies has transformed the field of human 
genetics. Next-generation sequencing (NGS) can identify all variation in the genome (e.g. 
common, rare and structural variants) in a cost-effective manner. Although whole genome 
sequencing (WGS) offers advantages over whole exome sequencing (WES), the latter is a 
powerful and economic method to detect novel high-impact alleles relevant for complex traits 
such as adverse drug reactions.  
In addition, one strategy to increase the statistical power of a study is to select phenotypic 
outliers (individuals who are at both ends of a phenotype distribution), rather than using non-
selected individuals. This is due to the fact that the alleles that contribute to the trait are enriched 
in the phenotype extremes. Therefore, following this strategy, even with modest sample sizes it 
may be possible to identify novel candidate genes and/or alleles associated with diseases and drug 
outcomes (Nebert, 2000, Cirulli and Goldstein, 2010, Zhang et al., 2006, Westlind-Johnsson et 
al., 2006). The combination of WES coupled with a carefully selection of extreme phenotype 
individuals (Shendure and Ji, 2008) has proven to be a powerful method to detect low-frequency 
susceptibility variants (Ng et al., 2010, Gurwitz and McLeod, 2013, Panoutsopoulou et al., 2013).  
Taking all this information into consideration, we selected 8 patients with severe 
neuropathy to perform WES. To identify the severe-phenotype patients, we used not only the 
severity of the symptoms during treatment, but also modifications of treatment regimen and long-
lasting disabilities.  
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By WES we detected two rare high-impact variants in CYP3A4 (CYP3A4*20 and 
CYP3A4*25). CYP3A4*20 is an INDEL leading to a premature stop codon previously described 
in one individual with impaired elimination of CYP3A4 substrates (Westlind-Johnsson et al., 
2006). For the novel CYP3A4.25 (p.P389S) protein we demonstrated that it had decreased 
stability and reduced amounts of protein were detected in a HEK293 expression system. An 
independent cohort of 228 well-characterized paclitaxel treated patients was used to screen for 
additional variants in CYP3A4 exons.  
Here, we identified three more carriers of CYP3A4*20, and two carriers of CYP3A4 
missense variants: CYP3A4.8 with diminished activity (Eiselt et al., 2001) and CYP3A4.27. For 
this latter, again we characterized the enzymatic activity and detected less protein expression. In 
total, 3% of the Spanish patients carried CYP3A4 defective variants, suggesting that these could 
explain part of CYP3A4 variability and differences in paclitaxel toxicity.  
When performing the statistical analyses, we observed an over-representation of defective 
CYP3A4 variants in patients with paclitaxel treatment modifications caused by the neuropathy 
and in those with high-grade paclitaxel-induced neuropathy. Specifically, patients carrying loss 
of function (LOF) CYP3A4 variants (i.e. CYP3A4*20) had a significantly higher risk of 
neuropathy and of paclitaxel treatment modifications, when compared with wild-type CYP3A4 
patients (P=0.042 and P=5.8x10-3, respectively). It is important to highlight that previous reports 
only identified markers associated with neuropathy grade, but not with neuropathies resulting in 
objective clinically relevant consequences: treatment modifications (i.e. paclitaxel dose 
reductions and treatment suspensions; which do not have a subjective interpretation, but are 
objective events annotated in the clinical records). Carriers of missense variants showed an 
intermediate phenotype, concordant with a decreased but not abolished CYP3A4 activity. In line 
with a previous study (de Graan et al., 2013), the allele CYP3A4*22, with reduced activity, had a 
tendency towards increased paclitaxel treatment modifications. All these results support the 
implication of CYP3A4 in paclitaxel-induced neuropathy. 
In conclusion, applying WES to patients with extreme neuropathy we identified for the 
first time a marker associated with paclitaxel dose-limiting neuropathy and that may provide a 
basis for paclitaxel treatment individualization. This study emphasizes the need to screen for rare 
genetic variants in selected cohorts of patients.   
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4. High frequency and founder effect of the CYP3A4*20 in the Spanish population classifies 
CYP3A4 as a polymorphic enzyme (Article 4) 
 
Interestingly, in Article 3 we found four carriers of the CYP3A4*20 allele in a population 
of 236 Spanish paclitaxel-treated patients (2% of carriers). CYP3A4*20 was first discovered in an 
individual with impaired elimination of CYP3A4 substrates. Functional studies on this allele 
showed a lack of enzyme activity (Westlind-Johnsson et al., 2006) and the allele was described 
as a rare event, in agreement with the highly conserved nature of CYP3A4 (Rahmioglu et al., 
2011, Ozdemir et al., 2000). Indeed, only three LOF variants have been described in the literature 
(CYP3A4*6, CYP3A4*20, CYP3A4*26). CYP3A4*20 is the most common defective allele being 
carried by 0.2% and 0.07% of Europeans and 0.05% and 0.02% of Africans, according to Exome 
Variant Server and ExAC browser, respectively. Thus, the described allele frequency of this allele 
differed with the one we found in Article 3 and we decided to follow up this finding and study 
the origin and distribution of CYP3A4*20 allele in different populations.  
We collected more than 4000 individuals from European, African and Asian populations 
and genotyped CYP3A4*20 allele. We found that 1.2% of Spanish individuals (24 out of 1977) 
carried the CYP3A4*20 allele, compared to 0.2% in Portugal (1 out of 450). No other carriers 
were found in the rest of European, African or Asian populations (that accounted a total of 2118 
individuals). Focusing on the Spanish population, the frequency of CYP3A4*20 carriers varied 
depending on the region. For example, we observed one CYP3A4*20 carrier every 26 individuals 
in Castilla y León, one every 33 in Comunidad Valenciana and one every 48 in Extremadura. 
These results constitute the first proof that CYP3A4 LOF alleles can be classified as 
polymorphisms (i.e. with allele frequencies above 1% in some region of Spain) and can affect a 
large number of individuals, at least in specific populations.  
We also conducted a haplotype analysis to investigate if the variant descended from an 
ancestral mutation or was an independent event. To perform it, we analyzed four microsatellites 
(i.e. D7S651, D7S2498, D7S2480 and D7S666) and we genotyped four additional SNPs in the 
CYP3A locus (i.e. CYP3A4*22 (rs35599367), CYP3A4*1B (rs2740574), CYP3A7*2 (rs2257401) 
and CYP3A5*3 (rs776746)). Haplotype reconstruction suggested that CYP3A4*20 appeared in a 
single haplotype present in 4% of the chromosomes in the Spanish population. It contained the 
most common Caucasian variants (Ingelman-Sundberg et al., 2007) for the functional CYP3A 
SNPs (i.e. wild type CYP3A4*22, CYP3A4*1B and CYP3A7*2 and variant CYP3A5*3 allele). 
Since CYP3A4*20 is independent of the intronic polymorphism CYP3A4*22, which has been 
previously associated with a decreased elimination of CYP3A4 substrates (Wang et al., 2011, 
Elens et al., 2013b), individuals carrying both of these two alleles may have a highly reduced 
CYP3A4 activity. 
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The high frequency of CYP3A4*20 in Spain, compared to other countries outside the 
Iberian peninsula, together with a haplotype spanning 700 Kb and shared by all mutation carriers, 
suggest a recent occurrence of the allele. We estimated that CYP3A4*20 appeared about 1000 
years ago, which is compatible with a single origin of the mutation in Spain, and then spreading 
to different geographical areas in recent times. 
CYP3A4 plays a crucial role in the biotransformation of a wide range of drugs, including 
many clinical compounds (Klein and Zanger, 2013), and contributes to the metabolism of 
endogenous substrates (e.g. vitamin D3, arachidonic acid, bile acids and steroid hormones) 
(Nakamura et al., 2002, Nebert and Russell, 2002). In Cyp3a knock-out mice no major phenotype 
was detected except for drug metabolism impairment (van Herwaarden et al., 2007, Hashimoto et 
al., 2013), although in female mice transgenic for CYP3A4 deficient lactation due to reduced 
serum estradiol levels was detected (Yu et al., 2005). Thus, CYP3A4*20 heterozygous carriers 
may show altered response upon treatment with narrow therapeutic index drugs, although not 
when treated with drugs with wide therapeutic indexes.  
The work by Westlind-Johnsson et al supports this concept as they identified an 
individual heterozygous for CYP3A4*20 with a 6-fold higher exposure to a drug metabolized by 
CYP3A4 and low systemic midazolam clearance (Westlind-Johnsson et al., 2006). This 
individual had a Spanish mother. Regarding homozygous carriers of CYP3A4*20, they might not 
have any clinical manifestation but a severe toxicity profile when exposed to drugs metabolized 
by CYP3A4. This idea is reinforced by the identification of a patient homozygous for CYP3A4*26 
that experienced a severely diminished tacrolimus clearance (Werk et al., 2014).  
In conclusion, thanks to a WES strategy in phenotype outliers we identified a defective 
rare allele relevant for drug metabolism that is population specific. The high frequency of the 
allele found in the Spanish population demonstrates a polymorphic nature of CYP3A4 gene. 
Furthermore, the key role of CYP3A4 in drug metabolism, together with preliminary clinical 
evidences, support an increased risk of adverse drug reactions in CYP3A4*20 carriers and 
suggests the importance of implementing CYP3A4*20 genotyping in the clinic, at least for the 
Spanish population. 
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5. Targeted sequencing reveals low-frequency variants in EPHA genes as markers 
of paclitaxel-induced peripheral neuropathy (Article 5) 
 
As observed in the previous article, defective low frequency coding variants are expected 
to have stronger effects on neuropathy than common variants (Cirulli and Goldstein, 2010), and 
may contribute to the neuropathy variability observed in paclitaxel-treated patients.  
However, only our group has used WES to study paclitaxel-induced neuropathy (Article 
3). Regarding targeted NGS, during the course of this Thesis Beutler et al performed the 
sequencing of CMT genes in paclitaxel treated patients. They found that three non-synonymous 
recurrent single nucleotide variants in ARHGEF10 (i.e. rs9657362, rs2294039, and rs17683288) 
and rare non-synonymous variants in PRX were associated with chemotherapy-induced 
neuropathy (Beutler et al., 2014). To further explore the hypothesis of low frequency coding 
variants having an impact on paclitaxel-induced neuropathy, we selected 228 patients with 
extreme-neuropathy phenotype (high versus no/low neuropathy) to perform massive sequencing 
of candidate genes. We included genes involved in paclitaxel pharmacokinetics (i.e. CYP2C8, 
CYP3A4, ABCB1, SLCO1B1 and SLCO1B3), four EPHA genes in which common variants have 
been previously associated with paclitaxel-induced neuropathy (i.e. EPHA4, EPHA5, EPHA6 and 
EPHA8), and 30 CMT genes. The hypothesis for including CMT genes is that these genes may 
harbor non-pathogenic genetic variants that, while not leading to CMT, may predispose to 
chemotherapy-induced neuropathy. 
Missense and LOF variants with <0.5% minor allele frequency and passing quality filters 
were analyzed following a gene-based analysis. The results revealed that low frequency missense 
variants in EPHA6 were associated with increased paclitaxel-induced neuropathy risk (P=0.041). 
Indeed, all EPHA6 variant carriers had high neuropathy and all the variants were located in the 
ephrin receptor ligand binding domain, suggesting an alteration of the protein function and further 
supporting the association with neuropathy. Using the same gene-based analysis we detected a 
similar trend for EPHA5 and EPHA8. Moreover, two of the variants found in EPHA5 and in 
EPHA8 were LOF, both of them corresponding to high neuropathy patients. In total, 15% (19 of 
131) of patients in the high neuropathy group carried low frequency non-synonymous coding 
variants in EPHA5/6/8 genes.  
We performed validation in an independent non-selected cohort (i.e. with different grades 
of neuropathy) of 202 paclitaxel-treated patients with cycle by cycle neuropathy data and 
performed targeted sequencing for EPHA5, EPHA6 and EPHA8 coding region. Thirteen EPHA8 
variant carriers were identified but only one EPHA6 and one EPHA5 carriers were detected. These 
results suggested that EPHA6 and EPHA5 variants (present in 5 out of the 131 patients with high-
neuropathy group in the discovery series) are less frequent in an unselected patient population 
which included many moderate-neuropathy patients (not represented in the discovery set). 
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Despite this fact, when applying the accumulated paclitaxel dose analysis, low-frequency 
variants in EPHA5/6/8 genes were statistically associated with neuropathy (HR=1.96, P=0.028).  
In ExAC browser, 0.1% of the European non-Finish individuals are carriers of LOF 
variants in either EPHA5, EPHA6 or EPHA8. Additionally, on more than 100,000 Icelandic 
individuals, two complete human knockouts for EPHA5 and one for EPHA6 were identified 
(Sulem et al., 2015). While no phenotype has been assigned to these individuals, based on the 
literature and on our results, a high susceptibility to drug-induced neuropathy would be expected 
for them.  
Of the LOF variants detected, three occurred in CMT genes (ARGHEF10, IKBKAP and 
DHTKD1). The patients with variants in ARGHEF10 and IKBKAP belonged to the no/low 
neuropathy group. This is in agreement with the fact that activating mutations in ARGHEF10 and 
not LOF variants can cause CMT (Chaya et al., 2011). Concerning IKBKAP, it causes CMT 
following a recessive model, this can be compatible with a lack of neuropathy in our IKBKAP 
heterozygous individual (Dong et al., 2002). Intriguingly, a variant in DHTKD1 was present in 
two patients with different neuropathy grades: one patient with high neuropathy (grade 3) and the 
other with no neuropathy (grade 0). However, recent evidences question the role of DHTKD1 in 
CMT disease and may explain the latter finding. Moreover, two patients with high neuropathy 
were carriers of the CYP3A4*20 frameshift allele (already described in Article 3) and another one 
from the same group carried a LOF in SLCO1B1.  
Additionally, a patient belonging to the no/low neuropathy was carrier of a splicing 
variant affecting the last exon of CYP3A4, but the effect of this variant on the splicing of the gene 
and how it affects the enzyme function remains to be studied.  
Regarding CMT genes, conversely to Beutler et al (Beutler et al., 2014) no significant 
association with paclitaxel-induced neuropathy was found for variants neither in PRX nor in 
ARHGEF10. Nevertheless, a trend towards protection was detected for the common variant 
rs9657362 in ARHGEF10 (Beutler et al., 2014, Boora et al., 2015). Interestingly, we have 
observed a tendency of increased neuropathy risk for the CMT genes SEPT9 and SH3TC2, when 
performing the gene-based analysis. The differences observed among these studies may be related 
to dissimilarities in neuropathy assessment, in the selection of patients, or in the distribution of 
low-frequency variants which have been shown to be population-specific. Thus, further validation 
in large independent series is required. 
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In this study we detected for the first time, low-frequency variants in EPHA5, EPHA6 
and EPHA8 conferring increased risk to suffer from paclitaxel-induced neuropathy. Moreover, 
the function of tyrosine kinase ephrin receptors in neural development (Flanagan and 
Vanderhaeghen, 1998) and in nerve regeneration after damage (Coulthard et al., 2012, Boyd et 
al., 2014), in combination with the fact that knockout mice for EPHA4, EPHA5, EPHA6 and 
EPHA8 present different neurological phenotypes, suggest a relevant role for EPHA5/6/8 genes 
in peripheral neuropathy caused by paclitaxel and also by other neurotoxic drugs.  
 
6. Paclitaxel-induced peripheral neuropathy as a multifactorial trait 
 
Paclitaxel-induced neuropathy is a multifactorial trait in which genetics (e.g. EPHA, 
CYP3A4 and CYP2C8*3 variants), physiopathologic conditions (e.g. diabetes, alcoholism, liver 
diseases) and other relevant factors (e.g. age, concomitant drugs) play a role (Figure 5). Evidences 
supporting the importance for genetics derive from initial candidate gene approaches (Leskelä et 
al., 2011, Hertz et al., 2013, Hertz et al., 2014), GWAS (Baldwin et al., 2012, Leandro-Garcia et 
al., 2013) and subsequent studies supporting some of the associations (Abraham et al., 2014, 
Apellániz-Ruiz et al., 2015, Boora et al., 2016).  
Thus, some of the genetic risk factors underlying paclitaxel-induced neuropathy have 
already been identified. The final goal is to integrate all risk factors contributing to paclitaxel-
induced neuropathy into a multifactorial model that would allow a personalized paclitaxel 
treatment, avoiding severe neuropathy that may compromise treatment success and may affect 
permanently patients’ quality of life.  
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Figure 5. Factors contributing to paclitaxel-induced peripheral neuropathy. Genetic markers highlighted in pink 
have considerable evidences supporting them to be included in a model to predict peripheral neuropathy risk in patients 
treated with paclitaxel. 
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1. No significant association is found between CYP2C8*3 allele and the risk of paclitaxel-induced 
peripheral neuropathy when a maximum neuropathy grade analysis is performed in a cohort of 
343 patients. However, a trend towards increased neuropathy is observed when using an 
accumulated paclitaxel dose analysis. CYP2C8.3 shows a similar enzymatic activity towards 
paclitaxel than CYP2C8 wild type in a mammalian expression system (HEK293 cell line). Taking 
into account the results of this study together with previous evidences, we propose that CYP2C8*3 
allele influences paclitaxel-induced neuropathy but with a low/ moderate effect. 
 
2. The common SNPs rs7349683 in EPHA5, rs301927 in EPHA6 and rs209709 in EPHA8 are 
confirmed as markers of paclitaxel-induced peripheral neuropathy. The role of EphA receptors in 
relevant neuronal functions such as nerve repair after injury, suggests that these SNPs could also 
constitute neuropathy risk markers for other neurotoxic drugs. 
 
3. Defective coding variants in CYP3A4 increase the risk of paclitaxel-induced peripheral 
neuropathy and of paclitaxel treatment modifications caused by neuropathy (i.e. dose reductions 
and treatment suspensions). Thus, CYP3A4 is identified as an additional predictive marker of 
paclitaxel-induced neuropathy.  
 
4. The loss-of-function allele CYP3A4*20 has a high frequency in Spain (with 1.2% of the Spanish 
population carrying this allele). The fact that CYP3A4*20 is a rare allele outside Spain and that 
all CYP3A4*20 carriers share a common haplotype with low frequency, suggests a Spanish 
founder effect. The key role of CYP3A4 in drug metabolism suggests an increased risk of adverse 
drug reactions for CYP3A4*20 carriers, and supports CYP3A4*20 genotyping in the Spanish 
population. 
 
5. Non-synonymous low-frequency variants in the genes EPHA5, EPHA6 and EPHA8 are 
associated with increased risk of paclitaxel-induced neuropathy. Interestingly, low-frequency 
variants in EPHA6 were present exclusively in patients with high neuropathy and affected the 
ephrin receptor ligand-binding domain. These results support the use of NGS to detect common 
and low frequency variants causative of drug adverse events such as paclitaxel peripheral 
neuropathy. 
 
6. The genetic markers identified in this Thesis may provide the basis for a multifactorial model 
predictive of paclitaxel neuropathy. This could recognize patients at high risk of developing 
neuropathy, and provide with a personalized paclitaxel treatment. 
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1. No encontramos una asociación significativa entre el alelo CYP2C8*3 y la neuropatía periférica 
inducida por paclitaxel cuando analizamos el grado máximo de neuropatía desarrollada en 343 
pacientes tratados con paclitaxel. Sin embargo, observamos una tendencia hacia una mayor 
neuropatía cuando utilizamos un análisis de dosis acumulada. Para el paclitaxel la enzima 
CYP2C8.3 tiene una actividad enzimática similar al CYP2C8 silvestre en un sistema de expresión 
de células de mamífero (línea celular HEK293). Teniendo en cuenta los resultados de este estudio 
y las evidencias previas existentes, proponemos que el alelo CYP2C8*3 tiene un efecto en la 
neuropatía causada por paclitaxel pero que este es bajo/ moderado.   
 
2. Confirmamos que las variantes comunes rs7349683 en EPHA5, rs301927 en EPHA6 y 
rs209709 en EPHA8 son marcadores de la neuropatía periférica causada por paclitaxel. El papel 
que desempeñan los receptores de efrinas tipo A en funciones neuronales tales como la reparación 
de los nervios después de una lesión, sugiere que estos polimorfismos también podrían ser 
marcadores de riesgo de neuropatías causadas por otros compuestos neurotóxicos.  
 
3. Las variantes codificantes de pérdida de función en CYP3A4 incrementan el riesgo a desarrollar 
neuropatía periférica causada por paclitaxel y a tener modificaciones de tratamiento causadas por 
la neuropatía (reducciones de dosis y suspensiones de tratamiento). Por tanto, el CYP3A4 es 
identificado como un marcador predictivo adicional para la neuropatía producida por el paclitaxel. 
 
4. El alelo con pérdida de función CYP3A4*20 es frecuente en España (1.2% de los españoles 
porta este alelo). El hecho de que el alelo CYP3A4*20 sea raro fuera de España y que los 
portadores de esta variante tengan un mismo haplotipo poco frecuente en la población, sugiere un 
efecto fundador español. El relevante papel del CYP3A4 en el metabolismo de fármacos sugiere 
que los portadores del CYP3A4*20 tienen un mayor riesgo a sufrir efectos adversos, y apoya el 
genotipado de este alelo en España. 
 
5. Variantes no sinónimas y de baja frecuencia en los genes EPHA5, EPHA6 y EPHA8 están 
asociadas a un mayor riesgo a desarrollar neuropatía inducida por paclitaxel. Es un hecho 
interesante que todas las variantes de baja frecuencia en EPHA6 se encontraron en pacientes con 
alta neuropatía y todas se localizaban en el dominio de unión a ligando. Estos resultados apoyan 
el uso de NGS para detectar variantes comunes y de baja frecuencia en genes que contribuyen en 
los efectos adversos causados por fármacos como es el caso de la neuropatía periférica producida 
por el paclitaxel. 
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6. Los marcadores genéticos identificados en esta Tesis podrían proporcionar la base para un 
modelo multifactorial predictivo de la neuropatía. Este podría detectar a los pacientes con mayor 
riesgo a desarrollar neuropatía, y proporcionar un tratamiento personalizado del paclitaxel.  
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Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in 
metastatic breast cancer.  
 
Tomás Pascual-Martínez*, María Apellániz-Ruiz*, Cristina Pernaut, Cecilia Cueto-Felgueroso, 
Pablo Villalba, Carlos Álvarez, Luis Manso, Lucía Inglada-Pérez, Mercedes Robledo, Cristina 
Rodríguez-Antona, Eva Ciruelos.  
 
Abstract: 
Background: Metastatic breast cancer (MBC) progressing after endocrine therapy frequently 
activates mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves 
increased progression free survival (PFS) compared with exemestane. However, there is great 
inter-patient variability in toxicity and response to exemestane-everolimus treatment. The 
objective of this study was to explore the implication of single nucleotide polymorphisms (SNPs) 
on outcomes from this treatment through a pharmacogenetic analysis. Patients and Methods: 
Blood was collected from 90 postmenopausal women with hormone receptor-positive, HER2-
negative MBC treated with exemestane-everolimus following progression after prior treatment 
with a non-steroidal aromatase inhibitor. Everolimus pharmacokinetics was measured in 37 
patients. Twelve SNPs in genes involved in everolimus pharmacokinetics and pharmacodynamics 
were genotyped and associations assessed with drug plasma levels, clinically relevant toxicities 
(non-infectious pneumonitis, mucositis, hyperglycemia and hematological toxicities), dose 
reductions or treatment suspensions due to toxicity, progression free survival (PFS) and overall 
survival. Results: We found that CYP3A4 rs35599367 variant (CYP3A4*22 allele) carriers had 
higher everolimus blood concentration compared to wild type patients (P=0.019). ABCB1 
rs1045642 was associated with risk of mucositis (P=0.031), while PIK3R1 rs10515074 and 
RAPTOR rs9906827 were associated with hyperglycemia and non-infectious pneumonitis 
(P=0.016 and 0.024, respectively). Furthermore, RAPTOR rs9906827 was associated with PFS 
(P=0.006). Conclusions: CYP3A4*22 allele influenced plasma concentration of everolimus and 
several SNPs in mTOR pathway genes were associated with treatment toxicities and prognosis. 
These results require replication, but suggest that germline variation could influence everolimus 
outcomes in MBC.  
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Deep sequencing reveals microRNAs predictive of tyrosine kinase inhibitors response in 
clear cell renal cell carcinoma patients 
 
Jesús García-Donás*, Benoit Beuselinck*, Lucia Inglada-Perez*, Osvaldo Graña, Patrick 
Schöffski, Agnieszka Wozniak, Oliver Bechter, Pascal Wolter, Maria Apellániz-Ruiz, Luis 
Javier Leandro-García, Emilio Esteban, Daniel E Castellano, Aranzazu González del Alba, 
Miguel Angel Climent, Susana Hernando, José Angel Arranz, Manuel Morente, David G. Pisano, 
Mercedes Robledo, and Cristina Rodríguez-Antona 
 
Abstract: 
Purpose: The majority of metastatic clear cell renal cell carcinoma (ccRCC) patients are treated 
with tyrosine kinase inhibitors (TKIs) in first line, however, a fraction are refractory to these 
drugs. MicroRNAs (miRNA) are regulatory molecules that have proven to be accurate biomarkers 
in cancer. Here we identified miRNA predictive of progressive disease under TKI treatment. 
Patients and methods: Whole miRNA expression was quantified by deep-sequencing in a 
discovery set of 74 metastatic ccRCC cases uniformly treated with TKIs. MiRNAs differentially 
expressed in patients progressing under TKI treatment were identified and validated by qRT-PCR 
in an independent series of 64 patients. Integration of miRNA expression with clinicopathologic 
factors in a combinatorial model predicted poor response to TKIs.  
Results: Twenty nine miRNAs were found to be differentially expressed in the tumors of patients 
who progressed under TKI therapy (P values from 6x10-9 to 3x10-3). Among six miRNAs 
selected for validation, an over-expression of miR-1307-3p, miR-155-5p, miR-221-3p, miR-425-
5p and miR-222-3p was confirmed in patients with progressive disease as best response 
(P=4.6x10-3, 6.5x10-3 and 0.034, 0.055 and 0.070, respectively). Furthermore, a 2 miRNA-based 
classifier could discriminate individuals with progressive disease upon TKI treatment 
(AUC=0.75, 95%CI=0.64-0.85; P=1.3x10-4) with a better predictive value than 
clinicopathological risk factors commonly used. miRNAs significantly associated with 
progression-free survival and overall survival (P=6.8x10-8 and 7.8x10-7 for top hits, respectively) 
were identified, and 7 miRNAs were found to overlap as predictive for early progressive disease, 
progression-free survival and overall survival.  
Conclusion: This first miRNome comprehensive study demonstrates a predictive value of 
miRNAs for TKI response and provides a new set of relevant makers that can help rationalize 
metastatic ccRCC treatment. 
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Single nucleotide polymorphism associated with activity and toxicity of cabazitaxel in 
patients with advanced genitourinary transitional cell carcinoma.  
 
Ignacio Duran, Carlos Hagen, José Ángel Arranz, María Apellaniz-Ruiz, Begoña Pérez-
Valderrama, Nuria Sala, Nuria Lainez, Xavier García-Del Muro, Esther Noguerón, Miguel Ángel 
Climent, Pablo Maroto, Albert Font, Jesús García-Donas, Enrique Gallardo, Pilar López-Criado, 
Aránzazu González Del Alba, María Isabel Sáez, Sergio Vázquez, Raquel Luque, Cristina 
Rodríguez-Antona.  
 
Abstract: 
Aims: We aimed to identify SNPs predictive of cabazitaxel toxicity and response within a phase 
II clinical trial using this compound in advanced transitional cell carcinoma after progression to 
a platinum-based regimen.  
Methods: Eleven SNPs in CYP3A4, CYP3A5, CYP2C8, ABCB1 and TUBB1 were genotyped in 
45 patients.  
Results: CYP3A5 rs776746 A-allele was associated with protection against gastrointestinal 
toxicity (OR=0.06, 95%CI=0.007-0.63, P=0.018) and with reduced progression free survival 
(HR=5.1, 95%CI=1.7-15.1, P=0.0038, multivariable analysis). ABCB1 SNPs were associated 
with total number of grade 3-4 toxicity events (P values of 0.009, 0.041, and 0.043, respectively).  
Conclusions: Polymorphisms in CYP3A5 and ABCB1 may define a subset of patients with 
different cabazitaxel toxicity and efficacy and therefore could be used as markers for treatment 
optimization. 
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Drug Metabol Personal Ther. 2016 Mar 1; 31(1):3-8 
 
Human genetics: international projects and personalized medicine.  
 
Apellaniz-Ruiz M, Gallego C, Ruiz-Pinto S, Carracedo A, Rodríguez-Antona C.  
 
Abstract: 
In this article, we present the progress driven by the recent technological advances and new 
revolutionary massive sequencing technologies in the field of human genetics. We discuss this 
knowledge in relation with drug response prediction, from the germline genetic variation 
compiled in the 1000 Genomes Project or in the Genotype-Tissue Expression project, to the 
phenome-genome archives, the international cancer projects, such as The Cancer Genome Atlas 
or the International Cancer Genome Consortium, and the epigenetic variation and its influence in 
gene expression, including the regulation of drug metabolism. This review is based on the lectures 
presented by the speakers of the Symposium "Human Genetics: International Projects & New 
Technologies" from the VII Conference of the Spanish Pharmacogenetics and Pharmacogenomics 
Society, held on the 20th and 21st of April 2015. 
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J Med Genet. 2015 Oct; 52(10):647-56. 
 
Recommendations for somatic and germline genetic testing of single pheochromocytoma 
and paraganglioma based on findings from a series of 329 patients.  
 
Currás-Freixes M, Inglada-Pérez L, Mancikova V, Montero-Conde C, Letón R, Comino-Méndez 
I, Apellániz-Ruiz M, Sánchez-Barroso L, Aguirre Sánchez-Covisa M, Alcázar V, Aller J, 
Álvarez-Escolá C, Andía-Melero VM, Azriel-Mira S, Calatayud-Gutiérrez M, Díaz JÁ, Díez-
Hernández A, Lamas-Oliveira C, Marazuela M, Matias-Guiu X, Meoro-Avilés A, Patiño-García 
A, Pedrinaci S, Riesco-Eizaguirre G, Sábado-Álvarez C, Sáez-Villaverde R, Sainz de Los 
Terreros A, Sanz Guadarrama Ó, Sastre-Marcos J, Scolá-Yurrita B, Segura-Huerta Á, Serrano-
Corredor Mde L, Villar-Vicente MR, Rodríguez-Antona C, Korpershoek E, Cascón A, Robledo 
M.  
 
Abstract: 
BACKGROUND: Nowadays, 65-80% of pheochromocytoma and paraganglioma (PPGL) cases 
are explained by germline or somatic mutations in one of 22 genes. Several genetic testing 
algorithms have been proposed, but they usually exclude sporadic-PPGLs (S-PPGLs) and none 
include somatic testing. We aimed to genetically characterise S-PPGL cases and propose an 
evidence-based algorithm for genetic testing, prioritising DNA source. METHODS: The study 
included 329 probands fitting three criteria: single PPGL, no syndromic and no PPGL family 
history. Germline DNA was tested for point mutations in RET and for both point mutation and 
gross deletions in VHL, the SDH genes, TMEM127, MAX and FH. 99 tumours from patients 
negative for germline screening were available and tested for RET, VHL, HRAS, EPAS1, MAX 
and SDHB. RESULTS: Germline mutations were found in 46 (14.0%) patients, being more 
prevalent in paragangliomas (PGLs) (28.7%) than in pheochromocytomas (PCCs) (4.5%) 
(p=6.62×10(-10)). Somatic mutations were found in 43% of those tested, being more prevalent in 
PCCs (48.5%) than in PGLs (32.3%) (p=0.13). A quarter of S-PPGLs had a somatic mutation, 
regardless of age at presentation. Head and neck PGLs (HN-PGLs) and thoracic-PGLs (T-PGLs) 
more commonly had germline mutations (p=2.0×10(-4) and p=0.027, respectively). Five of the 
29 metastatic cases harbored a somatic mutation, one in HRAS. CONCLUSIONS: We 
recommend prioritising testing for germline mutations in patients with HN-PGLs and T-PGLs, 
and for somatic mutations in those with PCC. Biochemical secretion and SDHB-
immunohistochemistry should guide genetic screening in abdominal-PGLs. Paediatric and 
metastatic cases should not be excluded from somatic screening. 
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Functional and in-silico assessment of MAX variants of unknown significance.  
 
Iñaki Comino-Méndez, Luis J Leandro-García, Guillermo Montoya, Lucía Inglada-Pérez, 
Aguirre A de Cubas, María Currás-Freixes, Carolyn Tysoe, Rocío Letón, Álvaro Gómez-Graña, 
Veronika Mancikova, María Apellániz-Ruiz, Cristina Rodríguez-Antona, Mercedes Robledo, 
and Alberto Cascón.  
 
Abstract: 
The presence of germline mutations affecting the MYC-associated protein X (MAX) gene has 
recently been identified as one of the now 11 major genetic predisposition factors for the 
development of hereditary pheochromocytoma and/or paraganglioma. Little is known regarding 
how missense variants of unknown significance (VUS) in MAX affect its pivotal role in the 
regulation of the MYC/MAX/MXD axis. In the present study, we propose a consensus 
computational prediction based on five "state-of-the-art" algorithms. We also describe a PC12-
based functional assay to assess the effects that 12 MAX VUS may have on MYC's E-box 
transcriptional activation. For all but two of these 12 VUS, the functional assay and the consensus 
computational prediction gave consistent results; we classified seven variants as pathogenic and 
three as nonpathogenic. The introduction of wild-type MAX cDNA into PC12 cells significantly 
decreased MYC's ability to bind to canonical E-boxes, while pathogenic MAX proteins were not 
able to fully repress MYC activity. Further clinical and molecular evaluation of variant carriers 
corroborated the results obtained with our functional assessment. In the absence of clear 
heritability, clinical information, and molecular data, consensus computational predictions and 
functional models are able to correctly classify VUS affecting MAX. 
KEY MESSAGES: A functional assay assesses the effects of MAX VUS over MYC 
transcriptional activity. A consensus computational prediction and the functional assay show high 
concordance. Variant carriers' clinical and molecular data support the functional assessment. 
  
Appendix: Other articles 
187 
Ann Oncol. 2015 Sep; 26(9):1987-93.  
 
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of 
the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).  
 
Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, Sevilla I, Escudero P, Sastre J, 
García-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, 
Alonso-Gordoa T, Díez JJ, Carrato A, García-Carbonero R.  
 
Abstract: 
BACKGROUND: The management of advanced neuroendocrine tumors (NETs) has recently 
changed. We assessed the activity of pazopanib after failure of other systemic treatments in 
advanced NETs. 
METHODS: This was a multicenter, open-label, phase II study evaluating pazopanib as a single 
agent in advanced NETs (PAZONET study). The clinical benefit rate (CBR) at 6 months was the 
primary end point. Translational correlation of radiological response and progression-free 
survival (PFS) with circulating and tissue biomarkers was also evaluated. 
RESULTS: A total of 44 patients were enrolled. Twenty-five patients (59.5%) were progression-
free at 6 months (4 partial responses, 21 stable diseases) with a median PFS of 9.5 months [95% 
confidence interval (CI) 4.8-14.1]. The CBR varied according to prior therapy received, with 
73%, 60% and 25% in patients treated with prior multitarget inhibitors, prior mTOR inhibitors 
and both agents, respectively. A nonsignificant increase in PFS was observed in patients 
presenting lower baseline circulating tumor cell (CTC) counts (9.1 versus 5.8 months; P = 0.22) 
and in those with decreased levels of soluble-vascular endothelial growth factor receptor-2 
(sVEGFR-2) (12.6 versus 9.1 months; P = 0.067). A trend toward reduced survival was 
documented in patients with VEGFR3 rs307821 and rs307826 missense polymorphisms [hazard 
ratio (HR): 12.3; 95% CI 1.09-139.2; P = 0.042 and HR: 6.9; 95% CI 0.96-49.9; P = 0.055, 
respectively]. 
CONCLUSIONS: Pazopanib showed clinical activity in patients with advanced NETs regardless 
of previous treatments. Additionally, CTCs, soluble-s VEFGR-2 and VEGFR3 gene 
polymorphisms constitute potential biomarkers for selecting patients for pazopanib 
(NCT01280201). 
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J Natl Cancer Inst. 2015 Mar 11; 107(5)  
 
Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. 
 
Cascón A, Comino-Méndez I, Currás-Freixes M, de Cubas AA, Contreras L, Richter S, Peitzsch 
M, Mancikova V, Inglada-Pérez L, Pérez-Barrios A, Calatayud M, Azriel S, Villar-Vicente R, 
Aller J, Setién F, Moran S, Garcia JF, Río-Machín A, Letón R, Gómez-Graña Á, Apellániz-Ruiz 
M, Roncador G, Esteller M, Rodríguez-Antona C, Satrústegui J, Eisenhofer G, Urioste M, 
Robledo M.  
 
Abstract: 
Disruption of the Krebs cycle is a hallmark of cancer. IDH1 and IDH2 mutations are found in 
many neoplasms, and germline alterations in SDH genes and FH predispose to 
pheochromocytoma/ paraganglioma and other cancers. We describe a paraganglioma family 
carrying a germline mutation in MDH2, which encodes a Krebs cycle enzyme. Whole-exome 
sequencing was applied to tumor DNA obtained from a man age 55 years diagnosed with multiple 
malignant paragangliomas. Data were analyzed with the two-sided Student's t and Mann-Whitney 
U tests with Bonferroni correction for multiple comparisons. Between six- and 14-fold lower 
levels of MDH2 expression were observed in MDH2-mutated tumors compared with control 
patients. Knockdown (KD) of MDH2 in HeLa cells by shRNA triggered the accumulation of both 
malate (mean ± SD: wild-type [WT] = 1±0.18; KD = 2.24±0.17, P = .043) and fumarate (WT = 
1±0.06; KD = 2.6±0.25, P = .033), which was reversed by transient introduction of WT MDH2 
cDNA. Segregation of the mutation with disease and absence of MDH2 in mutated tumors 
revealed MDH2 as a novel pheochromocytoma/paraganglioma susceptibility gene. 
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Breast Cancer Res Treat. 2015 Jan; 149(2):385-94.  
 
Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. 
 
Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, 
Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste M, Osorio A, Blasco MA, 
Rodriguez-Antona C, Benitez J.  
 
Abstract: 
Recently, we observed that telomeres of BRCA1/2 mutation carriers were shorter than those of 
controls or sporadic breast cancer patients, suggesting that mutations in these genes might be 
responsible for this event. Given the contradictory results reported in the literature, we tested 
whether other parameters, such as chemotherapy, could be modifying telomere length (TL). We 
performed a cross-sectional study measuring leukocyte TL of 266 sporadic breasts cancer patients 
treated with first-line chemotherapy, with a median follow-up of 240 days. Additionally, we 
performed both cross-sectional and longitudinal studies in a series of 236 familial breast cancer 
patients that included affected and non-affected BRCA1/2 mutation carriers. We have measured 
in leukocytes from peripheral blood: the TL, percentage of short telomeres (<3 kb), telomerase 
activity levels and the annual telomere shortening speed. In sporadic cases we found that 
chemotherapy exerts a transient telomere shortening effect (around 2 years) that varies depending 
on the drug combination. In familial cases, only patients receiving treatment were associated with 
telomere shortening but they recovered normal TL after a period of 2 years. Chemotherapy affects 
TL and should be considered in the studies that correlate TL with disease susceptibility. 
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VEGF, VEGFR3, and PDGFRB Protein Expression Is Influenced by RAS Mutations in 
Medullary Thyroid Carcinoma.  
 
Mancikova V, Inglada-Pérez L, Curras-Freixes M, de Cubas AA, Gómez A, Letón R, Kersten I, 
Leandro-García LJ, Comino-Méndez I, Apellaniz-Ruiz M, Sánchez L, Cascón A, Sastre-Marcos 
J, García JF, Rodríguez-Antona C, Robledo M.  
 
Abstract: 
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have achieved remarkable clinical results 
in medullary thyroid carcinoma (MTC) patients. However, the considerable variability in patient 
response to treatment with TKIs remains largely unexplained. There is evidence that it could be 
due, at least in part, to alterations in genes associated with the disease via their effect on the 
expression of TKI targets. The objective of this study was to evaluate the influence of RAS 
mutations on the expression levels in MTC tumors of eight key TKI target proteins. 
METHODS: We assessed by immunohistochemistry the expression of EGFR, KIT, MET, 
PDGFRB, VEGF, VEGFR1, VEGFR2, and VEGFR3 in a series of 84 primary MTC tumors that 
had previously been molecularly characterized, including 14 RAS-positive, 18 RET(M918T)-
positive, and 24 RET(C634)-positive tumors, as well as 15 wild-type tumors with no mutations 
in the RET or RAS genes. 
RESULTS: In contrast to RET-positive tumors, RAS-positive tumors expressed neither 
PDGFRB nor MET (p=0.0060 and 0.047, respectively). Similarly, fewer RAS-positive than RET-
related tumors expressed VEGFR3 (p=0.00062). Finally, wild-type tumors expressed VEGF more 
often than both RAS- and RET-positive tumors (p=0.0082 and 0.011, respectively). 
CONCLUSIONS: This is the first study identifying that the expression of TKI targets differs 
according to the presence of RAS mutations in MTC. This information could potentially be used 
to select the most beneficial TKI treatment for these patients
